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I have to admit it is with much relief, with a tinge of nostalgia, as I pen down my 
thoughts at this point in time. Relief that the end is almost in sight after a journey 
fraught with deep valleys of disappointments and mountains of discouragement to 
overcome, nostalgia as I listened to the varied discussions (scientific or otherwise) 
accompanied with random peals of laughter in the laboratory while others engage in 
the seemingly mundane tasks of clearing the waste bins and refilling of pipette tip 
boxes. Looking back now, I wondered how exactly I had spent my past six years in the 
laboratory. “Gone in a flash” or “in a twinkling of an eye” aptly describes my stint 
as a graduate student, but not so for my friendships with the people who had been so 
much a part of my life and to whom I would not miss this opportunity to express my 
sincere appreciation and deepest thanksgiving for.  
To Prof Shazib Perviaz; I can still recall with clarity my first meeting with Prof – how 
I had to run after him for several days in a roll, just to meet him for a few minutes 
each time, and trying my best to convince him that he won’t regret taking me taking 
me on as a Honours student (he already had almost half a dozen of Hons students 
under his wing). But, encouraged by my friend’s advice that, “he is very nice, and he 
doesn’t reject people easily!” I persevered in my request, to which he graciously 
conceded eventually. Through the years, he was always the considerate and kind boss 
to this quiet soul, being there when I needed his advice, supportive when I wanted to 
experiment with ideas for my work. “Well, that’s research”, will be his encouraging 
response should things fail to fall into place, teaching me the valuable lesson in 
having the appropriate attitude towards research. Playing the devil’s advocate during 
presentations when he had to toughen us to handle criticism was his mode of training 
for all graduate students in our weekly lab meetings, to which all of us stood to gain 
ultimately, though it probably disturbed him quite a fair bit to have to play the bad 
guy.  
To beloved Jayshree mama; her sensitivity and kindness towards myself, and all other 
students in the lab, simply endeared her to everyone around her. I will always 
remember how your face would light up brightly, with a twinkle in your beautiful eyes 
and a wide genuine heartwarming smile, whenever I share any piece of good news 
with you, rejoicing alongside me as if my blessings had been your own. Jay mama, 
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your kindness will always be a sweet aroma lingering in the lab and in the hearts of 
student who have had their lives touched by you.   
To my camaraderie, students and members of the Apoptosis and Tumor Biology group 
in the Department of Physiology, thanks for being there for me throughout the six 
years. Your presence certainly was a source of encouragement and joy for me, as we 
worked long hours together, with our sporadic tea breaks to chill and crap or engage 
in frivolous talk. You guys certainly injected so much color and excitement into lab 
work. Special mention to the class of 2005, Chew Hooi, Inthrani, Zhi Xiong, Huda 
and Greg, and my maxi mentor Miss Poh, the jing-bang of individuals to whom we 
have grown so much closer to as we troughed and laughed together through the 
years, witnessing the growth, marriages and pregnancies of each other. Cheers to 
moving on to the “bigger and better places”! 
To my fiancé, Joe, my parents and beloved brother; no words can fully express how 
much each of you has sacrificed for me and the important role you play in every 
single phase of my life.  
Most important of all, I can say, nothing would have been possible without You, 
Jesus. Thank You Lord, the source of my joy and strength. My hope of mercy and 
grace through the ups and downs in my life, You were the one who provided me with 
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The TNF receptor family member TRAIL has shown promise as a target-specific 
agent against certain classes of tumor cells. The heightened interest in evaluating the 
potential use of TRAIL in the clinical settings stems from observations that TRAIL 
receptors, DR4 and DR5, are selectively expressed on tumor cells. However, despite 
this preferential sensitivity, resistance to TRAIL remains a clinical problem, which 
has resulted in a strong push toward identifying mechanisms underlying TRAIL 
resistance as well as developing means to override or bypass these pathways for 
reverting TRAIL sensitivity. To that end, a plethora of compounds are under 
investigation for their ability to revert tumor cells‘ responsiveness to TRAIL. We 
recently demonstrated that the phosphatidylinositide-3-kinase (PI3K) inhibitor, 
LY294002, and its inactive analog LY303511 (LY30), sensitized tumor cells to drug-
induced apoptosis, independent of PI3K/Akt pathway. Intrigued by these findings, we 
investigated the effect of LY30 on TRAIL-induced apoptosis in human cancer cell 
lines. Preincubation of cells with LY30 significantly amplified TRAIL signaling as 
evidenced by enhanced DNA fragmentation, caspases 2, 3, 8, and 9 activation, and 
significant inhibition of tumor colony formation. We link this execution signal to the 
ability of LY30 to oligomerize and upregulate DR4/5, similarly demonstrated in 
SHEP-1 neuroblastoma cell line, and downregulate cFLIPS, thus facilitating assembly 
and signaling via the death initiating signaling complex.  The subsequent exposure to 
TRAIL resulted in processing/activation of caspase 8 and cleavage of its substrate, the 
BH3 protein Bid, and mitochondrial membrane permeabilization resulting in the 
egress of cytochrome c and SMAC, cleavage of X-linked inhibitor of apoptosis 
protein, and activation of caspase 9. Though inhibition of receptor oligomerization 
failed to protect cells against LY30+TRAIL induced death, we observed a reduction 
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in the activation of procaspase-8 and Bid. Nonetheless, functional knockdown of 
death receptors abolished the TRAIL-sensitizing ability of LY30 and restored 
viability to the cells. Preliminary work in this thesis shows that the sensitizing ability 
of LY30 is not restricted to HeLa cells and that it is able to achieve an enhancement 
of TRAIL-induced cell death in Jurkat cells, a non-solid tumor model. This was 
accompanied by the synergistic activation of caspases-2/3/8/9.  We also provide 
evidence here that LY30 is able to revert sensitivity to TRAIL-resistant HT29 
adenocarcinoma cell line. Thus, the work in this thesis highlights the potential of 
LY30 as an adjuvant in tumor cells for TRAIL-induced cell death, along with 
implications for the design of novel chemotherapeutic strategies to overcome the issue 
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1. CANCER IN SINGAPORE 
1.1 Prevalence of cancer  
The Cancer Registry in Singapore was set up in January 1968, as cancer was 
recognized as one of the major reportable heath disease, besides other diseases such as 
chronic kidney disease, stroke and acute myocardial infarction that have been 
diagnosed and treated in Singapore. It was founded primarily to provide information 
on cancer patterns and trends in Singapore which revealed that the proportion of 
cancer deaths among all causes of death rose steadily from 14.8% (1968-72) to 27.1% 
(1998-2002). The latest 2003-2007 statistics reported a continuous upward trend in 
the number of cancer incidents, with a total of 45, 176 incidents reported within this 
period, out of which 48.6% were reported in males and 51.4% cases in females, with 
breast cancer, colorectal cancer and lung cancer as the most common cancers.  
 
1.2 Development of oncogenicity 
Homeostasis, the ability or tendency of an organism or cell to maintain internal 
equilibrium by adjusting its physiological processes, plays an important role in 
ensuring a functional and healthy body. Cancers arise, when this equilibrium goes 
awry, when proto-oncogenes switch into their oncogenic forms, leading to the process 
of tumorigenesis where cells develop capabilities for sustained proliferation or to 
resist death signals. This can be attributed to a variety of factors, among which is the 
overexpression or constitutive activation of prosurvival proteins such as Bcl-2 or 
Akt/Protein kinase B (PKB). Impediment of cell death signaling within a cell, like 
increased levels of inhibitors of apoptosis (IAPs) or reduction in pro-death proteins 
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such as the death receptors or caspases, endows the cell with a survival advantage, 
rendering it insensitive to homeostatic commands to commit suicide. These 
observations provide novel effector pathways regarding growth and cell fate 
regulation, presenting novel avenues for intervention towards oncogenesis.  
 
2. CELL DEATH 
Cell death, as the foil to cell proliferation, has been one of the most intensively 
studied research area. Almost every aspect of life is intimately dependent on the 
appropriate regulation of cell death, which either contributes to or forms the basis of 
most human diseases pathogenesis. Cell death can be classified according to its 
morphological appearance (which includes apoptotic, necrotic, autophagic or 
associated with mitosis), enzymological criteria (with or without the involvement of 
distinct classes of proteases, such as caspases, calpains and cathepsins or of 
nucleases), functional aspects (programmed or accidental, physiological or 
pathological) or immunological characteristics (immunogenic or nonimmunogenic) 
[1, 2]. However, due to a lack of distinct correlation between ultrastructural 
alterations and biochemical cell death characteristics, identification of the diverse 
forms of cell death now relies on morphological changes within the dying cell [3].  
 
 
2.1 Necrosis  
‗Necrotic cell death‘ or ‗necrosis‘ is morphologically characterized by cytoplasmic 
swelling (oncosis) and swelling of organelles leading to plasma membrane rupture 
and subsequent loss of intracellular contents. Hence, necrosis lacks specific 
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biochemical markers, apart from the presence of plasma membrane permeabilization, 
and can be detected only by electron microscopy. It was initially classified as a 
disordered and accidental form of cell death until recent studies have suggested that 
necrosis, like apoptosis and autophagy, is controlled by a regulated program and that 
necrosis could serve to maintain tissue and organisomal integrity. This is indicated by 
the fact that necrosis can occur during mammalian development (e.g. death of 
chondrocytes controlling the longitudinal growth of bones) or in adult tissue 
homeostasis (e.g. intestinal epithelial cells). Several mediators have been implicated 
in necrotic cell death, but it is still unclear how they interrelate with each other. 
Typical alterations that accompany (or define) necrosis include mitochondrial 
alterations, such as uncoupling and production of reactive oxygen species, or 
mitochondrial membrane permeabilization. Additionally, lysosomal membrane 
permeabilization, nuclear changes (hyperactivation of PARP-1 and concomitant 
hydrolysis of NAD
+
) and increases in cytosolic concentration of calcium resulting in 
mitochondrial overload and activation of non-caspase proteases e.g. calpains and 
cathepsins have also been reported to induce necrotic cell death. A crucial role for the 
serine/threonine kinase RIP1 has been demonstrated in several, but not all, instances 
of necrotic death [4, 5]. 
 
2.2 Autophagy 
Autophagy—or self-eating—involves the breakdown of intracellular organelles in 
lysosomal vesicles to allow continued energy production under conditions of 
starvation or nutrient stress. This process is an essential part of growth regulation and 
maintenance of homeostasis in multicellular organisms [6]. Autophagic vacuole 
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formation is also activated as an adaptive response to a variety of intracellular and 
extracellular stimuli such as aggregated or misfolded proteins and damaged 
organelles, nutrient deprivation, hormonal or therapeutic treatment and during 
bacterial infection. It is morphologically defined (especially by transmission electron 
microscopy) as a type of cell death that occurs in the absence of chromatin 
condensation, accompanied by massive autophagic vacuolization (double-membraned 
autophagic vacuoles) of the cytoplasm. A precise sequence of molecular events occur 
whereby parts of the cytoplasm are sequestered within double membrane vacuoles, 
termed autophagic vacuoles, are formed, followed by their fusion with lysosomes to 
form autophagolysosomes occurs during autophagic cell death. Both autophagosome 
inner membrane and its luminal contents are degraded by acidic lysosomal 
hydrolases, marking the completion of the autophagic pathway.  
 
Many genes involved in autophagy have been discovered and they are now called Atg 
(Autophagy-related) genes. Many of them are involved in the process of 
autophagosome formation that features two ubiquitin-like conjugation systems well-
conserved among eukaryotes: the Atg12–Atg5 and the Atg8(LC3)–PE 
(phosphatidylethanolamine) systems [7]. LC3 is the only reliable marker of 
autophagosome formation in mammalian cells, with the relative amount of LC3-II 
reflecting the abundance of the autophagosomes. Autophagic cells are characterized 
biochemically by cleavage of LC3 and its punctate redistribution inside the cell [8, 9]. 
 
2.3 Apoptosis 
Apoptosis is a form of programmed cell death that involves the activation of tightly 
regulated energy-requiring intracellular machinery that has been conserved 
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throughout evolution. It affects single cells asynchronously, typically in the absence 
of inflammatory changes. Apoptosis has been discovered as an essential component 
during morphogenesis of embryonic tissues, in the regulation of immune response as 
well as in homeostasis of adult organs and tissues. This program is also involved in 
the elimination of cells exposing the organism to danger, such as virally infected cells 
or cells with damaged DNA. Therefore, deregulation of apoptosis has been linked to 
various disease pathologies, including neurodegenerative diseases, autoimmunity and 
cancer.  
Apoptotic cells are characterized by distinct morphological changes, an important 
experimental proof of the underlying process, such as cellular shrinkage, membrane 
blebbing, nuclear chromatin condensation and fragmentation. Initially, cell membrane 
integrity is maintained while subtle changes e.g. externalization of phosphatidylserine 
occurs. Eventually, however, the entire cell breaks into membrane-bound fragments, 
termed apoptotic bodies [10], which are engulfed by surrounding phagocytes 
(macrophages and dendritic cells) without eliciting an inflammatory response.  
 
 
2.3.1 Molecular Mechanisms of Apoptosis 
The distinct morphological changes, as described above, are regulated by an ordered 
series of biochemical events leading to cell death. These events have been divided 
into two phases: an initial commitment phase, whereby the cell receive a signal and 
commits itself to cell death, followed by the executioner phase resulting in the 
eventual morphological changes and demise of the cell. Central to the apoptotic 
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mechanisms are a group of proteases called caspases, which are the principle 
executioners of apoptotic cell death [11, 12].  
 
2.3.2 Caspases  
Caspases are a family of aspartate-sepcific cysteine proteases that propagate death 
signaling by cleaving key intracellular proteins [13, 14]. They specifically recognize 
and cleave a tetrapeptide, containing a specific aspartic acid (Asp) residue, sequence 
on their substrate [15]. They are synthesized in normal cells as inactive 
zymogens/proenzymes that can be rapidly activated by autoproteolytic cleavage or 
cleavage by other caspases at their specific Asp residues [16]. A phylogenetically 
distinct class of caspases (caspase-1, 4, 5, 11 and 12) are involved in the inflammatory 
responses via the proteolytic processing of inflammatory cytokine precursors of 
interleukin 1β (IL 1β) and IL 18.  Currently, of the 14 members identified in the 
caspsae family, 7 are known to mediate apoptosis [12, 17]. During apoptosis, 
―initiator‖ caspases (caspase-2, 8, 9 and 10) with long prodomains [18, 19] serve as 
upstream signal transducers to proteolytically activate downstream ―executioner‖ 
caspases like caspase-3, 6 and 7. The long prodomain of the initiator caspases 
contains a death effector domain (DED) which allows it to interact homotypically 
with adaptor proteins, such as Fas-associated death domain protein (FADD) or 
caspase-recruitment domains (CARDs), leading to their activation through 
autoproteolytic processing. Downstream executioner caspases, which contain short 
prodomains, are subsequently activated by proteolytic processing by initiator 
caspases. Executioner caspases act on a variety of substrate resulting in the 
proteolysis of key cellular proteins, with poly-(ADP-ribose) polymerase (PARP) as 
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the best characterized [20]. PARP is a nuclear protein implicated in DNA repair, and 
is one of the earliest proteins targeted for specific caspase cleavage. Caspase cleavage 
and inactivation of iCAD (Inhibitor of caspase-activated DNAse) permits 
translocation of CAD to the nucleus where it is responsible for internucleosomal DNA 
cleavage, generating oligonucleosomal DNA fragments [21, 22]. Caspase cleavage of 
lamins [23] and cytoskeletal proteins like actin and fodrin result in nuclear shrinkage 
and cytosolic reorganization respectively. The effector caspases also mediate the 
membrane blebbing phenomenon by activating several adaptor proteins such as Rho-
associated kinase 1 (ROCK1), p-21 activated kinase (PAK) and gelsolin [10, 24, 25].  
2.3.3 IAPs – The Last Line of Defence 
Activation and/or activity of caspases can be blocked by a family of caspase 
inhibitory proteins called Inhibitor of Apoptosis Proteins (IAP). Members include X-
linked IAP (XIAP), c-IAP1, c-IAP2, survivin, NAIP, Bruce, ILP-2 and Livin [26-29]. 
They are characterized by one or more tandem repeats of an evolutionarily conserved 
70 amino acids domain termed baculovirus IAP repeat (BIR) at their N terminus [30-
32] that enables them to directly bind to, and inhibit caspases. Some IAPs contain a 
C-terminal RING finger domain that has been identified as an essential motif for the 
activity of ubiquitin ligase (E3) which brings about the ubiquitinylation and 
degradation of proapoptotic proteins [33-36]. The best characterized human IAP, 
XIAP, is known to inhibit mature caspase-9 via its third BIR domain (BIR3), while its 
flexible linker connecting BIR1 and BIR2 specifically targets processed caspase-3 and 
7 [37-39]. Additionally, XIAP undergoes RING-domain-dependent 
autoubiquitinylation that marks them for proteasomal degradation. Such 
autoubiquitinylation process is a mechanism through which certain IAPs can 
negatively regulate their activity, hence lowering the apoptotic barrier allowing for 
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cells to undergo apoptosis [40]. On the other hand, XIAP utilizes its E3 ligase activity 
to target active caspase-3 for proteasomal degradation, and in this case, conferring a 
survival advantage against apoptotic signal. Both mechanisms function in a 
counteracting fashion to maintain a fine balance and the regulatory signal through 
which an IAP decides to enhance degradation of itself or their targets still remains 
unclear. Another fascinating aspect between caspases and IAPs is found in the 
bidirectional inactivating effect they have on each other. IAPs inhibit caspases [41], 
yet this interaction comprises an intrinsic regulatory mechanism whereby active 
caspases can cleave, and inactivate, IAPs. So far, XIAP, c-IAP1 and Livin have been 
reported to undergo specific and functional cleavage by caspases [42-45]. Cleavage of 
XIAP produces 2 subunits: one that comprises of BIR1 and BIR2, and the second, 
BIR3-RING. The N-terminal BIR1-2 fragment has a reduced propensity to inhibit 
caspase-3 and 7, while the BIR3-RING still retains its ability to inhibit caspase-9. 
However, this fragment is unable to inhibit Fas-induced apoptosis, and it has been 
postulated that this cleavage product may act in a dominant negative manner by 
sequestering full-length XIAP and thus, abolishing its inhibitory effect on caspase-9. 
In some cases, IAP-mediated inhibition of caspases can be prevented by an IAP 
antagonist such as Smac/DIABLO [46], Omi/Htra2 and XIAP associated factor 1 
(XAF-1) that binds to the BIR domains of IAPs [47, 48]. Mitochondrial 
Smac/DIABLO [49], along with cytochrome c, is released into the cytosol and binds 
to IAP during apoptosis, eliminating the interaction between caspases and IAPs, thus 
antagonizing their inhibitory activity on caspases while XAF-1, a nuclear protein, has 
been observed to sequester XIAP in the nucleus [50].  
Intensive studies on how caspases are activated during apoptosis have lead to the 
identification of two forms of cell death, namely, receptor-mediated (Extrinsic/Type I) 
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and mitochondrial-dependent (Intrinsic/Type II) pathway. Both forms are 





Figure 1: Two major apoptotic death signaling pathways in the cell. The extrinsic 
death pathway is exemplified by binding of CD95 ligand to CD95 death receptor, 
while the intrinsic or mitochondrial apoptotic signaling is usually a result of cellular 
insults such as DNA damage. The two pathways are interlinked by Bid, which could 




2.3.4 Mitochondrial-dependent (Intrinsic) Apoptosis 
 
The mitochondrial-dependent pathway can be activated in response to a variety of 
stressful stimuli such as UV irradiation, cytotoxic drugs such as vincristine, etoposide 
or during withdrawal of growth factors. These would cause a perturbation on the 
membrane of the mitochondria, thus triggering the induction of apoptosis mainly by 
inducing the release of caspase-activating proteins, such as apoptosis inducing factor 
(AIF) [55], Smac/DIABLO and cytochrome c [56] into the cytosol. Cytosolic 
apoptotic protease activating factor-1 (Apaf-1), containing a caspase recruitment 
domain (CARD), binds with procaspase-9, along with ATP and the released 
cytochrome c, to form a signaling platform called apoptosome that results in the 
autocatalytic processing and activation of initiator caspase-9 [57, 58]. This then 
activates the executioner caspase cascade, including caspase-3/6/7, leading to 
eventual controlled breakdown of the cell.  
 
2.3.4.1 Permeabilization of the mitochondria 
Mitochondria membrane permeablization (MMP) can occur via outer or inner MMP. 
However, these mechanisms by which MMP occur are not mutually exclusive to each 
other. Mitochondrial outer membrane permeabilization (MOMP) involves members 
of the Bcl-2 family, who play important roles in promoting or inhibiting apoptosis by 
inducing the release of proapoptogenic factors from the mitochondria or by 
safeguarding the integrity of the mitochondria membrane against such release [59-61]. 
Mitochondria inner membrane permeabilization involves the mitochondrial 
permeability transition pore complex (PTPC) formed at the contact sites between the 
outer and inner mitochondria membranes have been suggested to play important roles 
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in the mechanism of cytochrome c release from the mitochondria during 
mitochondria-dependent apoptosis. The main components of the PTPC include the 
voltage dependent anion channel (VDAC), the outer membrane protein and adenine 
nucleotide transporter (ANT) on the inner mitochondria membrane [62, 63]. The 
PTPC also includes several other proteins like hexokinase II, mitochondrial creatine 
kinase as well as cyclophillin-D [64], which all have a role in modulating the activity 
of PTPC. The PTPC usually exists in a closed conformation, however, various stimuli 
such as reactive oxygen species [65], ions (mainly Ca2+ and Mg2+) [66, 67], depleted 
adenine nucleotides [68] and changes in mitochondrial membrane potential levels, can 
cause the PTPC to adopt an open conformation, allowing for the entry of water and 
solutes. This causes physical rupture of the outer mitochondria membrane as the 
mitochondria swells resulting in the release of proapoptogenic proteins from within.  
As mentioned earlier, inner and outer MMP are not mutually exclusive events. 
MOMP can be mediated by both the proapoptotic Bcl-2 family proteins [69] as well 
as the PTPC [70]. And conversely, there are also emerging evidence that the Bcl-2 
family proteins are significant in regulating the opening of PTPC by interacting 
directly with ANT or inhibiting the activity of VDAC [71-75].  
 
2.3.4.2  Bcl-2 family  
The first mammalian homologue of the negative regulator for apoptosis, CED-9 in 
nematode Caenorhabditis elegans, is the anti-apoptotic Bcl-2 protein [76]. It was first 
discovered when the B-cell lymphoma 2 (Bcl2) gene, activated by chromosomal 
translocation in human follicular lymphoma, was discovered to promote proliferation 
rather than inhibiting cell death [77]. This discovery established that cell survival and 
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death were under different genetic control and that disturbances in both were likely to 
be crucial in oncogenesis.  
Mammalian Bcl-2 has at least 20 relatives, all of which contain at least one conserved 
Bcl-2 Homology (BH) domain (BH1 to 4). This family of BH-containing proteins 
includes the antiapoptotic Bcl-2, Bclw, BclxL and Mcl-1 as well as two other groups 
of proapoptotic proteins; consisting of the Bax and the BH3-only proteins [59]. The 
antiapoptotic proteins contain all four BH domains, as well as a hydrophobic 
carboxyl-terminal domain that targets them to the cytoplasmic face of three 
intracellular membranes: the nuclear envelope, the endoplasmic reticulum (ER) and 
the outer mitochondria membrane. Bcl-2 is an integral outer mitochondria membrane 
protein under normal physiological conditions and serves to maintain its integrity, 
preventing the release of apoptogenic proteins from the mitochondria. It has also been 
found to play a role in ER stress induced apoptosis, whereby it modulates ER calcium 
homeostasis through enhancing calcium transport across the ER membrane [78]. Mcl-
1 and BclxL are two major anti-apoptotic Bcl-2 family proteins expressed in the liver 
and cooperatively control hepatic integrity during liver development [79]. Mcl-1 has 
also been found to be involved in cortical neurogenesis and for ensuing the survival of 
neurons after DNA damage [80]. Bclw mediates survival of postmitotic Sertoli cells 
and it has been observed that mice that contain mutant Bclw display progressive and 
nearly complete testicular degeneration [81-83].  
Members of the Bax proapoptotic family proteins, such as Bax, Bak and Bok, contain 
sequences that are similar to those in those in Bcl-2, mainly in the BH1, BH2 and 
BH3 regions. Bax and Bak are were believed to function mainly at the mitochondria 
and it is widely accepted that the presence of either Bax or Bak is required for 
efficient induction of apoptosis as inactivation of both genes impaired apoptosis in a 
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range of tissues. Bax exists as an inactive cytoplasmic monomer in healthy cells, 
sequestered by various proteins such as 14-3-3 proteins [84] and the heat shock 
proteins, but changes conformation during apoptosis and translocates to the OMM and 
oligomerizes. On the other hand, Bak is an oligomeric integral mitochondria 
membrane protein which changes its conformation to form larger aggregates that 
compromises mitochondrial membrane integrity during apoptosis. Oligomerization of 
Bax/Bak is believed to provide or contribute to the permeabilization of the OMM, 
allowing for the efflux of proapoptotic proteins, as mentioned in the previous section. 
However, the mechanism the release of proteins still remains controversial. One 
school of thought alludes to the ability of Bax/Bak to form channels and consistent 
with this hypothesis is the observation that Bax oligomers can form pores in 
liposomes that allow passage of cytochrome c [85, 86]. Alternatively, Bax might 
interact with components of the PTPC such as VDAC for translocation of apoptotic 
proteins into the cytosol. Shimizu S et al, 2000 provided direct evidence that VDAC 
and Bax forms a novel channel that allows for passage of cytochrome c in a planar 
lipid bilayer. Interestingly, Bax and Bak have been found to reside in the ER as well, 
and are able to control apoptosis/proliferation via regulating ER calcium levels [87]. 
A recent study revealed that reticular Bak retains its ability to induce release of 
cytochrome c from the mitochondria in response to ER targeted BH3-only proteins, 
demonstrating an ER-to-mitochondria signaling route that is independent of the 
canonical Bax/Bak-dependent mitochondrial gateway [88]. Additionally, when co-
expressed with BclxL, Bak induces dramatic conformational modifications and 
swelling of the reticular cisternae [89], but Bax was shown to lack this potential, 
indicating that both multidomain homologues may not always carry out a completely 
overlapping range of cellular activities. Whilst Bax and Bak are widely distributed, 
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expression of Bok has been found to prevalent in the reproductive tissues. It has been 
observed to translocate to the nucleus [90], and has been suggested to be an essential 
mediator of p53-dependent apoptosis [91], as well as being under the regulation of the 
cell cycle [92].  
The third class of proapoptotic Bcl-2 members is the BH3-only proteins and as its 
name suggests, these members share homology with its other relatives only in the 
BH3 domain. Bid, Bim, Bad, Noxa and Puma are several members from this family 
and they usually act by binding to, and neutralizing their pro-survival relatives [93, 
94] or binding to, and activating the proapoptotic Bcl-2 members [95-98]. Individual 
BH3-only proteins are usually held in check by diverse mechanisms such as 
sequestration by proteins such as dynein light chains or scaffold protein 14-3-3 for 
Bim [96] and Bad [99] respectively. Bid is kept in its inactive state until proteolytic 
processing by several proteins including caspase-8 or [100] c-Jun-N-terminal kinase 
(JNK) [101] while Noxa and Puma are under transcriptional regulation [102, 103].  
 
2.3.5 Receptor-mediated (Extrinsic) Apoptosis  
In contrast, the extrinsic pathway utilizes plasma membrane ―death receptors‖ to 
efficiently engage the caspase cascade. Ligand binding to its cognate death receptor 
leads to receptor oligomerization and assembly of the Death Inducing Signaling 
Complex (DISC), a signaling platform similar to Apaf-1, where procaspase-8 [104] is 
recruited and undergoes proteolytic cleavage and activation. Death receptor signaling 
is mediated by members from the Tumor Necrosis Factor (TNF) ligand and receptor 
superfamily. However, the subsequent events following death receptor activation 
leading to apoptosis has been proposed to be dependent on it being a type I or type II 
cells [51, 52]. Type I cells have been observed to undergo robust initiator caspase-8 
15 
 
activation [105], committing the cells to apoptosis, that is sufficient to induce a strong 
amplification signal through the downstream executioner caspases like caspase-3/6/7, 
leading to cell death. On the other hand, type II cells only weakly activate initiator 
caspase-8, insufficient to generate a strong proapoptotic signal, and so require the 
involvement from intrinsic mitochondrial pathway described in the earlier section 
[51]. A molecular link between the death receptor and the mitochondrial apoptosis 
pathway can be found at the level of cytosolic Bid, a member of the BH3 domain-only 
subgroup of Bcl-2 family [100] that is a cleavage substrate for activated caspase-8. 
Cleaved bid (tBid) then translocates to and activates the mitochondrial-dependent 
pathway to augment the apoptotic signal from the death receptors [106]. 
Overexpression of antiapoptotic protein Bcl-2 can block apoptosis in type II but not in 
type I cells [51, 107]. However, such exact classification of cells as type I or type II 
has been debated in recent years. Further studies have shown that death receptor 
mediated signaling in certain type I cells also require mitochondrial events such as 
loss of mitochondrial transmembrane potential and cytochrome c release similarly to 
other type II cells [108]. They suggested that it is perhaps the speed of caspase-8 
activation that differs between both types of cells, with type I having a rapid and more 
extensive DISC formation upon death receptor activation.  
 
2.3.5.1  TNF superfamily ligands and receptors 
The discovery of TNF-α arose from studies of the effects of endotoxin-induced serum 
factors capable of mediating tumor regression, leading to an intense interest in the 
application of this molecule for therapeutic purposes [109]. Only in the last two 
decades has it become apparent that TNF-α is a representative member of a large 
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family of cytokines that exert a fundamental effect in cell proliferation and death, 
inflammation, immunological and neuronal cell function. Members like TNF-α, LTβ 
and RANKL provide crucial signals for the morphogenesis of secondary lymphoid 
organs during development while BAFF, CD40-L, OX-40L and CD27-L [110-112] 
are required for development and activation of immune precursor cells to fully 
competent effectors. Pro-apoptotic members include TNF, Fas and TRAIL that 
contribute to the function of cytotoxic effector cells and participate in the homeostasis 
of the lymphocytic cells by inducing activation-induced cell death in immunce cells 
that have fulfilled their functions. These molecules are type II transmembrane 
proteins, characterized by the confinement of the C-terminus of the protein within the 
extracellular space [111]. Although TNF-related ligands are synthesized as 
membrane-bound molecules, most of them also exist as soluble forms, generated by 
specific proteolytic processing of their C-teminus or by alternate splicing of the exon 
encoding the transmembrane domain. For TNF, a zinc-dependent metalloprotease, 
called TACE (TNFα-converting enzyme) has been shown recently to specifically 
cleave TNF [113]. These ligands have a 20-30% identity; in a 150 amino acid domain 
on their C-terminus which is the hallmark of these ligands known as TNF homology 
domain (THD), also the region for binding to their cognate receptors. Family 
members display structural similarities, which are reflected by similar mechanisms of 
receptor recognition and activation. These ligands recognize their receptors through 
the THD which forms a structure composed of anti-parallel β-sheets arranged in a 
jellyroll structure. Structural and biochemical data supports that all active ligands 
exist as homotrimers that activate their receptors through inducing receptor 
oligomerization [114-116].  
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Members of the TNF-receptor superfamily currently form a group of around 29 
proteins including TNF-R1 (p55), TNF-RII (p75), CD40, p75 NGFR, TRAMP, Fas, 
DR4 and DR5. They exist primarily as type I transmembrane proteins and are grouped 
according to the presence of conserved cysteine residues in their extracellular ligand-
binding domain. Generally, receptors from this superfamily contain 2 to 6 of such 
cysteine-rich domains (CRDs), each of which is characterized by a region of 
approximately 6 cysteine residues that are interspersed within a stretch of 40 amino 
acids. Intracysteine disulfide bonds formed between the CRDs of individual subunit 
members promotes the stable formation of a typical functional trimeric or multimeric 
TNF superfamily receptor. The CRDs are also responsible for making distinct 
contacts with its ligand(s).  
A subgroup termed the death receptors has been defined from the TNF-receptor 
superfamily by virtue of their ability to induce apoptosis. They are characterized by a 
similar intracellular region of about 80 amino acids, designated death domain (DD), 
which allows for the transmission of cytotoxic signal upon ligand binding. The first 
published structure of a TNF ligand bound to its receptor was that of LTα bound to 
TNF-R1. The asymmetric unit contains three receptor and three ligands arranged as a 
hexameric complex, whereby a single ligand trimer binds to three receptor molecules 
[114]. Further publications reported similar structures for TRAIL and TRAIL 
receptor-2, confirming that the 3:3 stoichiometry is the likely basis of a signaling unit. 
Transmission of extracellular death signal is triggered upon ligand binding to the 
death receptors and transduced via the cytoplasmic DD region of the receptor 
intracellularly to recruit other DD containing adaptor molecules to the receptor 
signaling complex and facilitating DISC formation. Therefore, receptors lacking a 
viable death domain are unable to transducer this signal and are known as decoy 
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receptors. Here, the focus will be on the three most comprehensive pathways: the 
TNF/TNF-R, Fas-L/Fas and the TRAIL/TRAIL-R pathways [117].  
 
2.3.5.2  TNF and TNF-Receptor 
Whist the initial discovery of TNF uncovered its cytotoxicity, it is now known that 
TNF can induce a plethora of signals in cells, which include cell activation, 
proliferation, differentiation as well as apoptosis. It is predominantly synthesized in 
activated macrophages and observed to bind two receptors, TNF-R1 and TNF-R2 that 
are expressed ubiquitously at comparable levels with the exception of erythrocytes. 
TNF-R1 mediates most biological activities of TNF-α including apoptosis, antiviral 
activity as well as activation of NF-ĸB while TNF-R2 is particularly involved in T-
lymphocytes [118]. Since these receptors are widely expressed, it is not surprising that 
almost all cell types respond to TNF, for example TNF is involved in activation burst 
in neutrophils [119], enhanced cytotoxic activity and cytokine synthesis in 
macrophages [120] and mediates synthesis of acute phase proteins in hepatocytes 
[121]. An important cellular target of TNF is the endothelium where it causes the 
release of platelet-activating factor and various other cytokines, as well as inducing 
the expression of adhesion proteins. These responses results in increased vascular 
permeability, anticoagulant activity and leukocyte adhesion [120, 122].  
Activation of TNF-R1 by TNF-α leads to the recruitment of TNFR1-associated death 
domain protein (TRADD), through homophillic interaction between the DD of both 
proteins, which serves as an adaptor molecule allowing for differential signaling to 
occur via different interactions with a range of signaling intermediates, thus mediating 
various biological outcomes [123]. For instance, TRADD can recruit FADD and lead 
19 
 
to caspase-8 activation and apoptosis via the extrinsic pathway. However, TNF-α is 
not cytotoxic to most cells because TRADD can recruit TRAF-2 (TNF-α receptor 
associated factor-2) [124] and a serine-threonine kinase RIP (Receptor interacting 
protein) to form distinct complexes initiating the activation of NF-ĸB and JNK 
signaling pathways. It has been well established that activation of NF-ĸB serves to 
protect cells against apoptotic stimuli, hence, inhibition of NF-ĸB is required for 
efficient apoptosis induction by TNF-α [125]. Additionally, it has been shown that 
induction of NF-ĸB inhibits TNF-α mediated JNK activation and that blocking of NF-
ĸB results in sustained activation of JNK, promoting TNF-α induced apoptosis. Deng 
et al, 2003 reported that activated JNK induces caspase-8-independent cleavage of 
Bid at a distinct site to generate a cleavage product jBid, leading to the preferential 
release of Smac from mitochondria and subsequently apoptosis [101].  
 
2.3.5.3  CD95-L and CD95-receptor 
CD95, or Apo-1/Fas, was the first member of the TNF receptor superfamily to be 
associated with apoptosis [126]. This receptor is widely expressed, predominantly in 
thymocytes and activated T-cells, and abundantly expressed in the liver, heart and 
kidney. Our understanding of the function of CD95-receptor and its ligand has been 
mainly elucidated by the finding of mutant forms of these proteins in mouse strains 
suffering from autoimmune diseases. Lpr (lymphoproliferation) mice lacking a 
functional CD95-receptor and gld (generalized lymphoproliferative disease) mice 
bearing mutant CD95 both exhibit various autoimmune phenomenons such as 
lymphadenopathy, splenomegaly, and similar symptoms resembling systemic lupus 
erythematosus in humans [127]. Recently, it has been identified that dysfunctional 
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CD95 in children results in autoimmune lymphoproliferative syndrome (ALPS). This 
loss-of-function phenotype in mouse and man indicates the key role of CD95 in the 
regulation of immune response and maintenance of self-tolerance [128, 129]. CD95 
has also been implicated in the progression of viral diseases such as HIV-1 or 
Hepatitis B virus infections where massive apoptosis occurs. It was shown that T-
lymphocytes from HIV-1 infected patients exhibit an elevated expression of CD95 
and sensitivity towards CD95-mediated apoptosis and this process may result in the 
continuous depletion of CD4
+
 T-cells during AIDS disease [130, 131]. A high 
constitutive expression of CD95L detected in Sertoli cells of the testis and epithelial 
cells of the anterior eye chamber lead to the proposal that CD95L is responsible for 
the maintenance of immune privileged sites. This was substantiated by animal studies 
whereby apoptosis is not observed in gld mice upon viral inoculation into their 
anterior eye chamber, leading to destruction of the tissue due to inflammation 
resulting from a failure to eliminate the infiltrating lymphocytes and granulocytes in 
these mice with defective CD95L [132, 133].  
Recent data demonstrated that several chemotherapeutic drugs induced apoptosis via 
inducing CD95-L expression in leukemic, hepatocellular and neuroblastoma cells. 
CD95L neutralizing agents inhibited apoptosis induced by these drugs [134-136]. 
Interestingly, it has been shown that irradiation directly oligomerizes and thereby 
activates death receptors such as CD95 and TNF-R1. This is presumably mediated by 
energy transfer which induces conformational change of the receptors, not requiring 
CD95L expression, but directly engaging the CD95 signaling pathway [137, 138].  
As mentioned briefly previously, induction of death signaling, in this case CD95L, 
occurs through receptor ligation with the trimeric death ligand, which triggers the 
subsequent trimerization of the receptor. The death signal is transmitted via the DD of 
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the clustered receptors, which recruits an adaptor protein, Fas-associated death 
domain protein (FADD), containing both DD as well as a death effector domain 
(DED), enabling it to bind DD of CD95 via homotypic interactions. DED of FADD 
also recruits initiator procaspase-8/10 via interactions with their DED on their long 
prodomains. This entire complex of proteins is termed Death Inducing Signaling 
Complex (DISC) and allows for cross-activation of procaspases-8/10 due to their 
induced proximity at the DISC [139]. Activated caspase-8 can cleave downstream 
executioner caspases like caspase-3 resulting in induction of apoptosis in these cells 
and depending on the type of cells; some might require the involvement of 
mitochondria to amplify the death signal for efficient apoptosis [140]. 
 
3. TRAIL/APO2L AND TRAIL-RECEPTOR 
TRAIl/APO2L and its cognate receptors were characterized more than a decade ago, 
generating immense interest with regards to its distinctive ability to induce tumor 
specific cell death, without affecting normal cells. This cytokine will be discussed in 
greater details within this section, and its role in chemotherapy, in the last section of 
Introduction. 
3.1  TRAIL 
TRAIL was identified by two independent groups based on its sequence homology 
with CD95L and TNF-α, displaying a 28% aminiacid sequence identity to CD95L and 
23% identity with TNF [141]. It is a 281 amino acid-containing type II 
transmembrane protein in which the carboxyl terminus with the receptor-binding 
domain lies extracellularly. Cleavage by cysteine proteases, specifically from 
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monocytes and neutrophils, yields a biologically active soluble form of the ligand. In 
contrast to other members in the TNF super family of ligands whose expressions are 
tightly regulated and only transiently expressed on activated cells, mRNA of TRAILis 
detected in a wide variety of tissues including PBMC, spleen, thymus, prostate, ovary, 
small intestine, colon and placenta but not the liver, testis or brain. Crystal structures 
have revealed that, like other TNF ligands, it occurs as a trimer resembling bell-
shaped, truncated pyramids with variable loops protruding out of a compact core of 
conserved anti-parallel β-sheets (THD). However, TRAIL is unique in its structure, 
with an inner sheet containing a 15-residue long insertion that spans the whole outer 
surface of the monomer. The trimer is assembled by packing the subunits to form 
large and mostly hydrophobic interfaces, resulting in a very stable interaction [142, 
143]. It has also been discovered that Cysteine 230 plays a key role in coordination of 
a Zn(II) ion, with each monomer contributing to one coordination position; and a 
chloride counter ion occupying the fourth coordination position [144, 145]. The zinc 
ion is essential for the structural integrity and, hence, the biological activity of Apo2L. 
Mutation of Cys230 to alanine or serine strongly affected its ability to kill target cells 
by decreasing the stability of its trimeric structure and reducing the binding affinity of 
TRAIL to its receptors (decreased by at least 200-fold).  
 
3.2 TRAIL-receptor 
Subsequent work led to the identification of four novel membrane bound and closely 
related members of the TNF receptor superfamily, as well as a fifth soluble receptor 
that binds TRAIL [141, 146, 147]. The first of which was cloned by using the 
sequence of the death domain from the TNF-R1 to search an EST database. TRAIL-
R1/DR4 (Death Receptor 4) is a 468 amino acid type I transmembrane protein, with 2 
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cysteine-rich (CRD) motifs extracellularly. The cytoplasmic domain contains a DD 
that is similar to that found in TNF-R1 and CD95. The expression pattern of TRAIL-
R1 is as widespread as TRAIL, but it has also been detected in liver, testis and brain. 
Simultaneously, TRAIL-R2/DR5 (Death Receptor 5) was also identified, a 411 amino 
acid receptor also containing 2 CRD motifs, with the same expression pattern [148]. 
Both DR4 and DR5 were capable of eliciting cell death upon TRAIL binding due to 
the presence of intracellular  DD.  
 In contrast, TRAIL-R3/DcR1 (Decoy Receptor 1) and TRAIL-R4/DcR2 (Decoy 
Receptor 2), lacking and containing truncated DD respectively, may act instead as 
antagonistic ―decoy‖ receptors [149, 150]. DcR1 is a 299 amino acid protein lacking a 
cytoplasmic segment, and instead remains bound to the cell via a GPI linker. 
Expression of DcR1 is limited compared to other TRAIL-receptors and while 
overexpression of this receptor confers protection against TRAIL-induced apoptosis, 
removal of DcR1 from the cell surface by phosphatidylinositol phospholipase C 
sensitizes cells to the cytoxic effects of TRAIL. DcR2 has the same widespread 
expression as DR4 and DR5 and was also found to confer protection against TRAIL-
induced death. Overexpression of DcR2 in a TRAIL-sensitive cell line rendered these 
cells resistant to the apoptotic trigger of TRAIL. Additionally, it has also been 
proposed that DcR2 inhibits apoptosis via the activation of the anti-apoptotic NF-ĸB 
pathway [151]. However, no direct correlation between the sensitivities of cells to 
TRAIL and the expression pattern of either DR4/5 or DcR1/DcR2 was observed in 
subsequent studies. Further discussion on the various factors contributing to TRAIL-
resistance in cells will be conducted in the subsequent sections. The fifth, and last, 
receptor for TRAIL has been termed osteoprotegerin (OPG), a soluble dimeric TRAIL 
receptor acting mainly as a regulator of the development and activation of osteoclasts 
24 
 
in bone remodeling. This activity is, however, not due to its interaction with TRAIL. 
The higher affinity ligand for OPG is the TNF-like cytokine TRANCE/RANKL 
which also binds to the receptor activator of NF-ĸB (RANK) [152]. Nonetheless, 
OPG is still able to bind TRAIL, albeit at a lower affinity compared to other TRAIL-
receptors. There is mounting evidence to suggest OPG can act in a paracrine or 
autocrine manner by binding TRAIL and promoting the survival of prostate cancer 
and multiple myeloma cells [153]. It was also observed to promote survival of 
microvascular-endothelial cells, though the role of TRAIL in this has not been 
confirmed. Nevertheless, it is likely that the role of OPG as a survival factor is highly 
dependent on the relative concentrations, the timing, location and expression pattern 
of TRAIL and OPG in the microenvironment. In summary, more work remains to be 
done to study the importance of OPG-TRAIL interaction. 
3.3 Physiological Function for TRAIL 
Animal models of TRAIL knockout mice, the use of neutralizing anti-mouse TRAIL 
monoclonal antibodies and soluble recombinant human DR5 have provided much 
information regarding the expression and physiological role of TRAIL. TRAIL-/- 
mice are viable and display neither heamatological nor reproductive defects in pups or 
adults, indicating that the TRAIL/TRAIL-Receptor system does not have a significant 
role during development.  
Expression patterns of TRAIL provide an indication to its natural function. While 
TRAIL mRNA and protein expression widely found in a variety of cells and tissue, 
studies in mice and humans showed that it is not expressed on the surface of freshly 
isolated T-cells, B-cells, monocytes, dendritic cells, natural killer (NK) cells of NKT-
cells. However, most NK cells, monocytes, peripheral T-cells and dendritic cells 
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express TRAIL after stimulation with interferons (IFN) suggesting an important role 
of TRAIL in innate immunity [154]. IFNs are a family of cytokines, playing essential 
role on immune surveillance, having both anti-viral and anti-tumor effects. It was 
noticed that transcriptional induction of TRAIL is one of the earliest events following 
IFN administration in various cells types and luciferase reporter constructs, 
transfected into Jurkat cells, indicated transcriptional regulation by IFNs. IFNs inhibit 
virus replication by activating apoptosis in infected cells and by inducing an anti-viral 
state in the surrounding, uninfected cells. In response to IFN-γ, cytomegalovirus-
infected human fibroblasts become sensitive to TRAIL-induced apoptosis, while 
neighbouring cells downregulate their death receptors and increase their expression of 
TRAIL. TRAIL expression by NK cells is crucial for limiting viral replication in vivo 
and rous sarcoma virus infected mouse cells are susceptible in vivo to killing through 
TRAIL pathway by immune cells such as NK and CD4
+
T-cells that carry membrane 
bound TRAIL [155]. Conversely, it has been observed that adenovirus inhibit TRAIL-
induced apoptosis by causing internalization of DR5, suggesting that certain viruses 
may prevent apoptotic death in infected cells by blocking the TRAIL pathway. These 
findings indicate that TRAIL may be critical for defense mechanisms that eliminate 
infected cells and limit viral replication [156].  
Furthermore, TRAIL contributes to host immunosurveillance against primary tumor 
development. TRAIL neutralization promoted tumor progression in mice inoculated 
with carcinogen methylcholanthrene (MCA). The increased tumor promoting effect of 
MCA was also observed in TRAIL-/- mice [157]. Moreover, the emergence of 
TRAIL-sensitive fibrosarcoma cells in TRAIL-/- and IFN-deficient mice implies an 
immune selection pressure against TRAIL-sensitive cells during tumor development 
[158]. Lymphoid maglinancies have been reported to develop in more than 25% of 
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TRAIL-/- mice after 500 days of life. Tumors need to develop and gain metatastic 
potential by acquiring resistance to TRAIL if this ligand is involved in immunue 
surveillance against human tumor metastases. Indeed, allelic losses of chromosomal 
segments encoding both DR4 and DR5 have been observed in several cancers, 
including non-Hodgkin‘s lymphoma and lung, breast, colon, prostate, hepatocellular 
and head and neck cancers, suggesting their tumor suppressive role [159, 160]. 
Finally, various roles of TRAIL have been described in autoimmunity. 
Experimentally induced autoimmune diseases in mouse models, such as rheumatoid 
arthritis, diabetes, describe an inhibitory function of TRAIL in the progression of 
these diseases. However, it has also been reported to be involved in the acceleration of 
autoimmune disease. Hence, the general consensus is that TRAIL may exert dual 
fuctions: inhibiting or accelerating autoimmune disease, depending on the time, the 
extent and the location of TRAIL expression [161].  
In summary, although the physiological roles of TRAIL has not been clearly 
delineated, increasing evidence supports its role in immune surveillance against 
oncogenically transformed and virally infected cells, as well as a function in the 
attenutation of autoimmunity.  
3.4  TRAIL Resistance 
Despite early promising results, studies have shown that a number of cancer cells are 
resistant to TRAIL, especially highly maglignant tumors such as pancreatic cancer, 
neuroblastoma and melanomas. Susceptibility to TRAIL-induced apoptosis can be 
regulated at several levels in the apoptosis signaling pathway. Though various 
mechanisms employed by tumors to escape apoptosis induction have been described, 
a general consensus for resistance to TRAIL has not yet been identified. In this 
27 
 
section, we will discuss briefly regarding some of the commonly known mechanisms 
conferring resistance to TRAIL that contributes to varying extents in different tumor 
cells. 
 
3.4.1   Resistance at the DR level 
3.4.1.1  Surface expression of DRs 
Interaction of TRAIL with its cognate receptors TRAIL-R1/R2 triggers the 
transduction of TRAIL-induced apoptotic signaling via the formation of DISC, 
allowing for activation of the downstream death executors, caspases.  Hence, any 
changes with regards to the protein/surface expression of TRAIL-receptors, or to the 
components of the DISC signaling complex has a profound effect on the ability of 
TRAIL to function efficiently as a death inducing ligand. As summarized in Table 1, 
the level of TRAIL-receptors present on tumor cell surface is an apparent regulator of 
TRAIL-induced apoptosis. A lack of expression of TRAIL receptor-1 due to 
epigenetic silencing correlated with resistance to TRAIL-induced apoptosis in ovarian 
cancer cells [162, 163]. Similarly, deficient surface transport leading to reduced 
surface TRAIL receptor-1 increases resistance of colon cancer cells to TRAIL [164]. 
Mutations resulting in loss-of-function TRAIL-receptor 1/2 have also been observed 
in head and neck squamous, breast cancer cells and non-Hodgkin's lymphoma [159, 
160, 165-167].  
 
In addition, post-translational modifications of the death receptors have been 
postulated to play key roles in their abilities to transmit signals upon TRAIL ligation.  
A link between death-receptor O-glycosylation and TRAIL-signaling demonstrates 
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that O-glycosylation promotes ligand-stimulated clustering of DR4 and DR5, which 
mediates recruitment and activation of the apoptosis-initiating caspase-8 [168].  
mRNA expression of the peptidyl O-glycosyltransferase GALNT14 correlated with 
TRAIL sensitivity in non–small-cell lung carcinoma, pancreatic carcinoma and 
melanoma cell lines, whereby overexpression of GALNT14 increased responsiveness 
of cells to TRAIL. Additionally, S-palmitoylation of TRAIL receptor 1 has also been 
identified recently to be required for its raft localization as well as for its ability to 
oligomerize and provide efficient TRAIL-induced signal transduction [169].  
Moreover, sensitivity of cells to TRAIL can also be a function of the ratio of TRAIL-
decoy to –death receptor.  TRAIL receptor 3/4, also known as decoy receptor-1/2, has 
been shown by Mèrino et al, 2006 to differentially inhibit TRAIL by either competing 
with TRAIL receptor 1/2 for binding to the ligand, thus abolishing death signal 
transduction, or is corecruited with TRAIL-receptor 2 within the DISC where it 
inhibits activation of initiator caspase-8 [170, 171]. Furthermore, mutant TRAIL 
receptor-2 can similarly compete for ligand binding by acquiring a decoy attribute as 
demonstrated by Bin et al, 2007 [172]. Such mutant retains their ability to bind 
TRAIL, yet lack the capacity to form functional apoptotic transmitting DISC upon 
TRAIL ligation. Consequently, a perturbation in the ratio of TRAIL-decoy to –death 
receptor surface expression has been implicated in determining responsiveness of 
cells to TRAIL. 
 
3.4.1.2  DISC components: c-FLIP and caspase-8 
Resistance to TRAIL has also been observed to be correlated with high levels of 
cellular FLICE inhibitory protein (c-FLIP) that is able to inhibit activation of caspase-
8 at the DISC. C-FLIP contains two death effector domains (DED), and a caspase-like 
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domain that lacks a cysteine residue critical for catalytic activity accounting for its 
lack of enzymatic activity and inability to transmit death signal induced by TRAIL. Its 
association with the DISC via homotypic interactions with the DED-containing 
FADD blocks the autoproteolytic cleavage of caspase-8 and halts the transduction of 
death signal at the DISC level. Hence, caspase-8/cFLIP ratio is a major determinant of 
TRAIL resistance whereby high levels of cFLIP leads to lack of sensitivity to TRAIL 
that has been observed in various cancer cells including lung and breast cancer cells, 
colon carcinomas, melanomas, hepatocarcinomas, B-cell chronic lymphocytic 
leukemia as well as glioblastomas [173-178]. It has also been noted that low levels of 
caspase-8 protein expression is a determinant of TRAIL resistance in small cell lung 
carcinoma, leukemia cells as well as colon cancer DLD1 cell line. Silencing by 
methylation [163] or a point mutation on the gene and increased degradation of the 
protein [179] resulted in low expression of caspase-8 in these cell lines respectively.  
 
3.4.2 Resistance at the mitochondrial level 
Despite triggering classical extrinsic apoptosis, TRAIL induced death 
signaling also involves mitochondrial death amplification as alluded to in the earlier 
section.  Therefore, inhibitors of MOMP have been shown to adversely effect 
downstream signaling following TRAIL ligation.  These are discussed as follows: 
3.4.2.1  The Bcl-2 Family 
The ratio of pro- versus anti-apoptotic Bcl-2 members is crucial in determining the 
success of death signal propagation and amplification from the initial apoptotic signal 
imparted from the death receptors [97].  Song et al, 2006 showed that increased 
resistance to TRAIL was associated with an increase in Bcl-xL levels using human 
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prostate adenocarcinoma DU-145 and human pancreatic carcinoma MiaPaCa-2 cells 
as a model [180]. This resistance can be reverted by knocking down the expression of 
Bcl-xL. Similarly, there have been reports on the inhibitory effect of other 
antiapoptotic Bcl-2 members, such as Mcl-1 and Bcl-2, on the sensitivities of 
cholangiocarcinoma [173, 181] and colon carcinomas to TRAIL [182]. Conversely, 
TRAIL/Apo2L fails to activate caspase-9 or induce apoptosis in isogenic HCT116 
colorectal cancer cells that are deficient in proapoptotic BAX [183-187]. It has been 
further observed that TRAIL was unable to induce cytochrome c release as well as 
subsequent apoptosis in MEFs in the absence of Bax and Bak [184].  
 
3.4.2.2  The IAP Family 
High XIAP expression has been postulated to be the cause of resistance to TRAIL in 
pancreatic cancer cells and colon carcinoma [188-191]. On the flip side, 
inhibition/downregulation of IAP members restores sensitivities of cells to TRAIL-
induced apoptosis [192-196]. The inhibition of caspases by IAPs can be relieved by 
mitochondrial protein Smac/DIABLO. Smac/DIABLO binds to and inhibits IAPs 
upon its release from the mitochondria during apoptosis, eliminating the interaction 
between caspases and IAPs. Hence, any defect in Smac/DIABLO release from the 
mitochondria will naturally tilt the balance in favor of cell survival in response to 
apoptotic stimuli. TRAIL was shown to cause release of Smac/DIABLO from 
mitochondria [186, 197], but this release was greater in TRAIL-sensitive than in 
TRAIL-resistant melanoma cell lines and was associated with downregulation of 
XIAP levels [197]. Studies by Ng et al, 2002 suggested a major apoptosis resistance 
factor blocking the Apo2L/TRAIL apoptotic signaling events present downstream of 
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the mitochondrial activation in prostate tumor cells, which could be reverted by 
overexpression of Smac/DIABLO [198]. 
3.4.3 Other Signaling pathways involved in TRAIL Resistance 
In addition to the direct involvement of the receptor components and mitochondrial 
amplification loop in the development of TRAIL resistant phenotype, other major 
determinants of cell fate include the phosphatidylinostol-3-kinase (PI3K)/Akt 
signaling pathway, the transcription factor; nuclear factor ĸB (NF-ĸB), the mitogen-
activated protein (MAP) kinases. Each of these well-studied signaling entities plays 
key roles in the death/survival circuitry within a cell and thus, is involved as 
important regulators of TRAIL-induced apoptosis in tumor cells.  
3.4.3.1  The PI3K-AKT Axis 
An oncogene is a gene that has been altered from its original form (proto-oncogene) 
that predisposes normal cells to change into cancerous tumor cells by conferring onto 
the cell proliferative advantage and the ability to resist normal death signaling. An 
oncoprotein is then the transcription product of the oncogene that plays vital roles in 
granting a survival advantage to the cell. The plethora of oncogenes and proteins 
involved in cellular transformation are essentially proteins that are involved in 
proliferation, survival and death signaling and one signaling pathway crucial to the 
development of oncogenesis is the   prosurvival PI3K/Akt module. Jimenez et al, 
1998 were the first to clone and characterize p65-PI3K, a mutant of the regulatory 
subunit of PI3K, that result in the constitutive activation of PI3K, thus contributing to 
cellular transformation. In this regard, PI3K/AKT has generally been shown to exert a 
negative impact on TRAIL-induced death through its ability to increase the 
expression of antiapoptotic protein like c-FLIP, XIAP and Bcl-2 [173, 178, 194, 199-
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201]. The role PI3K/AKT exerts upon TRAIL-induced apoptosis has also been 
validated by genetic studies showing that tumors cells with an activating somatic 
mutation in PI3K are relatively resistance to apoptosis triggered by TRAIL. TRAIL-
resistant ovarian carcinomas, neublastomas, melanocytes, gastric cancers and 
leukemia cells have been observed to contain increased activation of PI3K/AKT [178, 
194, 199, 200].  Furthermore, it has been suggested that, in addition to inhibiting the 
death stimuli triggered by TRAIL, signaling through TRAIL-receptors in TRAIL 
resistant cells could induce cell proliferation instead, via activation of PI3K/AKT 
[202].  
 
3.4.3.2  The Transcription Factor NF-ĸB 
Signaling through TRAIL-receptor1/2 induces the activation of NF-kB, probably 
through RPA-interacting protein (RIP). The NF-kB family of dimeric transcription 
factors participates in the control of inflammatory response, immunue regulation, cell 
proliferation as well as apoptosis. This family is composed of five component 
subunits that form homo/heterodimeric complexes which regulate transcription by 
binding to NF-ĸB consensus sequences on the promoter regions of its target genes 
that include various pro- and anti-apoptotic proteins . This could explain the 
controversial observations that NF-kB can play enhance [203-206] or inhibit [171, 
207, 208] the apoptotic effects induced by TRAIL. Inhibition of  NF-kB activity in 
vitro sensitized tumor cells to TRAIL-induced apoptosis [205, 209], as well as 
mediating TRAIL-dependent tumor regression in vivo while other studies reported the 
pro-apoptotic role of NF-kB  in TRAIL-induced death via its ability to upregulate 
TRAIL-receptor 4 or through downregulating XIAP [205, 206]. Additionally, it has 
also been demonstrated in TRAIL-resistant cells that activation of NF-kB stimulates 
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these cells to undergo proliferation or enhanced survival.  Tumor cells with defective 
death receptor signaling showed NF-kB –dependent enhanced proliferation or 
metastasis and invasion. A plausible scenario is that when apoptosis is suppressed in 
these tumor cells, TRAIL-mediated activation of NF-kB activation tilts the TRAIL 
signal from induction of apoptosis to promoting cellular proliferation/survival in the 
absence of an effective apoptotic signal transmission from TRAIL-receptors.  
However, Rajani Ravi et al, 2001 have proposed that such observations regarding the 
disparity in the role of NF-kB in tumor cells could be due to the differential roles of 
RelA (p65) and c-Rel subunits of NF-ĸB. The relative levels of these subunits were 
postulated to determine whether NF-ĸB favors apoptosis or survival. Overexpression 
of RelA reduces caspase-8, DR4 and DR5 expression while increasing that of IAP1/2 
after TRAIL treatment and is largely anti-apoptotic. Conversely, overexpression of c-
Rel enhances DR4, DR5, and Bcl-Xs and inhibits cIAP1, cIAP2, and survivin after 
TRAIL treatment rendering it largely proapoptotic. Hence, even with a blockage in 
the canonical death receptor pathway, TRAIL ligation stimulates activation of NF-ĸB, 
and depending on the relative levels of RelA or c-Rel, induces tumor cell proliferation 
or death respectively.  
 
3.4.3.3  The MAPK Pathway 
Lastly, the MAP kinases are a superfamily of proteins that transduces a large variety 
of extracellular stimuli into and are crucial for the maintenance of intracellular 
processes such as growth and development, apoptosis and responses to external 
stresses. The three main subfamilies identified are: extracellular signal-regulated 
kinases (ERKs), c-Jun N-terminal kinases (JNKs), and p38-MAPKs. It has originally 
been shown that ERKs are important for cell survival [210] whereas JNKs and p38-
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MAPKs were deemed important transducers for stressful signals and thus involved in 
apoptosis. However, studies unraveled further intricacies in the role these kinases play 
in determining the ultimate fate of a cell; depending upon the context i.e. cell type and 
its intracellular mileu, or the type of extracellular signals that triggers the kinases. All 
three kinases have been found be activated in response to TRAIL stimulation, though 
they are conflicting reports suggesting that ERK, JNK or p38 signaling can either 
suppress, or enhance the apoptotic efficacy of TRAIL [190, 202, 211-217]. Activation 
of ERKs has been observed not to be strictly pro-survival [200, 216, 218, 219] and it 
has been reported that activation of the death inhibitory ERK1/2 signaling pathway 
overrode the apoptotic signal from Fas, TNF and TRAIL receptors in HeLa cervical 
cells. Stimulation of these receptors rapidly induced ERK1/2 activation and they 
showed that inhibition of this signaling pathway was sufficient to sensitize the cells to 
apoptotic signaling from death receptors. This is corroborated by Tae-Jin Lee et al, 
2006 [190] and G Ortiz-Ferrόn et al, 2006  who independently demonstrated the 
inhibitory role of ERK1/2 in relation to TRAIL-induced apoptosis. Similarly, there 
have been contrasting conclusions regarding the function of JNK/p38 with regards to 
TRAIL sensitivity. Mucha, S R et al, 2008 observed that JNK inhibition sensitises 
hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related 
apoptosis-inducing ligand [211]. This lead them to conclude that expression and 
TRAIL-dependent feedback activation of JNK likely represent a mechanism by which 
cancer cells escape TRAIL-mediated tumor surveillance, suggesting that JNK 
signaling in this context hampers the death trigger of TRAIL. On the other hand, other 
groups have shown that activation of JNK/p38 actually sensitizes the tumor cells to 
TRAIL-induced apoptosis [216, 217, 220]. Hence, it would appear that the eventual 
outcome of activation of MAPKs induced by TRAIL is highly contextual dependent; 
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perhaps reflecting molecular variations between different cell types or inconsistencies 
in experimental setups.  
3.5 Strategies to Restore Cancer Cell Sensitivity to TRAIL 
Tumor cells engage a variety of mechanisms to evade TRAIL-induced 
apoptosis as summarized in Table 1, resulting in either a moderate or complete 
resistance to this death-inducing ligand.  Identifying such underlying mechanisms of 
resistance provides a rational approach towards the design of novel compounds, or a 
complementation with existing therapies, that serve to re-sensitize such resistant 
tumor cells to TRAIL. Knowledge of the root cause of resistance in a particular tumor 
setting and efforts in thwarting its effects would allow for successful implementation 
of TRAIL as an anti-tumor agent. Interestingly, and fortunately,  it has been observed 
in a number of studies that treatment of resistant cells with either TRAIL or subtoxic 
doses of the sensitizing drug has minimal effect on cell viability. Yet, they produce 
marked synergistic effect when used in combination. The crux of the matter lies in 
providing, or enhancing, a proapoptotic environment for a more effective death 
stimuli transduction upon TRAIL ligation to its receptors, or in dampening the 
dominant prosurvival/anti-apoptotic mileu within the resistant tumor cells that is 
achieved upon application of another drug in combination with TRAIL. As such, the 
measures initiated for re-sensitizing tumor cells to TRAIL can be broadly classified 
into several groups; mainly drugs/compounds that has an effect on the death 
receptors, the proteins involved in the induction of mitochondrial-dependent apoptosis 
or major proteins involved in the execution of apoptosis. In this section, we discuss in 
further detail, the molecular mechanisms by which drugs re-sensitize or enhance 
sensitivity of tumor cells to TRAIL-induced apoptosis. 
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Level of TRAIL resistance Proteins involved Causes Ref 
Receptor and DISC signaling TRAIL receptor -1 and 
TRAIL receptor -2 
Reduced levels of cell surface receptor available for transmitting apoptotic signal  due 
to: 
Downregulation of total receptor protein levels through silencing of receptor gene 
1) Deficient transport of receptors to cell surface 
2) Intracellular retention of receptors 
3) Constitutive receptor endocytosis 
[162, 164, 221-
223] 
  Dysfunctional receptor due to: 
1) Mutation on receptor gene 
2) Post-translational modifications: Lack of O-glycosylation/palmitoylation on 
receptors 
[160, 168, 169, 
223] 
 Decoy receptors 1/2/3 1) Competitive binding with TRAIL receptors 1/2 for TRAIL 
2) Forms dysfunctional receptor complexes with TRAIL receptors 1/2  
[170, 171, 224, 
225] 
 FLIP Increase in protein levels has inhibitory effect on activation of initiator Caspase-8 at 
DISC 
[173-177, 190, 
191, 223, 226] 
 Initiator capases-8 Reduced protein levels via: 
1) Epigenetic silencing 
2) Accelerated degradation 
[163, 179, 227] 
Mitochondria dependent signaling Prosurvival Bcl-2 members Increase in levels of Bcl2/BclxL/Mcl-1: Blocks release of pro-apoptotic factors from 
mitochondria 
[173, 180, 181, 
188, 207, 228-
231] 
 Proapoptotic BH3-only 
members 
Deficiency/mutation in Bax protein: Negative effect on release of pro-apoptotic factors 
from mitochodria 
[183, 184, 187] 
 SMAC/DIABLO Defective release from mitochondria – unable to play inhibitory role on IAPs [189, 197] 
 Imhibitor of apoptosis 
protein 
Increase in XIAP /survivin protein levels – inhibits activation/activity of caspases-3/9/7 [189] 
Other major signaling pathways NFKB Predominant signal in TRAIL-resistant cells due to its ability to upregulate 
antiapoptotic proteins e.g. XIAP, cFLIP, Bcl-xL, TRAIL receptor-3 
[171, 207, 232] 
 MAPKs Controversies  with regards to their role in TRAIL-induced apoptosis [200, 202] 
 PI3K-PKB/Akt Prosurvival signaling pathway, able to increase anti-apoptotic proteins  thus inhibiting 
TRAIL-induced apoptosis 
[173, 178, 194, 
200] 
Table 1: Mechanisms of resistance in cancer cells to TRAIL-induced apoptosis.  
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3.5.1 Modulation of the extrinsic pathway  
Ligation of TRAIL to its cognate receptors represents the apical event in induction of 
apoptosis. Hence, compounds that are able to either increase the number of functional 
TRAIL-receptors on the cell surface, or facilitate ligand binding, thus enhancing DISC 
apoptotic signaling upon application of TRAIL represents a logical and viable method to 
improve the sensitivities of cells, specifically tumor cells, to TRAIL-induced apoptosis. 
Indeed, various independent studies have demonstrated the ability of several compounds, 
or chemotherapeutic drugs, to re-sensitize tumor cells to TRAIL-induced apoptosis via 
the above mentioned mechanisms. 
 3.5.1.1 Upregulation of death receptor 
Naturally occuring flavonoids, or its derivatives, such as quercetin [233], LY303511 
[216], luteolin [234] and apigenin [235] have been  used in various studies to restore or 
enhance the sensitivities of tumor cells to TRAIL-induced apoptosis. Shenoy et al, 2008 
have recently demonstrated the ability of LY303511, an inactive analogue of LY294002, 
to enhance the sensitivity of SHEP-1 neuroblastoma cells to TRAIL-induced apoptosis. 
Pretreatment of these cells with LY303511 resulted in a MAPK-dependent surface 
upregulation of DR4 and DR5 allowing for more interaction with TRAIL, leading to 
increased caspase-8 activation and thus, increased apoptosis. It is noteworthy that several 
of these compounds, in combination with TRAIL, did not exhibit toxicity towards normal 
cells as compared to their tumorigenic counterparts in vitro. In addition, induction of 
apoptosis by the combined treatment with quercetin and TRAIL was not blocked by 
overexpression of Bcl-xL, which is known to confer resistance to various 
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chemotherapeutic agents. These results suggest that this combined treatment may provide 
an attractive strategy for treating tumors with intrinsically defective mitochondrial 
apoptotic machinery.  
Several chemotherapeutic drugs have been shown to also increase the protein 
levels of death receptors [236, 237]. Nimmanapalli, R., et al 2001, showed that 
pretreatment of prostate cancer cell with paclitaxel enhances TRAIL-induced apoptosis 
by inducing death receptors 4 and 5 protein levels and such increase in receptor levels 
was similarly observed with the use of common chemotherapeutic drugs like vincristine, 
vinblastine, etoposide, camptothecin, and adriamycin. The investigators reported that the 
sequential treatment of xenografted nude mice with these chemotherapeutic drugs 
followed by TRAIL resulted in a complete eradication of established tumors and 
achieved survival without detectable toxicity [238].  
Extensive studies on the mechanism of death receptor upregulation have 
demonstrated that many of these sensitizing drugs upregulates the DRs transcriptionally. 
The increase in mRNA levels of DR4 and DR5 has been attributed to transcription factors 
such as p53, NF-κB, C/EBP Homologous Protein (CHOP) and Activating Protein-1 (AP-
1) [204, 239-242].  
 
3.5.1.2 Oligomerization of death receptors – enhanced receptor-mediated 
apoptotic signal 
Receptor clustering is a natural phenomenon observed for various receptors including the 
B-cell receptor, TCR-CD3 complex, platelet-derived growth factor receptor and members 
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of TNF family receptors like TNF, DR5 and CD95. Ligand-induced receptor clustering 
results in a high local density of receptors, transactivation of receptor-associating 
signaling molecules and a local assembly of the signaling elements of the activated 
receptors, thus facilitating the transduction of extracellular signal into the cell. Research 
by various groups has implicated the role of rafts in enhancing cytotoxicity of the death 
ligands through aggregation of cognate receptors into specific microdomains on 
membrane termed lipid rafts (Table 2). Delmas, Rebe et al, 2004 showed that 
redistribution of CD95, DR4 and DR5 in rafts account for the synergistic toxicity of 
resveratrol and death receptor ligands in colon carcinoma, and that such synergy is 
independent on upregulation of total receptor protein levels. This redistribution facilitates 
the caspase cascade activation in response to death receptor stimulation.   
The aggregation of death receptors at the cell surface is also postulated to enhance the 
sensitivity of these tumor cells to TRAIL-induced apoptosis since it has been shown that 
TRAIL can bind receptor trimers that are pre-clustered.  In support of this school of 
thought, chemotherapeutic drugs such as doxorubicin and cisplatin have been observed to 
potentiate the cytotoxicity of TRAIL, as well as CD95L via ceramide-enriched membrane 
platforms. It has also been noted that quercetin sensitizes colon adenocarcinoma cells to 
TRAIL-induced apoptosis via redistribution of death receptors in lipid rafts without any 





Figure 2: The cellular role of ceramide: Death receptors, e.g. CD95, trigger a 
translocation of the ASM onto the cell surface. Surface ASM releases ceramide that 
induces a fusion of small rafts to large ceramide-enriched membrane platforms. These 
platforms serve to mediate clustering of activated receptor molecules, which is a pre-
requisite for the initiation of cellular signaling. 
 
Additionally, our work has established the importance of death receptor clustering 
whereby pre-incubation of HeLa cervival carcinoma cells with the quercetin derivative, 
LY303511, resulted in an increase in  immunoprecipitated cross-linked oligomerized 
DR5 using limiting amounts of anti-DR5 antibody in the pull-down experiment. This was 
further confirmed using gel filtration to study the presence of higher molecular weight 
DR5 clusters in cells treated with LY30 as compared to untreated cells [244]. 
Corroborating these data are studies on cyclooxygenase-2 (Cox-2) inhibitors that are 
known to increase TRAIL efficacy by rearrangement of the extrinsic pathway proteins 
such as DR5, FADD and caspase-8 followed by DR5 clustering into lipid rafts or 
caveolae [245]. Similarly, aplidin is an antitumor agent that has been shown to activate 
the extrinsic apoptotic pathway in Jurkat cells via lipid raft clustering of DR5 [246] and 
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the polypheonl, resveratrol has also been observed to sensitize colon carcinoma cells to 
TRAIL by inducing death receptor clustering [247]. 
3.5.1.3  Downregulation of c-FLIP protein 
Research has convincingly shown the inhibitory effect c-FLIP has on the extrinsic 
pathway of apoptoisis due to its structural similarity to caspase-8, bequeathing it the 
ability to act as its negative competitor at the DISC level. Selective inhibition of c-FLIP 
expression with small interfering RNA oligonucleotides (siRNAs) has been found to be 
sufficient to sensitize tumor cells for TRAIL-induced apoptosis. Interestingly, drugs such 
as quercetin and rosiglitazone that have been shown to sensitize tumor cells to TRAIL 
through upregulation of death receptors were also observed to be able reduce cellular 
levels of c-FLIP. Conversely, overexpression of c-FLIP abolished their abilities to 
sensitize tumor cells to TRAIL cytotoxicity. Down-regulation of c-FLIP by TRAIL 
sensitizing drugs was shown to involve different mechanisms. Compounds like 
withaferin A regulate both c-FLIPs and c-FLIPL transcriptionally in a NF-κB dependent 
manner, whereas quercetin and silibinin decreases protein levels of c-FLIP by regulating 
it at the post-transcriptional level via proteasomal degradation [233, 248].  
 
 
3.5.2  Modulation of Intrinsic Pathway  
3.5.2.1   Downregulation of IAPs   
As discussed earlier, various studies have clearly shown the importance of IAP family 
members in the regulation of TRAIL responsiveness in tumor cells [249] and 
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experimental downregulation such as silencing of IAP gene or pharmacological inhibition 
e.g. embelin [192, 250] of its members such as XIAP and survivin have been shown to 
effectively eradicate TRAIL resistance in melanoma cells, prostate cancer and leukemic 
cells [188, 193, 250, 251]. Additionally, since the presence of its negative inhibitor, 
Smac/DIABLO, serves to negate the inhibitory effects of IAPs, various investigators 
have reported a sensitizing effect on TRAIL-induced apoptosis in resistant tumor cells 
through using Smac mimetics/peptides [252, 253] or overexpression of Smac/DIABLO 
[254]. 
3.5.2.2  Downregulation of the anti-apoptotic Bcl-2 proteins 
Early studies have demonstrated the correlation between increasing Bcl-2 levels and 
TRAIL resistance, as well as the critical role this family of anti-apoptotic proteins play in 
engaging the mitochondrial cell death pathway [61, 255] to amplify the apoptotic signal 
transduced by TRAIL from the death receptors. Moreover these proteins have also been 
observed to be upregulated in a variety of tumors and as such, they have been targeted for 
inhibition in order to restore the apoptotic signaling through the mitochondria. Drugs that 
downregulates [256-258] or inhibits [259, 260] members of the anti-apoptotic Bcl-2 
family or activators of its pro-apopototic members, like Bax [261], were shown to 
enhance TRAIL-induced cell death in tumor cells successfully. Similarly, BH3 mimetic 
was demonstrated to potentiate TRAIL-mediated apoptosis by unsequestering Bim and 






Intrinsic and acquired resistance to conventional chemotherapy and radiation therapy has 
been a major obstacle for clinical oncology. Most DNA-damaging drugs-induced 
apoptosis usually requires the function of the tumor suppressor p53, which engages 
primarily the mitochondrial-dependent signaling pathway. However, tumor progression 
as well as conventional treatments eventually select for tumor cells in which p53 is 
inactivated thereby resulting in resistance to therapy. As such, a direct induction of cell 
death, circumventing the usual mitochondria-dependent elimination of tumor cells 
induced by these conventional therapies, through activation of death receptor-mediated 
apoptosis presents an alternative approach. 
 It is of utmost importance that the safety of these death-inducing ligands is guaranteed in 
the clinical situation for their eventual applications in chemotherapies. CD95L, TNF and 
TRAIL have received particular attention because they can induce apoptosis in 
transformed cells. However, the potential utility of systemically administered CD94L and 
TNF is limited by their acute toxic effects on normal cells in vivo, thereby limiting their 
potential widespread use in the treatment of cancer. TNF at high dose has shown low 
anti-tumor activity and severe sepsis-like toxicity with hypotension, dyspnea, fever and 
rigors while severe liver toxicity has been observed in systemic administration of rhFas 
due to Fas-mediated apoptosis in hepatocytes.  
3.6.1 TRAIL therapeutic approach 
TRAIL generated great excitement when it was reported that while it was able to exert 
cytostatic or cytotoxic effects in vitro on 32 of 39 cell lines from colon, lung, breast, 
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kidney, brain and skin cancer, several normal cell types were resistant in vitro to 
apoptosis induced by rhTRAIL [263]. It is noteworthy that there were no apparent 
relationships between the relevant molecular markers such as p53 and the sensitivity of 
cell lines to rhTRAIL. In addition, injection of recombinant TRAIL induced tumor cell 
apoptosis, suppressed tumor progression, and improved survival in mice bearing solid 
tumors, without causing tissue damage [154, 264]. This was observed in mouse 
xenografts models including breast, colon carcinomas, gliomas as well as multiple 
myeloma. The safety profile of TRAIL has also been evaluated in non-human primates 
due to the high homology in sequence identity of TRAIL and TRAIL receptors between 
human and these species. Human TRAIL, DR4, DR5, DcR1, DcR2 and OPG showed a 
97-99% extracellular sequence identity with chimpanzee while there is an 84-99% 
extracellular protein sequence identity between cynomolgus monkey and human 
counterparts. Disposition and safety assessment of recombinant human TRAIL 
(rhTRAIL) in rodents and non-human primates revealed no abnormalities 
associated with rhTRAIL exposure and that rhTRAIL is rapidly eliminated from the 
serum of all species studies [265].  
Unexpected warning concerns arose when human hepatocytes and neuronal cells were 
later shown to be TRAIL-sensitive. Jo et al, 2000 compared the sensitivity of hepatocytes 
isolated from  rats, mice, rhesus monkeys and human to TRAIL-induced apoptosis and 
found that TRAIL induced apoptosis in normal human hepatocytes in culture but not in 
hepatocytes isolated from the other species [266]. Furthermore, numerous preclinical 
studies utilizing different forms of recombinant TRAIL showed varying  levels of toxicity 
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Targets Drug/compound Mode of action Ref 
Receptor and DISC 
signaling 
HDAC inhibitor Shown to upregulate TRAIL-receptors/induce mitochondrial dependent apoptosis [267-269] 
 Paclitaxel, 15d-PGJ2, doxorubicin, 
Luteolin, Thapsigargin, etoposide, 
Apigenin, LY303511, camptothecin, 
silibinin, withaferin A, andrographolide 
Upregulating protein levels of TRAIL-receptor 1/2 [216, 234, 235, 238, 
240-242, 248, 270-
274] 
 Resveratrol, Doxorubicin, Quercetin, 
Aplidin 
Redistribution of TRAIL-receptors into lipid rafts, sensitizing cells to TRAIL-induced 
apoptosis 
[243, 246, 247] 
 Cisplatin, 5-fluorouracil Enhances DISC formation and apoptotic signaling  induced by TRAIL [275] 
  PPARγ Ligands, Silibinin, Withaferin A, 
Quercetin 





Bypasses Bcl-2 block on mitochondria apoptotic signaling, by binding to and inhibiting 
IAPs 
[253, 254] 
 Embelin 1. Inhibits XIAP 
2. Downregulates c-FLIP(S) 
[192, 279, 280] 
 Mithramycin A, kaempferol Reduces XIAP protein levels [196, 281] 
 HA14-1, BH3I-2, Gossypol, Daidzein, 
ABT-737, myricetin 
 Downregulates Bcl-2 or small molecule Bcl-2/Bcl-xL inhibitor or BH3 mimetic activity. [260, 262, 282-286] 
 Roscovitine, Kaemferol and Rottlerin Downregulates survivn and XIAP proteins [287-289] 
 Sorafenib Muitikinase inhibitor; inhibits Raf resulting in downregulation of Mcl-1 [230, 258] 
 flavopiridol Diminishes Mcl-1 expression [181] 
 Gefitinib EGFR  inhibitor; inhibits phosphorylation of Akt, and enhances TRAIL-induced 
apoptosis via activation of caspase-3 and caspase-9, and inactivation of Bcl-
xL/downregulation of XIAP 
[194, 290] 
 Curcumin, Daidzein Inhibits expressions of Bcl-2, Bcl-XL, survivin and XIAP, and induces expressions Bax, 
Bak, PUMA, Bim, and Noxa and death receptors 
[239, 283, 291, 292] 
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Targets Drug/compound Mode of action Ref 
NF-ĸB signaling 
pathway 
Bortezomib, MG132 1. Proteasome inhibitor; prevents NF-ĸB activation induced by TRAIL by 
inhibiting degradation of IĸB 
2. Increases surface expression of TRAIL-receptor 1/2 
3. Reduces c-FLIP expression 
[293-296] 
 
 AS602868 IĸB kinase-2 pharmacologic inhibitor; blocks TRAIL-induced NF-ĸB activation and 




Sulforaphane Downregulation of ERK and AKT signaling  [214, 297] 
 Arsenic trioxide Modulating PI3K/AKT signaling [298-300] 
 Melittin Activates JNK/p38 pathways and inhibits NF-ĸB signaling  [217] 




in several  model systems of normal human cells such as primary astrocytes, hepatocytes, 
keratinocytes and prostate epithelial cells in vitro [264, 301-304].  However, it was soon 
clarified that these studies utilized highly aggregated recombinant forms of TRAIL [305-
307], for e.g. His-TRAIL or cross-linked FLAG-TRAIL, which had tendencies to 
forminsoluble aggregates that leads to high-order multimerisation of death receptors. This 
potentiated the antitumor efficacy of these TRAIL preparations but also increases their 
toxicity to normal cells [266, 301, 308, 309]. In addition, they were not optimized for 
zinc content, which is crucial for stability and biological activity of the heterotrimeric 
structure of rhTRAIL [144, 145, 310, 311]. Hence, the recombinant version of nontagged, 
Zn-bound TRAIL containing amino acids 114-281 [263, 265] is preferred in subsequent 
clinical applications. Phase 1 clinical trials of this preparation of TRAIL, produced by 
Genetech and Amgen, administered intravenously to patients with advanced cancer 
concluded that rhTRAIL is safe and well tolerated
 
up to 15 mg/kg; at which humans 
produces serum concentrations consistent with those
 
demonstrating efficacy in tumor 
xenograft models. Enrollment is continuing at 8 mg/kg for expanded
 
safety data and 
further dose optimization. Contribution to the
 
standard treatment of advanced solid 
tumors and hematologic
 
malignancies will be evaluated in randomized trials.  
3.6.2 Agonistic antibodies targeting the TRAIL signaling pathway 
Although TRAIL can induce apoptosis in a variety of tumor cell, overexpression of decoy 
receptors has been suggested to confer TRAIL resistance to primary tumor cells. 
Utilizing agonistic antibodies against the death receptors present a viable solution to such 
an issue. The potential of this approach are the specific binding, as well as high affinity, 
of antibodies to the intended receptors and the longer in vivo half life of these agonistics 
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compared to that of rhTRAIL As a result, agonistic antibodies targeting DR4 and DR5 
have been generated by several groups [305, 312-315] and they have observed apoptosis 
in a broad range of tumor cell lines as well as tumor regression in vitro and in vivo using 
immunodeficient mice xenografted with  a variety of human tumors [315-317]. Three 
human monoclonal antibodies developed by Human Genome Sciences, one directed at 
DR4 (HGS-ETR1/maptumumab) and the other two at DR5 (HGS-ETR2/ lexatumumab 
and HGS-TR2) are currently undergoing clinical trial phases 1/2 and additionally, the 
tumoricical activity of these antibodies were not accompanied with hepatotoxicity in 
various tumor cell lines [313, 314]. Dose-escalation studies have been conducted in 
patients with non-Hodgkin‘s lymphoma and advanced solid maglinancies. Mapatumumab 
can be administered safely and feasibly at 10 mg/kg IV every 14 days in a study with 
patients with advanced solid maglinancies. The absence of severe toxicities and the 
attainment of plasma mapatumumab concentrations that are active in preclinical models 
warrant further disease-directed studies of this agent alone and in combination with 
chemotherapy in a broad array of tumors [318-320]. Similarly, lexatumumab was safe 
and well tolerated at doses up to and including 10 mg/kg every 21 days and was 
associated with sustained stable disease in several patients with solid maglinancies [321, 
322].  
 
3.6.3 Potential of combinational therapies 
Apart from the use of rhTRAIL and agonistic antibodies as monotherapy, combinations 
with traditional chemotherapies, as well as with novel compounds targeting proteins 
involved in the TRAIL signaling pathway, are under development, and seek to enhance 
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the clinical efficacy of rhTRAIL. There have been numerous publications demonstrating 
the success of these combinatorial treatments in inducing additive or a synergistic 
response in vitro, as described in Table 2, and in vivo. One of the most promising 
combination is with the HDAC inhibitors (HDAC‘is) whereby there is synergistic 
apoptotic response in cancer cell lines when used in conjecture with rhTRAIL by virtue 
of its ability to upregulate DR4, DR5 and pro-apoptotic members of the Bcl-2 family, 
leading to activation of both receptor-mediated as well as mitochondrial-dependent 
apoptotic pathway [267, 323-325]. Phase 1 and 2 studies with several HDAC‘is are 
ongoing [326].  
Importantly, tumor cells that are partially or completely resistant to TRAIL-based 
therapies can often be resensitized when treated in combination with chemotherapeutic 
drugs [327-333]. Combined treatment of colorectal tumours with 
maptumumab/lexatumumab and radiotherapy resulted in enhanced apoptotic effects in 
vitro and dose-dependent growth delay in vivo. Paclitaxel, vincristine, vinblastine, 
etoposide, doxorubicin, and camptothecin significantly augmented TRAIL-induced 
apoptosis in cancer cells through up-regulation of DR4, DR5, Bax, and Bak, and 
induction of caspase activation. The sequential treatment of mice with chemotherapeutic 
drugs followed by TRAIL induced apoptosis, inhibited angiogenesis, completely 
eradicated the established tumors, and enhanced survival of mice [334]. Mapatumumab, 
in combination with gemcitabine and cisplatin, is currently undergoing a Phase I study 
[327, 331, 333].  
In this regard, the proteasome inhibitor bortezomib has recently shown synergistic 
activity against established lymphoma cell lines, primary lymphomas and myelomas 
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[335, 336], as well as the TRAIL receptor-antibody resistant non-small cell lung cancer 
(NSCLC) cell lines [337] when combined with mapatumumab and lexatumumab. 
Activation of NFĸB pathway following DR4 or DR5 ligation has an inhibitory effect 
upon TRAIL-mediated apoptosis [171, 207]. Accordingly, agents that suppresses NFĸB 
activity has been shown to strongly synergise TRAIL-based apoptotic signaling in vitro 
and in vivo [203, 338, 339]. Other promising therapeutic agents in combination with 
TRAIL-based therapies under evaluation in preclinical studies or early clinical phases 
include molecules that target anti-apoptotic proteins along TRAIL signaling pathway 
such as the Bcl-2 family members and the IAPs [194, 340], as well as the mTOR kinase 
inhibitor, rapamycin [178, 341] that inhibits antagonistic prosurvival PI3K/AKT signal 
wthin the cell. 
 
 
4. REACTIVE OXYGEN SPECIES (ROS)  
4.1 Types of ROS 
Molecular oxygen is needed for normal aerobic metabolism of cells and due to its radical 
nature, it has a tendency to form Reactive Oxygen Species (ROS), which is a term 
encompassing oxygen derived free radicals and non radicals. Free oxygen radicals may 
be defined as any chemical species capable of independent existence that contains one or 
more unpaired electrons and examples include the superoxide anion, the peroxy radical, 
singlet oxygen and hydroxyl radical while non-radical ROS include molecules like 
hydrogen peroide (H2O2) and peroxynitrite (ONOO
-
). ROS are mainly associated with 
many phenomena involving oxidative stress such as aging, neurodegeration, 
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inflammation and chemotherapeutic effects etc, leading to the long held notion that any 
form of oxidative stress is detrimental to a cell. However, research in the recent years has 
redefined the role of ROS in the process of oncogenesis.  
 
4.2 Intracellular sources of ROS 
One of the major sources of intracellular ROS is the mitochondrial electron transport 
chain (ETC), where an estimated 1-3% of the total oxygen consumed leaks as partially 
reduced free oxygen radicals. Tumor cells are metabolically active and increased 
respiration thus leads to a continuous generation of ROS as a result of leakage of 
electrons from the ETC localized at the inner mitochondrial membrane. Generally the 
main sites of ROS production are observed at Complex I (NADH Hydrogenase) and 
Complex III (Ubiquinol/cytochrome c oxidio-reductase) [342] where electrons may leak 
out of the ETC to partially reduce molecular oxygen, via a single electron transfer, to 
form superoxide [343]. Mitochondrial manganese superoxide dismutase (MnSOD) 
converts superoxide to its dismutation product, H2O2 [344], upon which its reductive 
hemolytic cleavage of results in a highly oxidative and cytotoxic hydroxyl radical via a 
iron-dependent breakdown process known as the Fenton reaction. Inhibition of ETC at 
these complexes resulted in significant production of superoxide. While MnSOD is 
localized in the mitochondria, the other dismutase, Cu/ZnSOD is found in the cytosol.  
Another well characterized intracellular source of superoxide in neutrophils and 
macrophages is the small GTPase Rac-NADPH oxidase system [345], as with other 
oxidase systems in the cell like the xanthine oxidase complex. The NADPH oxidase 
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system in resting neutrophils consists of a membrane heterodimeric flavocytochrome 
(cytochrome b559) and unassembled cytosolic p40phox, p67phox, p47phox and the small 
guanosine triphosphate (GTP)-binding Rac protein [346]. Following receptor stimulation 
of neutrophils, these cytosolic components translocate to the membrane cytochrome b559 
where they associate to form an active oxidase complex, driving the one-electon 
reduction of O2  to generate O2
.-, resulting in the ―respiratory burst‖ frequently observed 
in neutrophils and macrophages that is critical for their immune activity against microbial 
intruders [347].  
Recent findings indicate a similar oxidase system for ROS production such as the 
mitogenic oxidase Nox in other cell types besides the phagocytes, including transformed 
cells. The Nox family consists of seven members that have different biological functions 
due to their differential expression and regulation in different tissues [348]. However, it 
has been shown that Nox proteins are involved in transmitting survival signals in various 
cancers such as pancreatic cancer, melanomas and prostate tumors [349].  
The endoplasmic reticulum (ER) is an membrane-bound organelle primarily involved in 
lipid and protein biosynthesis. Smooth ER contains enzymes such as like NADPH-
cytochrome P450 reductase that catalyze a series of reactions to detoxify lipid-soluble 
drugs and harmful metabolic products and reduce molecular O2 to produce O2
.-
  and/or 
H2O2. ER-related functions such as protein folding and secretion have been observed to 
undergo redox regulation [350, 351]. Additionally, the membrane that surrounds the 
nucleus has also been identified to contain an ETC, resembling those of ER, whose 
function has not been elucidated yet. It has been postulated that the leakage of electrons 
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at this site can also give rise to O2
.-
 [352]. Recently, a Nox 4 enzyme has also been 
identified in the nucleus, providing another intracellular source of ROS [353].  
 
4.3 Evidence favouring pro-oxidant environment in tumor cells 
Tumor cells are metabolically more active and as a result, survive in a slightly pro-
oxidant state that has been found to be favorable towards their continued oncogenic 
existence [354]. Cerruti, 1985 reviewed the earliest evidence for a role of prooxidant state 
in oncogenesis where serum of patients with hereditary diseases characterized by 
increased cancer incidence and spontaneous chromosomal breakages, leading to 
induction of oncogenesis, were shown to be able to induce chromosomal aberrations in 
test culture of lymphocytes from healthy doners. Such an effect, however, could be 
inhibited in the presence of O2
.-
  scavenging cytosolic enzyme, Cu/ZnSOD, indicating the 
significance of O2
.-
  in the clastogenic process. Furthermore, they observed that high 
oxygen tensions could promote the transformation frequency of irradiated mouse 
embryonic cells [355]. To further support the role of ROS in oncogenicity, tumor cells 
were observed to express lower levels of antioxidant enzymes such as MnSOD compared 
to their normal counterparts. Reduction in levels of MnSOD was shown to enhance the 
tumor invasiveness of the cells [356] and the converse was proven whereby 
reintroduction of the protein inhibited the maglinancy of these cancers [357]. Besides, as 
mentioned afore, Nox enzymes have been reported to induce cell proliferation through 
the production of O2
.-





4.4 Role of ROS in modulating cell death 
It is now accepted that ROS play a diverse roles in the regulation of cell death, depending 
on the type and concentration of ROS present in the intracellular mileu [359]. Generally, 
high doses of ROS are known to elicit necrotic effects through modification of 
intracellular proteins and DNA damage, leading eventually to the demise of the cell in 
response to the oxidative stress.  Furthermore, cellular antioxidant defenses are depleted 
following excessive oxidative stress, thereby priming the cells for apoptosis. Conversely, 
low concentrations of ROS tend to activate mitogenic responses through tyrosine 
phosphorylation of phosphatases or activating growth factor receptors directly as well as 
activating transcription factors that control proliferation such as NF-ĸB [360] or the 
MAPKs [361]. Interestingly, intermediate concentrations of H2O2 (< 500µM in most 
systems), resulted in a decrease in O2
.-
, triggering apoptosis [362].  
Previous works have demonstrated extensively, the importance of the balance between 
levels of O2
.-
  and H2O2 within a cell in the regulation of cell death. A slight increase in 
O2
.-
  favors the tumor phenotype whereby inhibition in the production of O2
.-
  or 
inhibition of SOD caused an increase and a decrease, respectively, in sensitivities of 
tumor cells to drug-induced apoptosis. A probable explanation is that the catalytic 
domain of the death executors, caspases, contains an oxidation-sensitive cysteine residue, 
whose thiol group gets oxidized under oxidative conditions [363], rendering them 
inactive for execution of cell death. On the other hand, an increase in intracellular H2O2 
can lead to cytosolic acidification, creating a permissive intracellular milieu for caspase 
activation and/or Bax conformational change and translocation to the mitochondria [364, 
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365], facilitating death execution and increased caspase activity in an acidic environment 






MATERIALS AND METHODS 
In this study, the property of LY30 as a TRAIL-sensitizing compound was being 
evaluated. In particular, the cellular response triggered by LY30 was assessed. Various 
methods for detection of apoptosis and its hallmarks were employed to determine the 
cellular processes involved in LY30+TRAIL treated cells. In addition, to delineate the 
major signaling molcule involved, blocking antibodies and RNAi-mediated silencing of 
the death receptors was carried out. These experimental methods are summarized as 
below: 
 
1. TUMOR CELL LINES 
The human cervical cancer cell line HeLa, human neuroblastoma cell line SH-SY5Y and 
Jurkat cells were purchased from American Type Culture Collection (ATCC; Rockville 
MD). HeLa cells and SH-SY5Y were cultured in Dulbecco‘s Modified Eagle‘s Medium 
(DMEM, Hyclone, Logan, Utah, USA) while Jurkat was maintained in (RPMI, Hyclone 
Logan, Utah, USA) and supplemented with 1% L-glutamine, 1% streptomycin-penicillin 
and 10% FBS. HeLa stably  transfected with pcDNA3.1 vector, a gift from Dr Roberta A 
Gottlieb (Scripps Cancer Center, La Jolla, CA, USA), containing the neomycin gene 
(HeLa-Neo and HeLa-Bcl-2) were cultured  in DMEM medium supplemented with 1% 
L-glutamine, 1% penicillin/streptomycin, 10% FBS and 20ug/ml G418.  HT29 colorectal 
carcinoma cells were generously provided by Dr. Bert Vogelstein (The Johns Hopkins 
University School of Medicine, Baltimore, MD) and maintained
 
in McCoy 5A (Gibco 
Invitrogen Corporation, Carlsbad, CA) supplemented with 10% fetal bovine serum FBS, 
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1% L-glutamine and 1% penicillin/streptomycin. All cell lines used were grown and 
passaged in a humidified incubator at 37°C with 5% CO2.  
 
2. ANTIBODIES 
2.1 For western blotting 
Mouse monoclonal Anti-Caspase-2 (Cell Signaling Technology, Inc. Danvers, MA) 
Rabbit polyclonal Anti-Caspase-3 (Cell Signaling Technology, Inc. Danvers, MA) 
Rabbit polyclonal Anti-Caspase-8 (Cell Signaling Technology, Inc. Danvers, MA) 
Mouse Monoclonal Anti-Cytochrome c (Cell Signaling Technology, Inc. Danvers, MA) 
Rabbit polyclonal SMAC (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
Mouse monoclonal Anti-Bid (Cell Signaling Technology, Inc. Danvers, MA) 
Mouse monoclonal Anti-FADD (BD transduction Labs, San Diego, CA, USA) 
Rabbit polyclonal Anti-DR4 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
Rabbit polyclonal Anti-DR5 (Cell Signaling Technology, Inc. Danvers, MA) 
Goat polyclonal Anti-DR5 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
Rabbit polyclonal Anti-c-FLIP (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
Mouse monoclonal Anti-XIAP (BD Pharmingen, San Diego, CA, USA) 
Rabbit polyclonal Anti-Caveolin (Abcam, Cambridge, UK) 
Goat polyclonal Anti-Flotillin (Abcam, Cambridge, UK) 
Mouse Monoclonal Anti-β-Actin (Sigma Aldrich, St Louis, MO, USA) 
Goat Anti-mouse IgG HRP conjugated secondary antibody (Pierce Chemical Co. 
Rockford, IL, USA) 
Goat Anti-Rabbit IgG HRP conjugated secondary antibody (Pierce Chemical Co. 
Rockford, IL, USA) 
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2.2 For flow and confocal analysis 
Anti-human TRAIL-R1 (TNFRSF10A/DR4)-Phycoerythrin (R&D systems, Inc 
Minneapolis, MN, USA) 
Anti-human TRAIL-R2 (TNFRSF10B/DR5)-Phycoerythrin (R&D systems, Inc 
Minneapolis, MN, USA) 
Alexa Fluor 610-R-phycoerythrin Goat Anti-mouse IgG (Invitrogen, Eugene, Oregon, 
USA) 
Alexa Fluor-488 Rabbit Anti-mouse IgG (Invitrogen, Eugene, Oregon, USA) 
Donkey Anti-goat IgG-Rhodamine (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
 
3. REAGENTS AND CHEMICALS 
The pan-caspase inhibitor, ZVAD-FMK and LY30 were obtained from Alexis 
Biochemicals, Lausen, Switzerland. Crystal violet, MTT, β-mercaptoethanol, 
Bromophenol Blue, DMSO, Tween 20, EDTA, DTT, glycine, Protein A, gel filtration 
molecular weight markers (MW-GF-200) and MTT were purchased from Sigma Aldrich, 
St. Louis, MO. Cholesterol quantification kit was bought from Calbiochem, Darmstadt, 
Germany. TRAIL and fluorogenic substrates of caspase-2, -3, -8 and -9 were purchased 
from Biomol, Plymouth Meeting, PA, USA. The Coomassie Blue reagent and DTSSP 
(3,3´-dithiobis[sulfosuccinimidylpropionate]) were obtained from Pierce Biotechnology 
Rockford, IL, USA. 10x PBS, 10 x SDS, Tris HCl buffer (pH 7.4) were purchased from 






4. CELL VIABILITY ASSAYS 
The focus of this thesis centered on the ability of LY30 to enhance or induce death in 
tumor cells and hence the crystal violet viability assay was used as a simple method for 
assessing tumor cell viability after drugs treatment. While cell viability was an important 
parameter in investigating the cytotoxicity of these drugs, we had to account for the 
colony forming ability of these cells after treatment using a modified version of the 
crystal violet assay.  
 
4.1 Crystal violet cell viability assay 
In a typical survival assay, HeLa cells (1 10
5 
cells/well) plated in 24 well plates were 
pre-incubated for 1 hr with 25µM LY30 and then treated with 20ng/ml of TRAIL for a 
period of 18 to 48hrs depending on the experiment. Cytotoxicity was determined by the 
Crystal Violet assay. After drug exposure, cells were washed once with phosphate 
buffered (PBS) before addition of 0.2ml of crystal violet solution to each well and 
incubation for 20min. The excess crystal violet solution was washed away using distilled 
water where non-viable cells gets detached and washed off in the process, leaving the 
attached viable cells that retained the crystal violet stain. Remaining crystals were 
dissolved in a 1% SDS in 1X PBS solution and viability was determined by reading 
absorbance at wavelength 595nm using a TECAN spectrophotometer.  
 
(Crystal Violet Solution: 0.75% crystal violet in 50% ethanol:distilled water with 1.75% 




4.2 MTT Assay 
3-(4,5-dimethylthiazol- 2-yl)-2,5 diphenyltetrazolium bromide (MTT) assay was used to 
assess cell viability for the suspension cell line, Jurkat.  Briefly, 1x10
6
 cells/well were 
seeded onto 6 well plates and exposed to drug treatments for 18 hours before incubation 
with MTT for 2 hours. Excess MTT solution was washed off after spinning down and the 
formazan crystals were then dissolved with 180µL Sorenson‘s glycine with 20µl DMSO 
and absorption was measured with a TECAN spectrophotometer at 570nm. 
 
(Solvent: Sorenson‘s glycine was prepared as 0.1 mM NaCl and 0.1 M Glycine (pH 10.5) 
in distilled water and stored at 4 °C).  
 
4.3 Determination of the tumor cells’ colony forming ability 




were pretreated for 1 hr with 25µM LY30 followed by 20ng/ml of 
TRAIL in a 24 well plate for 8 hrs. As this treatment period did not induce any visible 
cell death, cells were then washed and 4000 cells from each well were re-plated into 
100mm culture dishes and left to form colonies over a period of 8 to 12 days. Culture 
dishes were stained with crystal violet and colonies were scored manually in a 2cm x 2cm 
grid (on the culture plate) to determine colony forming abilities of cells. Only populations 
containing more than 50 cells were considered as colonies.  
 
5. APOPTOTIC ASSAYS 
5.1 Analysis of DNA fragmentation by Propidium Iodide Staining 
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Following treatment, the cells (1x10
6
) were washed and resuspended in 1ml of 1x PBS 
and immediately fixed with 70% ethanol:water while vortexing the cells to prevent 
clumping. The cells were then incubated for 30min at 4°C before they were washed once 
with 1 x PBS and resuspended in 500µl PI: RNAase solution for 30min for DNA content 
analysis. At least 10,000 events were analyzed by flow cytometry (Beckman Coulter, 
USA) with the excitation set at 488 nm and emission at 610 nm, after which they were 
analyzed with the WinMDI software. Histogram data indicating percentage of cells with 
sub-diploid DNA are representative of three independent observations. In a typical DNA 
analysis, the apoptotic population of cells are reflected in the histograms as displaying 
hypodiploid DNA content. 
(Buffers: PI stock solution (50X) was dissolved in sodium citrate buffer (38 mM) to a 
stock concentration of 0.5 mg/ml and kept in 4 °C and protected against light exposure. 
RNAse A was dissolved in 10 mM Tris-HCl (pH 7.5) and 15 mM NaCl to a stock 
concentration of 10 mg/ml and kept at -20 °C. PI: RNAse A solution was freshly 
prepared with 1/50 volume of PI and 1/40 volume of RNAse A stock solution in 38 mM 
sodium citrate buffer). 
 
5.2 Determination of Caspases 2, 3, 8 and 9 activities 
Caspases 2, 3, 8 and 9 activities were assayed using AFC and AMC-conjugated 
substrates. HeLa and HT29 cells (1x10
5
 cells/ml) were preincubated with specified 
concentration of LY30 for 1 hr, followed by treatment with indicated doses of TRAIL for 
the relevant time points. Cells were then harvested and washed with 1X PBS, 
resuspended
 
in chilled cell lysis buffer (BD Pharmingen, San Diego, CA, USA),
 
and 
incubated on ice for 10 min before incubation with their respective substrates and real-
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time measurements of enzyme-catalyzed release of AFC or AMC were obtained using 
TECAN spectrophotometer reader operating with Magellan software. Final fluorescence 
values obtained after 1hr incubation at 37ºC were normalized against the protein 
concentration of samples and plotted as x fold increase in caspase activity over the 
untreated control.  
 
5.3 Determination of Protein Expression by Western Blot Analysis  
Whole cell protein extracts were isolated after drug treatments using 1X RIPA lysis 
buffer. Cytosolic fractions, sucrose density gradient fractions and fractions from gel 
filtration were obtained using standard procedures (see each related method). Protein 
concentration was quantified using the Coomassie Blue reagent. Briefly, 1µl of the 
supernatant was added to 200µl of Coomassie Blue reagent into a 96-well plate and read 
for absorbance at 595nm using TECAN spectrophotometer. Equal amounts of proteins 
from the lysates were mixed with 5X Laemelli loading dye and boiled for 5min. The 
samples were then subjected to different concentrations (10% or 12%) of SDS-PAGE 
(sodium dodecyl sulfate-polyacrylamide gel electrophoresis) depending on the molecular 
weight of the target proteins and transferred onto PVDF membranes (BioRad 
Laboratories) subsequently. The membrane was blocked with 5% (w/v) fat-free milk in 
Tris-buffered saline containing 0.05% (v/v) Tween 20 TBST for 1hr and washed thrice 
with TBST to remove excess milk. The membrane was probed for the target protein with 
the relevant primary antibodies (refer to antibodies list above) overnight at 4ºC. The 
membrane was washed thrice to remove unbound primary antibody and probed again 
using appropriate HRP-conjugated secondary antibody in TBST containing 1% (w/v) fat-
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free milk at room temperature for 1hr. After three washes with TBST to remove any 
excess unbound secondary antibody, the proteins of interest were detected with Kodak 
Biomax MR X-ray film (Eastman Kodak Co., Rochestor NY) by enhanced 
chemiluminescence using the SuperSignal Chemiluminescent Substrate (Pierce, 
Rockford, IL, USA).  
5.4 Buffers used in SDS-PAGE and western blotting 
RIPA lysis buffer 
RIPA lysis buffer was prepared with 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% v/v 
Nonidet P40, 1% v/v deoxycholic acid,  0.1%  v/v SDS, 1 mM EDTA. Before use, the 
buffer was supplemented with protease inhibitors (1 mM PMSF, 10 μg/ml Aprotinine, 20 
μg/ml Pepstatin A) and phosphatase inhibitors (1 mM NaF, 1 mM Na3VO4). 
 
Running Buffer for SDS-Page gel: 10X (2L) 
Tris-base 60g, glycine 288g, SDS 20g, top to 2L with dH2O. 
 
Transfer Buffer for western blot: 1X (5L) 
Tris-base 12.1g, glycine 57.84g, methanol 1L, top to 5L with dH2O. 
 
Lammeli Loading Buffer: 5X (10 ml) 
100 mM Tris-HCL pH 6.8, 3.1 ml (1M), SDS 1g (10%), glycerol 2 ml (20%), β-
Mercaptoethanol 2.5 ml (25%), Bromophenol Blue 0.01g (0.1%), top to 10 ml with 2.4 
ml distilled H2O. 
 
Membrane Stripping Buffer: 1X (100ml) 
1 M Tris-HCl, 6.25 ml pH 6.8, β-Mercapoethanol 714 µl, 10% SDS 20ml , top to 100ml 





TBS was prepared as 500 ml 1 M Tris HCl (pH 7.4) with 87.6 g of NaCl in 10L of 
distilled water and stored at room temperature. 
 
TBST 
TBST was prepared as 2 L TBS with 2 ml of Tween-20 and stored at room temperature. 
 
5.5 Isolation of cytosolic fractions  
For isolation of  cytosolic fractions, cells were harvested and washed once with ice-cold 
1X PBS before  incubation on ice for 30min in Extraction buffer A. After incubation, the 
cells were homogenized with a dounce homogenizer and passaged for 30 strokes before 
being centrifuged at 300g for 10mins at 4 C to remove deris. Following which, the 
supernatant was centrifuged again at 12000g for 15mins at 4 C and the supernatants are 
used as cytosolic fractions. The fractions were then subjected to SDS-PAGE and western 
blotting as stated above. 
(Extraction buffer A: 50mM PIPES-KOH pH 7.4, 200mM mannitol, 68mM sucrose, 
50mM KCl, 5mM EGTA, 2mM MgCl2,
 
1mM DTT, pH 7.4 containing the protease 
inhibitor; 0.5 mM of PMSF). 
 
6. ASSESSMENT OF DEATH RECEPTORS 
Majority of this study focused on the effects of LY30 on the death receptors and this 
section describes the materials and protocols we undertook in this work to study the 
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changes in expression and distribution of death receptors and the relevance of such 
effects induced by LY30 by doing a transient silencing of death receptor genes. 





) were seeded in 100mm petri dishes and treated with LY30 and 
TRAIL accordingly before washing with ice cold 1X PBS and incubated for 30min at 4ºC 
in cell lysis buffer. The lysates were then pre-cleared with 20µl Protein A before 
incubating overnight on a rocker with rabbit polyclonal anti-DR5 and 40µl Protein A. 
The complexes were washed four times in lysis buffer at 1200rpm, for 5min at 4ºC before 
boiling for 10min in 1X Lammelli loading buffer and used for SDS-PAGE and western 
blotting for DISC components: FADD, caspase-8. Protein blots were probed for equal 
loading and for confirmation of DR5 in the pull down with goat anti-DR5 
(Lysis buffer: 30mM Tris–Hcl (pH 7.5), 150mM NaCl, 2mM EDTA, 10% glycerol, 1% 
Triton-X supplemented with 1mM PMSF, 10 mg/ml aprotinin, 20 mg/ml pepstatin A, and 
10 mg/ml leupeptin) 
 
6.2 Assessment of DR5 oligomerization 
For DR5 oligomerization studies, cells were treated for 30 min at 25
o
C with 2mM 
DTSSP, a cleavable cross-linker [367] before reaction was quenched with 50mM Tris 
HCL for 10 minutes and cells were washed twice with ice cold PBS and incubated for 30 
min at 4
o
C in lysis buffer. The lysates were precleared and incubated overnight on a 
rocker with limiting and excess amounts of the same anti-DR5 used for 
immunoprecipitation in DISC analysis. The limiting (0.4µg) and excess amounts (5µg) of 
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anti-DR5 were determined via a titration process where the limiting amount was 
determined by the highest amount of anti-DR5 that was just not sufficient to be able to 
immunoprecipitate any DR5. The complexes were washed four times with the cell lysis 
buffer and centrifuged at 12000 rpm for 5min at 4
o
C before boiling for 10min in 1X 
Lammelli loading buffer and used for SDS-PAGE and western blotting for DR5 
oligomerization using goat anti-DR5. Rabbit IgG was used as a control in the DR5 
immunoprecipitation experiments. 





) were seeded in T75 flasks and treated with LY30 for an hr before 
lysates were harvested. Gel filtration chromatography was done on a Superdex 200 
10/300 GL column (GE Healthcare) connected to a fast protein liquid chromatography 
system. Equilibration with eluent containing PBS and calibration was done with β-
amylase (200kDa), alcohol dehydrogenase (150kDa), albumin (66kDa), carbonic 
anhydrase (29kDa) and cytochrome c (12kDa). Void volume corresponded to the elution 
of Blue Dextran 2000. Cellular extracts were prepared and lysed in a 300µl volume of 
eluent containing 1% Triton X-100. 250µl of soluble extracts were injected onto the 
column for elution at a flow rate of 200µL/min. 200µL fractions were collected for 
loading into a SDS-PAGE gel. Position of DR5 proteins in the elution profile was 
determined by immunoblotting using goat anti-DR5. 
 










) were seeded in 100mm petri dishes and treated with LY30 for an hr. 
Cells were then harvested and washed with ice-cold 1xPBS before incubating in 500ml of 
HEPES buffer containing 1% Triton X-100 for 10mins. Lysates were subjected to 10 
passes through a 27G syringe before spinning at 300G for 5min at 4ºC to remove cellular 
debris. This is followed by sonication (3 sets of 10sec pulses at 40V) and protein 
quantification to determine equal amounts of protein used for subsequent 
ultracentrifugation. The lysate is mixed with an equal volume of 85% sucrose (w/v) in 
HEPES buffer, transferred to a centrifudge tube and overlaid with 2.5ml of a 30% sucrose 
and 1.5ml of a 5% sucrose solutions. The sucrose gradient was centrifudged for 21hr at 
4ºC in a Beckman rotor at 32,000RPM and nine 0.5ml fractions were harvested 
separately. 40µl was taken from the fractions and subjected to SDS-PAGE and Western 
blotting for relevant microdomains marker proteins and death receptors. 
 
(HEPES Buffer: 25mM HEPES, 150mM NaCl, pH7.4 containing 1% Triton X-100 and 
1mM PMSF, 10 mg/ml aprotinin, 20 mg/ml pepstatin A, and 10 mg/ml leupeptin ) 
 





) were treated with LY30 and TRAIL as accordingly and washed three 
times in PBS supplemented with 0.5% BSA. Cells were then incubated with 
phycoerythrin (PE)-conjugated mouse monoclonal anti-human DR5 or DR4 for 45 
minutes at 4 C as per manufacturer‘s instructions before washing and re-suspension in 
PBS for flow analysis using an excitation wavelength of 488.  PE-conjugated mouse 
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IgG2B was used as an isotype control. Data was analyzed and dot plots and histograms 
were plotted using WinMDI software.  
 
6.6 Confocal Analysis of surface DR4 and DR5 
Hela cells (1x10
5
) were plated in a 24 well plate on poly lysine coated cover slips. After 
1hr preincubation with 25µM LY30, cells were washed twice with 1x PBS and fixed with 
2% paraformaldehyde in 1xPBS for 15min at room temperature. They were washed three 
times with 1xPBS followed by an hour blocking with 5% BSA in 1xPBS.  Cells were 
then incubated with mouse anti-DR4/goat anti-DR5 (Santa Cruz, Santa Cruz, CA, USA) 
and rabbit anti-caveolin in 1XPBS with 5% BSA at 1:100 dilution for 2 hrs, after which 
they were washed three times with 1xPBS in 5% BSA followed by 1hr incubation with 
1:1000 fluorescence-conjugated secondary antibody in 1XPBS with 5%BSA. Cells were 
similarly washed three times with 1xPBS before the coverslips were mounted on 
glassslides and imaged with Olympus Fluoview FV1000 confocal microscope and images 
analyzed using Olympus Fluoview 1.7 viewer.  
 
6.7 Transient silencing of messenger RNA 
For knockdown of death receptors gene expression, 100nM of DR4 siRNA and 50 nM of 
DR5 siRNA were transfected into cells in Optimem1
TM
 medium using the Dharmafect1 
reagent (Dharmacon) according to the manufacturer‘s instructions. Briefly, 2 μl 
Dharmafect1 reagent was added to 200 μl of Optimem1 and the mixture was vortexed for 
10 seconds before a 5min incubation at 37 °C (Mixture A). In another tube, Mixture B 
containing siRNA was resuspended in 200 μl of Optimem1, vortexed and added drop-
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wise to the Mixture A followed by a further 20min incubation of this final mixture at 37 
°C. Next, 400 μl of the total transfection mix was added drop-wise to the respective 
wells.  After transfection with siRNA, cells were cultured in 10% serum for 48hrs before 
the assessment of protein expression by Western blotting and cell viability assays carried 
out using crystal violet assays after drug treatments.  
 
7. LIPIDS ANALYSIS 





) were seeded in 100mm petri dishes and treated with LY30 for an hr. 
Cells were then harvested and membrane mircodomains were isolated as described. 25µl 
was used from each fraction for cholesterol quantification using Cholesterol/Cholesteryl 
Ester Quantitation Kit (Calbiochem). 
 
7.2 Lipids Quantitation by HPLC 
Lipids were extracted using a modified Bligh and Dyer protocol (Bligh and Dyer, 1959). 
Cells were treated accordingly and washed with PBS before resuspension in 50ul of PBS. 
0.6ml of chloroform:methanol (1:2) was added to each sample and tubes vortexed at 4
 o
C 
for 1min, thrice, with intervals of 5 min incubation on ice. 0.3ml chloroform and 0.2ml 
1M KCL were added to each tube and vortexed for 30sec, followed by a minute 
incubation on ice. Vortexing and incubation was repeated twice. The samples were then 
spun for 2min at 9000 RPM to separate phases, with lower organic phase containing the 





samples were used for ceramide quantitation via high performance liquid 
chromatography (HPLC) mass spectrometry (MS) performed by collaborator‘s 
laboratory. Multiple reaction monitoring (MRM) measurements were performed with an 
Applied Biosystems 4000 Q-Trap mass spectrometer (Applied Biosystems, Foster City, 
Ca) which was directly connected to the LC.  
 
8. STATISTICAL ANALYSIS 
All experiments were performed at least three times for statistical significance. Numerical 
data were expressed as mean + SD. Statistical analysis was performed using the paired 












1. LY30 SENSITIZES CERVICAL CARCINOMA HELA CELLS TO TRAIL-
INDUCED CELL DEATH. 
1.1 Pre-incubation with LY30 enhances TRAIL-induced apoptosis in HeLa cells. 
A dose response curve for TRAIL was established in HeLa cells by evaluating the effect 
of increasing doses (20-1000ng/ml) of TRAIL on cell viability for 18hrs using the crystal 
violet assay (Fig 3B). HeLa cells responded to TRAIL exposure in a dose dependent 
manner, with a LD50 of approximately 70ng/ml. There was a relatively modest effect of 
TRAIL on cell viability (>80% viable cells) at concentrations of 20ng/ml or lower. 
Henceforth, the concentration of 20ng/ml of TRAIL was used to assess the death 
amplifying ability of LY30 on TRAIL-induced apoptosis in all subsequent experiments. 
HeLa cells were first incubated with 25uM LY30 for an hour, followed by treatment with 
20ng/ml TRAIL for 18hrs. All ensuing experiments were performed in this manner, 
without washing off of either drug after addition. Results showed that pre-incubation of 
HeLa cells with LY30 for 1hr followed by treatment with 20ng/ml of TRAIL for 18hrs 
significantly reduced cell viability (55% viability with LY30 and TRAIL in combination) 
compared to cells treated with TRAIL (85% viability) or LY30 (80% viability) alone (Fig 
3C). Further studies for apoptotic characteristics such as DNA fragmentation and caspase 
activity in this model demonstrated synergy in the increased cell death observed in LY30-























Figure 3: LY30 sensitizes HeLa cells to TRAIL-induced apoptosis (A) 
Chemical structure of LY294002 and LY303511, with a single atom substitution. 
(B) HeLa cells (1 10
5
)  were exposed to TRAIL (20-100ng/ml) for 18hr or (C) 
treated with 20ng/ml TRAIL in the presence or absence of a 1hr pre-treatment with 
25µM of LY30. Percentage of cell survival was determined by crystal violet assay. 
Data shown are the mean±S.D. of at least three independent experiments performed 







1.2 Pre-incubation with LY30 before TRAIL-treatment enhanced DNA 
fragmentation synergistically.  
DNA fragmentation is a hallmark of cellular apoptosis.  HeLa cells were fixed and 
stained with PI to assess for the extent of DNA fragmentation as a function of apoptosis 
after drug/s treatment. Cells with fragmented DNA will appear as the sub-diploid (sub-
G1) fraction of the cell cycle profile.   While exposure to TRAIL or LY30 alone for 24hrs 
resulted in minimal DNA fragmentation (10.2% and 6.9% sub-G1 population 
respectively), there was a synergistic increase in the fraction of cells in the sub-G1 phase 
for LY30-TRAIL treated cells (39%). Prolonging the incubation with these drugs till 
48hrs resulted in a dramatic shift of the profile to the sub-G1 fraction (77%), whilst 
TRAIL and LY30 individually caused moderate DNA fragmentation (24% and 20% 
respectively) at this time point (Fig 4). These data confirmed the synergistic effect of 
LY30 on the cytoxicity of TRAIL in HeLa cells and the presence of DNA fragmentation 
suggested induction of an apoptotic response by these compounds.   
 
1.3 LY30-TRAIL treatment reduces the colony forming ability of HeLa cells.  
Given the ability of LY30-TRAIL treatment to induce cell death, we were also interested 
in understanding the effect of LY30-TRAIL on the long-term survival/proliferative 
capacity of tumor cells. This is done by evaluating the effect of combined drug treatment 
on tumor colony forming units. HeLa cells were exposed to LY30 for 1hr before 
incubation with TRAIL for 8hrs, where no cell death could be observed at this point in 
time. Equal number of cells were then seeded onto 100mm petri dishes, and allowed to 
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form colonies over a period of 2 weeks. There was a marked reduction in colony 
formation for cells treated with both compounds upon staining by crystal violet stain (Fig 
5A). A significant decrease in clonogenic ability (20% of untreated cells) was reported 
for cells under combinatorial treatment as compared to cells treated singly with either 
TRAIL or LY30 (Fig 5B).  
Intrigued by the effect LY30 has on the sensitivity of HeLa cells towards TRAIL, as 
demonstrated by the greater extent of DNA fragmentation as well as reduction in colony 













Figure 4: LY30 enhances TRAIL-induced apoptosis in HeLa cells. HeLa cells 
(5 10
5
) were exposed to 20ng/ml of TRAIL for 24 and 48h in the presence or absence 
of a 1h pretreatment with 25µM LY30. PI staining was performed for cell cycle 
analysis as described in Materials and Methods. The set of cell cycle profiles shown 

















Figure 5: Reduction in tumor colony forming abilities of HeLa cells exposed to 
LY30 followed by TRAIL. (A) HeLa cells were exposed to 20ng/ml TRAIL for 8h in 
the presence or absence of a 1hr pretreatment with 25µM LY30. The cells were then 
re-seeded onto 100mm petri dishes and allowed to form colonies over 8 to 12 days, 
followed by staining with crystal violet for colony counts. (B) Data from 3 
independent experiments were analyzed and plotted to show the significant reduction 





1.4 LY30-induced TRAIL-sensitivity involves caspase-dependent signaling. 
Pre-treatment of HeLa cells with LY30 followed by TRAIL resulted in strong 
amplifications of caspase-2 and caspase-3 activities beginning from 3hrs and peaking at 
12hrs. Figure 6 shows the kinetics of caspase activation (caspase-2 and caspase-3. We 
observed the peak activation of caspases - presence of truncated (active form of caspases) 
caspase-2/3, occurred at 12hrs, the time point corresponding with the greatest increase in 
caspases activities, assayed using fluorogenic caspase-substrate (Fig 7). Greater amounts 
of truncated caspase-2 (18KDa) was observed for cells treated with both agents at various 
time points, compared to cells treated with either compound, and it corresponded with a 
concomitant decrease in its  48KDa pro-form. Similarly, truncated form of caspase-3 
(17KDa) was only observed for cells treated with LY30+TRAIL. There was a significant 
9-fold increase in caspase-2 activity as compared to the 3-4 fold induced by LY30 or 
TRAIL alone, relative to untreated cells, and a 13-fold increase in caspase-3 activity 
versus the 3-5 fold increase brought about by treatment with either LY30 or TRAIL 
singly, compared to the untreated cells at 12hrs. Such an immense synergistic activation 
and activities of caspases in the treated cells suggested their crucial role as the death 
executioners mediating apoptosis in this model. As such, it was imperative to assess the 
effect of the pan-caspase inhibitor, ZVAD-fmk [368], to validate the importance of 
caspase-mediated cell death in the system. Indeed, LY30-induced sensitization of HeLa 
cells to a caspase-dependent death is confirmed as prior addition of ZVAD-fmk restored 
cell viability to LY30-TRAIL-treated cells, from 50% to almost 100% viable cells, after 
18hrs of treatment (Fig 8A). In addition, ZVAD-fmk abrogated the population of cells in 
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the apoptotic sub-G1 fraction after 24hrs of LY30-TRAILtreatment, from the expected 






Figure 6: LY30+TRAIL treatment in HeLa cells results in processing and 
activation of procaspases. HeLa cells (5x10
5
) were exposed to 20ng/ml TRAIL in the 
presense or absence of a 1hre pre-treatment with 25µM LY30. Whole cell lysates were 
then used to assay for (A) caspase-2 and (B) caspase-3 processing by SDS-PAGE and 
Western blotting. (* indicates significant increase in cleaved caspase subunits in 







Figure 7: LY30+TRAIL treatment in HeLa cells strongly activates caspases. 
HeLa cells (1x10
5
) were exposed to 20ng/ml TRAIL (3-18hrs) following the presence 
or absence of a 1hr pre-treatment with 25µM LY30. Whole cell lysates were used to 
determine the activities of (A) caspase-2 and (B) caspase-3 using fluorescent-
conjugated substrates. Data shown are the mean±S.D. of at least three independent 
experiments. p-value was calculated using paired Student‘s t-test as described in 












Figure 8: LY30+TRAIL mediated apoptosis in HeLa cells is a caspase-dependent 
process. HeLa cells (1 10
5
) were incubated with pancaspase inhibitor, ZVAD-fmk 
(20µM)for 1hr followed by 18hrs treatment with TRAIL±LY30 and (A) cell viability 
was assessed by crystal violet staining. Upper panel: Crystal violet staining of viable 
cells after drug/s treatment. Data shown are the mean±S.D. of at least three 
independent experiments done in duplicates. (B) HeLa cells were stained with PI  for 
analysis of DNA fragmentation by flow cytometry. The set of cell cycle profiles 





2. LY30 ENHANCES TRAIL-MEDIATED APOPTOTIC SIGNALING BY 
ENGAGING MITOCHONDRIAL DEATH PATHWAY, WHICH CAN BE 
REVERTED BY OVEREXPRESSION OF BCL-2 PROTEIN. 
2.1 LY30 mediated sensitization to TRAIL-induced apoptosis resulted in 
increased cytosolic cytochrome c and Smac/DIABLO. 
Having shown that LY30-mediated sensitization of HeLa cells to TRAIL was a caspase-
dependent processs, we next investigated if the amplification of death signaling by this 
compound involved mitochondrial events. To that end, we studied the cytosolic release of 
mitochondrial proapoptotic proteins like cyt c and Smac/DIABLO. Cytosol-enriched 
fractions of HeLa cells treated with LY30 and TRAIL, both singly or in combination, 
from 6hrs till 18hrs was obtained and analyzed via western blotting for the 
aforementioned proteins. Results showed that exposure of HeLa cells to LY30-
TRAILresulted in a significant increase of cytosolic cyt c levels, followed by the egress 
of Smac/DIABLO, whereas TRAIL alone had no effect on the cytosolic translocation of 
these proteins (Fig 9). On a side note, the release of cyt c could be partially inhibited by 
the mitochondrial permeability transition (MPT) pore inhibitor cyclosporine A, 
suggesting that the MPT pore may be involved in mediating LY30-induced sensitization 






Figure 9: LY30 enhances cytochrome c and Smac release into the cytosol. Hela 
cells (4×10
6
) were exposed to 20ng/ml TRAIL (18hrs) after 1hr pre-treatment with 
25μM LY30. Levels of cytochrome c and Smac in the cytosolic fractions were then 





2.2. Caspase-9 activation occurs in the event of downregulation/inactivation of 
XIAP in LY30+TRAIL treated HeLa cells. 
As mentioned earlier, the inactivation and downregulation of IAPs by Smac/DIABLO is 
well characterized and such a phenomenon has been implicated in various TRAIL 
sensitization studies. Hence, with the observation of increased cytosolic Smac/DIABLO 
in LY30-TRAIL treated cells, we investigated the protein level of XIAP. No change in 
protein levels was observed at 3hrs, but there was a noticeable decrease in full-length 
XIAP at 6hrs for cells treated with both LY30 and TRAIL, which corresponded with an 
increase with the 30kDa cleaved fragment of XIAP (Fig 10A). In contrast, cells exposed 
to either TRAIL or LY30 alone displayed only slight levels of this cleavage fragment. 
This was accompanied by a synergistic increase in enzymatic activity of caspase-9, a 
classic mitochondria dependent initiator caspase as detected in whole cell lysates of HeLa 
cells treated with LY30 for 1hr prior to addition of TRAIL for 3-18hrs (Fig 10B). Taken 
together, these data indicate that LY30 induces sensitization of HeLa cells to TRAIL-
mediated apoptosis via the cytosolic translocation of mitochondrial proapoptotic proteins, 





Figure 10: LY30 inactivates XIAP and causes synergistic activation of caspase-9. 
(A) HeLa cells (0.5x10
6
) were treated as previously described and whole cell lysates 
were use to assay for XIAP expression by western blotting. (B) HeLa cells (0.3x10
6
) 
were exposed to 20ng/ml TRAIL (3-18hrs) after an hr pretreatment with 25µM LY30 
and whole cell lysates were assayed for caspase-9 activity using its AFC-conjugated 
substrate. Data shown are mean±S.D. of at least three independent experiments. p-
value was calculated using paired Student‘s t-test as described in Material and 








2.3. Overexpression of Bcl-2 confers protection against LY30 mediated 
sensitization to TRAIL-induced apoptosis. 
Bcl-2 protein is an important guardian of the mitochondrial events by regulating the 
release of apoptotic proteins from the mitochondria as mentioned previously. To further 
validate the involvement of mitochondria in the sensitization of these cells to TRAIL, we 
next exposed Bcl-2 over-expressing HeLa cells to the combined drugs treatment. It is 
noteworthy that over-expression of Bcl-2 protected HeLa cells against TRAIL-induced 
cell death to a large extent, demonstrating that TRAIL-induced apoptosis in these cells 
was mitochondrial-dependent, which is typical of a type II mitochondrial-dependent cell. 
There was a rescue (50% to 85% viable cells) upon LY30-TRAIL exposure, further 
indicating the significance of mitochondrial involvement in this system (Fig 11).  
 
These data highlighted the involvement of the mitochondria in LY30-mediated 
sensitization of HeLa cells to TRAIL-induced apoptosis, however, the upstream signal 
involving receptor-mediated activation of apoptosis remained elusive. Therefore in the 
next segment, we undertook a series of studies to examine the contribution/s of the 
cognate receptors of TRAIL, namely, DR4 and DR5, in LY30‘s ability to enhance 





                                         
 
 
                                                    
 
Figure 11: Overexpression of Bcl-2 confers protection against LY30 mediated 
sensitization to TRAIL-induced apoptosis. HeLa Neo/Bcl2 cells (0.15x10
6
) were 
treated with 20ng/ml TRAIL in the presence or absence of 1hr pre-treatment with 
8µM LY30. Upper panel: Western blot showing overexpresion of Bcl-2 proteins in 
HeLa Bcl2. Percentage of cell survival was determined by the crystal violet assay. 





3. LY30 ENHANCES DISC ASSEMBLY, DOWNREGULATION OF C-FLIPS 
AND ACTIVATION OF PROCASPASE-8 AS WELL AS RECRUITMENT OF 
MITOCHONDRIAL PATHWAY VIA INCREASED BID CLEAVAGE.  
 
3.1 DR5 is the predominant death-inducing receptor expressed on  HeLa cell 
surface. 
The mitochondrial dependent apoptotic signaling has been shown to be a possible 
downstream signal of the receptor-mediated extrinsic apoptosis pathway. Therefore, we 
next studied the role of Type I pathway in LY30-mediated TRAIL amplification. To that 
end, surface expression levels of TRAIL receptors, DR4 and DR5, were first analyzed by 
flow cytometry. HeLa cells in culture were stained with the anti-DR4 or anti-DR5 PE-
conjugated antibody for flow cytometry analysis. There was a significant percentage of 
cells (40% compared to 7%) staining positive for DR5 and DR4 respectively, when the 
density plot of fluorescence against forward scatter was drawn (Fig 12B). This was 
similarly observed in the histograms whereby cells stained for DR5 had a larger 
rightward shift compared to cells stained for DR4 (Fig 12A).  Henceforth, we went a step 
further to investigate the effect of LY30 via the extrinsic pathway initiator, DR5, and its 







Figure 12: Surface expression of DR4 and DR5 in HeLa cells. HeLa cells 
(0.15x10
6
) were stained with anti DR4 or DR5-PE and analyzed by flow cytometry 
and plotted in (A) Histograms and (B) Density plots of forward scatter against DR4 
and DR5-PE fluorescence. Data are representative of at least 3 independent 






3.2 Pre-treatment with LY30 enhances DISC assembly in HeLa cells and reduces 
protein level of c-FLIPs.  
In order to link the effect of LY30 on surface DR5 expression to the apoptotic signaling 
triggered by TRAIL, we sought to understand if the effect of LY30 was mediated through 
an increase in the formation of a death initiating and signaling complex – DISC, a well 
established cardinal event during death receptor mediated signaling. Firstly, HeLa cells 
were incubated for 1hr with or without LY30, followed by a 5min exposure to TRAIL. 
Whole cell lysates were then immunoprecipitated with anti-DR5 and western blotting 
was performed to analyze for the specific DISC components using anti-FADD or anti-
caspase-8 antibody. A different anti-DR5 was used to detect the immunoprecipitated DR5 
as a positive control. Neither FADD nor caspase-8 were recruited in the untreated lysates 
while lysates treated singly with LY30 or TRAIL displayed an interaction between DR5, 
caspase-8 and FADD. However, it should be noted that FADD has previously been 
shown in HeLa cells to exist as a doublet upon western blotting (24KDa and 25KDa), 
which was precisely what was detected in the lysates of LY30+TRAIL treated cells, as 
compared to the single 25KDa band detected in cells treated with a single drug (Fig 13). 
Furthermore, both forms of processed caspase-8 (43KDa and 41KDa) were observed only 
in cells that underwent LY30+TRAIL treatment whereas single agent-treated cells had a 
less efficient processing of caspase-8 as only the 43KDa band was detected in these 
lysates (Fig 13). These data indicate a stronger and more complete DISC assembly in 
LY30+TRAIL treated cells as compared to cells treated with either LY30 or TRAIL.  
Additionally, we studied the protein levels of c-FLIP, a known negative regulator of 
caspase-8 by virtue of its ability to compete with caspase-8 recruitment to the DISC, thus 
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inhibiting activation of procaspase-8. HeLa cells were treated with the respective drugs 
for 3hrs and whole cell lysates obtained for analysis of c-FLIP by western blotting. The 
results showed that LY30 induced a decrease in, while TRAIL had a minimal effect on, 
the protein level of c-FLIPs. However, combined drugs treatment brought about the 
greatest reduction in c-FLIPs (Fig 14). This would also allow for a more efficient 
activation of the extrinsic apoptotic pathway, given the elimination of its negative 




Figure 13: LY30 enhances DISC assembly. HeLa cells (3x10
6
) were exposed to 
20ng/ml TRAIL for 5 min with or without prior addition of 25µM LY30 for an hr. 
Cells were harvested and immuno-precipitated with anti-DR5. Analysis of DICS 


















3.3 TRAIL induces a greater extent of initiator caspase-8 and Bid processing in 
combination with LY30. 
To further corroborate the findings in LY30+TRAIL treated cells, we considered the 
activation of initiator caspase-8 as the functional outcome of enhanced DISC formation. 
Lysates from treated, TRAIL or LY30 or LY30+TRAIL, or untreated HeLa cells were 
analyzed for both caspase-8 processing as well as for caspase-8 activity via western 
blotting and using fluorescent-conjugated substrates. Indeed, cells pretreated with LY30 
for 1hr followed by 6hr exposure to TRAIL displayed an augmented processing of 
caspase-8 to its intermediates (41/43KDa) and fully processed 17KDa forms as compared 
to cells treated with TRAIL or LY30 alone. The effect of TRAIL-induced caspase-8 
processing was significantly enhanced in the presence of LY30 (Boxed area in Fig 15A, 
 
Figure 14: LY30 induces a decrease in protein levels of c-FLIPs. HeLa cells 
(5x10
5
) were exposed to 20ng/ml TRAIL, in the presense or absence of a 1hr pre-
treatment with 25µM LY30, for 3hrs. Whole cell lysates were then used to assay for c-




comparing 20ng/ml TRAIL alone and 25µM LY30 with 20ng/ml TRAIL), alone which 
did not cause any processing of caspase-8. Processing of caspase-8 is accompanied by an 
increase in caspase-8 activity beginning at 4hrs (Fig 15B). 
Proceeding downstream of DISC activation, we examined the substrate of caspase-8, Bid, 
which is also the connection between extrinsic (receptor) apoptotic pathway and intrinsic 
(mitochondrial) apoptotic signaling. Active caspase-8 can cleave full length 22KDa Bid 
to form a 15KDa product, tBid, that induces the release of proapoptotic factors from the 
mitochondria. Western blotting of cell lysates after drug/s treatment for 8hrs revealed an 
almost unnoticeable band corresponding to tBid for TRAIL or LY30 singly treated cells. 
On the other hand, we observed a prominent amount of tBid in LY30+TRAIL treated 
cells, which corresponded with the concomitant decrease in full length Bid (Fig 15C).  
Subsequently, we sought to explore the means whereby LY30 enhanced DISC assembly. 
It is generally understood that death receptors oligomerization is an essential step in 
successful induction of apoptosis by the death ligand, TRAIL, and we‘ve mentioned 
previously that several independent studies have observed the ability of compounds, such 
as resveratrol or doxorubicin, to sensitize tumor cells to TRAIL-induced apoptosis via 
inducing death receptor clustering, hence more efficient apoptotic signaling at the DISC 
level, at distinct regions on the cell surface termed rafts. Therefore, we embarked on 
another series of experiments, including confocal analysis of cell surface receptors as 
well as sucrose-gradient ultracentrifugation to examine the effect of LY30 on the 




4.  LY30 clusters death receptors on cell surface upon an hour pre-incubation 
with LY30 and also upregulates their surface expression at later time points.  
4.1 Incubation with LY30 induces oligomerization of DR5. 
Death receptor oligomerization studies have been demonstrated previously using 3,3´-
Dithiobis(sulfosuccinimidylpropionate) (DTSSP), a non cell permeable amine-reactive 
ester, making it ideal as a cross-linker for extracellular surface proteins. These studies 
showed that cross-linked oligomerized DR5 complexes could be immunoprecipitated 
more readily than non-oligomerized DR5. HeLa cells were first exposed to LY30 for 1hr 
before DTSSP was added to the medium to allow for cross-linking of surface 
oligomerized DR5 to occur. The cells were subsequently harvested and whole cell lysates 
were used to immunoprecipitate DR5 using limiting (0.4µg) or excess amounts (5µg) of 
anti-DR5. Limiting and excess antibody amounts were determined by a separate titration 
process whereby the limiting amount was taken to be the amount of antibody that could 
pull down the least amounts of detectable DR5, observed by western blotting, in 
untreated cells.  
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Figure 15: LY30 enhances caspase-8 activation and loss of pro Bid. (A) Whole cell 
lysates of HeLa cells (5x10
5
) were obtained after exposure for 8hrs to TRAIL (20-
100ng/ml) with or without an hr pretreatment with LY30 and used to assay for caspase-
8 processing by Western blotting. (B) HeLa cells (3x10
5
) were exposed to TRAIL (4-
18hrs), with or without an hr pretreatment with LY30, and whole cell lysates were used 
to determine the activities of caspase-8 using fluorescent-conjugated substrates. Data 
shown are the mean±S.D. of at least three independent experiments. (C) Cleavage of 








 As the results in Fig 16A show, cross-linked DR5 could be pulled down more easily in 
lysates that had prior exposure to LY30 compared to untreated lysates, in the presence of 
limiting amounts of anti-DR5. This would suggest the ability of LY30 to induce 
oligomerization of surface DR5, explaining the larger amount of DR5 pulled down in the 
limiting-antibody pull down experiment, contributing to enhanced TRAIL sensitivity in 
these cells. Moreover, gel filtration followed by western blotting was performed and the 
presence of oligomerized DR5 in the higher molecular weights fractions (200-400KDa) 














Figure 16: LY30 induces oligomerization of DR5. (A) Immunoprecipitation with 
rabbit IgG was used as control in pull-down experiments (upper panel). HeLa cells 
(4x10
6
) were exposed to LY30 for 1hr before treatment with DTSSP to cross-link 
oligomerized DR5. The oligomerized DR5 was subsequently immunoprecipitated with 
limiting and excess amounts of anti-DR5 followed by analysis using Western blotting 
(lower panel). (B) HeLa cells (12x10
6
) were exposed to LY30 for 1hr before whole cell 
lysates were harvested for gel filtration to collect high molecular weights fractions of 







4.2 LY30 induces death receptors to coalesce into distinct raft regions on cell 
surface membrane. 
To provide visual evidence in the ability of LY30 to cluster death receptors, we analyzed 
the surface distribution of death receptors using confocal microscopy. Though DR4 is 
weakly expressed in HeLa cells, we wanted to investigate whether LY30 will similarly 
induce clustering of the low amounts of DR4 present and so improving its apoptotic 
signaling efficiency. HeLa cells were first seeded on glass-bottom chambers before 
treatment with or without 25µM LY30 for an hr, followed by fixing, without 
permeabilizing the cell membrane. They were stained overnight with primary antibodies 
against DR4 and caveolin-1 or DR5 and caveolin-1, a specific raft marker. Subsequently, 
we incubated the cells with their respective fluorescence-conjugated secondary antibodies 
for 2hrs before analysis using confocal microscopy. Fig 17A reveals the initial diffuse 
staining pattern of both DR4 receptors (red fluorescence) and caveolin-1 (green 
fluorescence) around the untreated cells, without much colocalization. In contrast this 
pattern changed for both DR4 and caveolin-1 into a patchy staining pattern, indicating the 
colocalization and clustering of both molecules at raft domains upon LY30 treatment. 
This is observed by the presence of distinct yellow domains present on the cell surface. 
Similarly, such a trend was observed when we studied staining distribution of DR5 and 
caveolin-1 after exposure to LY30 (Fig 17B) whereby there was a noticeable change in 
the diffused staining pattern into domains where both DR5 and caveolin-1 coalesce. We 
also noted that though the staining pattern for both DR5 and caveolin-1 were diffused in 
the untreated cells, there was a slightly larger extent of colocalization (diffused yellow 
staining around the cells) as compared to DR4 with caveolin.  
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To better identify lipid rafts, cell fractions enriched in cholesterol and expressing raft 
proteins, caveolin-1 and flotillin, were identified on a sucrose-density gradient. A typical 
feature of lipid rafts is their resistance to extraction by the nonionic detergent Triton-X in 
a sucrose-containing density gradient at 4ºC. Thus, whole cell lysates of untreated and 
LY30-treated cells were collected in Triton-X containing buffer at low temperature and 
subjected to ultracentrifugation for 21hrs on a sucrose-density gradient to collect 10 equal 
volume fractions. Each fraction was then evaluated by western blotting for the presence 
of raft markers such as caveolin-1 and flotillin, and the levels of cholesterol in each 
fraction was analyzed using a Cholesterol Quantitation kit. As shown in Fig, 18, majority 
of the raft markers appear in the early fractions (2-5) of the sucrose gradient after 
ultracentrifugation, corresponding to regions of lighter density, a characteristic of the 
lipid raft regions. These fractions also contain large amounts of cholesterol after 
quantification, further establishing the localization of lipid rafts regions into these early 
fractions. Henceforth, fractions 2 to 5 from the density gradient were collected to analyze 
for the presence of death receptors, indicating their distribution at these specific regions. 
We observed an increase in the levels of both DR4 and DR5 in fractions 2-5 after an hr 
treatment with 25µM LY30 as compared to the untreated cells where only slight levels of 







Figure 17: LY30 induces DR4 and DR5 clustering on cell surface. HeLa cells 
(0.3x10
5
) were plated on glass-bottom chambers and exposed to 25µM LY30 for an 
hr. Confocal analysis for (A) DR4 and caveolin, and (B) DR5 and caveolin were 









              
   


















Figure 18: Lipid raft markers are enriched in early fractions (2-5) of sucrose 
density gradients. HeLa cells (20x10
6
) were harvested from culture and  subjected 
to sucrose-gradient  ultracentrifugation for isolation of lipid rafts. Subsequently, 9 
equal fractions were obtained and each fraction was used to analyse for (A) caveolin 
and flotillin by SDS-PAGE and Western blotting, and (B) cholesterol levels using 







Previous studies indicated that ceramide-enriched membrane platforms serve to re-
organize and cluster receptor molecules in the plasma membrane, which is a pre-requisite 
for efficient signalling via these receptors. Such membrane signaling platforms are 
generated upon ceramide production in the rafts regions containing high levels of 
sphingomyelin. TRAIL-sensitizing compounds have been shown to induce the 
conversion of sphingomyelin into ceramide, which has a high tendency to coalesce, 
forming ceramide-enriched platforms containing clustered receptor. As such, we went on 
to investigate the ability of LY30 to induce any changes in levels of ceramide or 
sphingomyelin. HeLa cells were treated with LY30 for 1hour before harvesting them for 
lipid extraction, followed by HPLC analysis of ceramide and sphingmyelin levels in these 
whole cell lysates. Results indicate that LY30 caused an increase in ceramide levels, with 
a corresponding decrease in sphingomyelin levels (Fig 20A), in the overall lipid profile of 
HeLa cells.  However, to identify lipid changes specifically within rafts regions, we next 
isolated raft-rich regions using sucrose density centrifugation after one hour of treatment 
with LY30 before subjecting them to lipid extraction and HPLC analysis. Fig 20B 
showed that LY30 induced a rise in the levels of ceramide and a drop in levels of 




























Figure 19: LY30 induces DR4 and DR5 translocation into membrane lipid rafts. 
HeLa cells (20x10
6
) were either treated with 25µM LY30 for 1hr or left untreated, 
then harvested for sucrose-gradient ultracentrifugation. Lipid raft-enriched fractions 
(2-5) were subjected to SDS-PAGE before using Western blotting to analyze the 






Figure 20: LY30 induces a drop in sphingomyelin levels, accompanied by an 
increase in ceramide levels. HeLa cells (4x10
6
) were treated with or without 25µM 
LY30 for an hr before (A) whole cell lysates and (B) lysates pooled from fractions of 
2-5 after sucrose gradient ultracentrifugation were harvested for lipid profiling using 






4.3 Disruption of membrane rafts and death receptors clustering reduces 
upstream activation of procaspase-8 and reduced cleavage of caspase-8 substrate, 
Bid. 
To define amplification mechanisms mediating the synergy of LY30 and TRAIL to 
trigger apoptosis, ceramide-enriched membrane rafts were destroyed by pre-incubation of 
the cells with methyl-β-cyclodextrin (MBC). MBC extracts cholesterol from plasma 
membrane and thus, interferes with the formation of ceramide-enriched platforms 
induced by LY30 that serves to cluster the death receptors. Fig 21 shows the dose 
dependent depletion of cholesterol by MBC in raft rich sucrose-gradient fractions and 
subsequently, 5mM of MBC was used to pre-treat the cells for 1hr followed by co-




Figure 21: Dose dependent depletion of cholesterol in raft-rich fractions by 
methyl-beta-cyclodextrin (MBC). HeLa cells (20x10
6
) were treated with increasing 
doses of MBC (1-10mM) for 1hr before lysates were harvested for sucrose-gradient 
ultracentrifugation to isolate lipid rafts. Subsequently, 9 equal fractions were obtained 
and each fraction was used to analyse for cholesterol levels using Cholesterol 









Figure 22: MBC prevents DR4 clustering on cell surface. HeLa cells (0.3x10
5
) 
were plated on glass-bottom chambers and pretreated with 10mM MBC before 
exposure to 25µM LY30 for 1hr. Confocal analysis for DR4 and caveolin were carried 






Figure 23: MBC prevents DR5 clustering on cell surface. HeLa cells (0.3x10
5
) 
were plated on glass-bottom chambers and pretreated with 10mM MBC before 
exposure to 25µM LY30 for 1hr. Confocal analysis for DR5 and caveolin were carried 




Confocal analysis of HeLa cells, pre-treated with MBC and 1h of LY30, stained for death 
receptors and caveolin was carried out to observe the effect of raft disruption on the 
distribution of death receptors. In accordance, the patchy staining of clustered DR4 and 
DR5 was observed after 1h of treatment with LY30, compared to untreated cells, which 
was abrogated in cells that underwent a prior 1h treatment with MBC (Fig 22 and Fig 
23). This indicates again that the clustering of death receptors occurs in the cholesterol 
rich rafts regions of the membrane.  Interestingly, pre-treatment of HeLa cells with MBC 
failed to rescue cells against LY30+TRAIL induced loss in viability (Fig 24). However, 
study of early upstream signaling events indicated that disruption of death receptors 
impeded the activation of procaspase-8, as well the cleavage and activation of its 
downstream target Bid (Fig 25).  
Figure 24: Inability of MBC to rescue HeLa cells against LY30+TRAIL induced 
apoptois. HeLa cells (1 10
5
) were pretreated with MBC (0.5-10mM) for 1hr 
followed by 18hrs treatment with TRAIL±LY30. Cell viability was assessed by 
crystal violet staining. Data shown are the mean±S.D. of at least three independent 





Figure 25: MBC reduces upstream apoptotic signaling. HeLa cells (3 10
5
) were 
pretreated with 10mM MBC followed by exposure to LY30+TRAIL and harvested 
after the indicated periods. Whole cell lysates were subjected to SDS-PAGE followed 
by Western blotting for (A) Caspase-8 and (B) its downstream target, Bid.  
(A) 




4.4 LY30 upregulates protein levels of DR4 and DR5 after one hour.  
In addition to clustering of receptors, the upregulation of protein levels of death receptors 
have also been identified as another major mechanism to enhance the efficacy of TRAIL 
cytotoxicity. Therefore, we collected whole cell lysates of HeLa cells treated with 25µM 
of LY30 to study the protein levels of death receptors at various time points using 
western blotting. As Fig 26 shows, though there was no discernable change after an hr 
exposure to LY30, there was a detectable increase in levels of both DR4 and DR5 by 
3hrs. 
However, an increase in protein levels does not strictly reflect an increase of the death 
receptors at the surface of the cell, especially in cells with a defective receptor transport 
system. Accordingly, we undertook an analysis of surface receptor with the same 
experimental setup using anti-DR4-PE, anti-DR5-PE antibodies and anti-IgG-PE, as 
control staining, by flow cytometry (Fig 27). Both histograms display a rightward shift, 
indicating an increase in the population of cells displaying greater fluorescence due to the 
higher surface levels of death receptors by 3hrs of treatment with LY30. Similarly, the 
density plots illustrate an increase in the percentage of cells at the upper right quadrant 
which indicates the population of cells with higher fluorescence, from 13% in control to 
38% in LY30-treated cells for surface DR4 staining and from 18% to 34% in DR5 for 
cells treated with LY30. This reflects the same trend as the observed increase in its 
protein levels.  
Our data so far has suggested that LY30 not only stimulates death receptors on cell 
surface to coalesce within lipid rafts domains, it is also able to upregulate the surface 
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expression of both death receptors at slightly later times. Consequently, we sought to 
understand the importance of death receptors in LY30‘s ability to sensitize tumor cells to 
TRAIL-induced apoptosis.  
 
 
                               
                               
  
Figure 26: LY30 upregulates protein level of DR4 and DR5. HeLa cells (0.5x10
6
) 
were treated with or without 25µM LY30 (1-5hrs) and lysates were harvested for 
SDS-PAGE and Western blotting to study the changes in protein levels of death 













Figure 27: LY30 increases cell surface expression of both DR4 and DR5. HeLa 
cells (0.5x10
6
) were exposed to 25µM LY30 for 1hr before staining for cell surface 
receptor using specific primary antibodies against (A) DR4 or (B) DR5 and 
corresponding fluoroscence-conjugated secondary antibodies as described in Materials 
and Methods before analysis using Flow cytometry. Upper panels: Corresponding 
density plots of forward scatter and secondary antibody fluorescence.  Lower panel: 
Histogram of conjugated secondary antibody fluorescence intensity versus cell 




5. KNOCKING DOWN OF BOTH DEATH RECEPTORS AND INHIBITION OF 
LY30-INDUCED ROS PRODUCTION ABOLISHED SENSITIZATION OF 
HELA CELLS TO TRAIL-MEDIATED APOPTOSIS.  
 
5.1 Pre-incubation with receptor blocking antibodies partially rescues HeLa cells 
from LY30+TRAIL induced death. 
Monoclonal antibodies that are able to bind DR4 or DR5 specifically were used to inhibit 
TRAIL-induced apoptosis as they function as competitive inhibitors for binding to the 
death receptors. Hence, these blocking antibodies were added to cells in culture medium 
for 6hrs, prior to 1hr exposure to LY30 followed by incubation with TRAIL for 18hrs 
before measuring cell viability using Crystal Violet assay. Left panels of Fig 28 shows 
HeLa cells after washing off the excess crystal violet stain and the right panels of the 
same figure shows the graph showing that percentage of viable cells increased for cells 
with 6hrs pre-incubation with the respective blocking DR4/DR5 antibody before 
LY30+TRAIL treatment. This would indicate that death receptors might play a crucial 
role in the ability of LY30 to enhance cytotoxicity of TRAIL. To further augment the 
significance of their presence, we continued to work along this line by doing knockdown 







Figure 28: Receptor blocking antibodies are able to partially rescue the cells from 
LY30+TRAIL treatment. HeLa cells (0.14x10
6
) were pre-incubated with (A) DR4 or 
(B) DR5 blocking antibodies for 6hrs before an 18hr treatment with 20ng/ml TRAIL, 
with or without an hr pre-incubation with 25µM LY30. Cell viability was determined 
using Crystal Violet assay (Right). Left panel: Crystal violet staining of viable cells 





5.2 Knock-down of either DR4 or DR5 confers moderate protection against 
LY30+TRAIL induced apoptosis.  
RNAi-mediated interference of DR4 or DR5 was carried out using DharmaFECT-1 
transfection reagent and HeLa cells were treated with either 20ng/ml TRAIL or 25µM 
LY30 for 18hrs or 1hr of LY30 followed by 18hrs with TRAIL before they were 
harvested to determine cell viability using Crystal Violet assay. Separate whole cell 
lysates were collected for western blotting to examine for successful knock-down of total 
protein levels of DR4 and DR5 using β-actin as loading control. Results display similar 
characteristics as that obtained from experiments using receptor blocking antibodies in 
combination with LY30+TRAIL whereby knock-down of either death receptors 
abrogated the usual reduction in viability brought about by LY30+TRAIL to a certain 
extent, from 42% to 69% and 57% for knocking down of DR4 and DR5 respectively. 
Downregulating the protein levels of death receptors also protected the cells against 
TRAIL-induced apoptosis, as shown by the increase from the initial 67% of viable cells, 
compared to untreated cells, caused by 20ng/ml TRAIL to approximately 80%. This set 
of data serves as a positive control for the biological effect of effective knocking down of 
death receptors since TRAIL is the positive activator of DR4 and DR5 mediated 
apoptosis. Western blotting using anti-DR4 and anti-DR5 showed a decrease in total 
protein levels of both death receptors in the whole cell lysate (Upper right panels of Fig 








Figure 29: Knock-down of either DR4 or DR5 confers partial protection against 
LY30+TRAIL induced apoptosis. HeLa cells (0.1x10
6
) were transiently transfected 
with either negative control siRNA or siRNA against (A) DR4 or (B) DR5 and allowed 
to recover for 48hrs post transfection. Cells were subjected to drug/s treatment for 18hrs 
and viability determined using Crystal Violet assay (Right panel). Left upper panel: 
Western blotting of DR4/DR5 after48hrs of transient knockdown. Left bottom panel: 





5.3 Knock-down of both death receptors significantly abolishes LY30+TRAIL 
induced apoptosis in HeLa cells and also protects against LY30-induced cell death. 
 Since TRAIL is able to induce apoptosis through activating both death receptors, we 
proceeded with double knock-down experiments to bring down protein levels of both 
DR4 and DR5 simultaneously in HeLa cells. We aim to study whether LY30 retains its 
ability to enhance TRAIL-induced apoptosis, and whether LY30, itself, can reduce cell 
viability in the absence of death receptors. HeLa cells were spared from TRAIL-induced 
apoptosis as observed from the increase in cell viability from 67% to 96%, indicating 
once again that knock-down of both death receptors was effective in blocking the 
apoptotic signal stimulated by TRAIL. Importantly, the extent of cell death was reduced 
significantly from 58% to 15% upon double knock-down of death receptors, compared to 
cells treated with LY30+TRAIL with unaltered levels of death receptors (Fig 30). 
Additionally, we studied the effect of blocking activated initiator caspase-8, the 
functional outcome of DISC activation, using caspase-8 tetrapeptide inhibitor and 
observed slight protection against cell death induced by both compounds (Fig 31A). 
Subsequently, we verified the data and we show here that HeLa cells were protected 
against LY30+TRAIL treatment noticeably after performing caspase-8 knockdown (Fig 
31B).  
To further validate the significance of death receptors in the context of LY30-induced 
cell death, we treated HeLa cells with increasing doses of LY30 (25-200µM). As the 
graph in Fig 32 shows, HeLa cells begin to lose their viability after 18hrs of treatment 
with increasing concentrations of LY30 from the initial 100% to around 60% of viable 
cells with the higher concentration of LY30 at 100µM. Such an effect, however, could be 
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reversed upon eliminating both the death receptors by RNAi, reinforcing our data 





Figure 30: Knockdown of both receptors rescues HeLa cells from LY30+TRAIL 
induced apoptosis significantly. HeLa cells (0.1x10
6
) were transiently transfected 
with either negative control siRNA or siRNAs against both DR4 and DR5 and allowed 
to recover for 48hrs post transfection. Cells were then subjected to drug/s treatment for 
18hrs and viability determined using Crystal Violet assay (lower panel). Upper panel: 







Figure 31: Knockdown of caspase-8 inhibited cytotoxicity of LY30+TRAIL. (A) 
HeLa cells (0.15x10
6
) were pretreated with 50µM of IETDase inhibitor before 
TRAIL±LY30 exposure for 18hrs and cells were subjected to Crystal Violet Assay for 
viability study.  (B) HeLa cells (0.1x10
6
) were transiently transfected with either 
negative control siRNA or siRNAs against caspase-8 and allowed to recover for 24hrs 
post transfection. Cells were then subjected to drug/s treatment for 18hrs and viability 
determined using Crystal Violet assay (lower panel). Upper left panel: Viable cells 
stained with Crystal Violet after treatment. Upper right panel: Cells were harvested 




























5.4 Inhibition of LY30-induced ROS production by Tiron protects against 
cytoxicity of LY30+TRAIL. 
Poh and Pervaiz [369] showed in 2005 that the LY compounds were able to sensitize 
tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production, and 
that use of antioxidant abolished their death sensitizing property. Here, tiron was used 
successfully to inhibit the production of ROS by LY30 (Fig 33A) and we also observe 
that this is accompanied by significant resistance of HeLa cells against cytotoxicity of 
LY30+TRAIL with increasing doses of tiron (Fig 33B). Furthermore, we show here that 
pre-treatment of cells with tiron before addition of LY30+TRAIL for 2h prevented the 
increase in death receptors induced by LY30+TRAIL alone (Fig 33C). This observation 
was more pronounced for DR4, and this reflects the greater ability of DR4 blocking 
 
Figure 32: Knockdown of both death receptors rescues HeLa cells from LY30-
induced reduction in cell viability. HeLa cells (0.1x10
6
) were transiently transfected 
with either negative control siRNA or siRNAs against both DR4 and DR5 and allowed 
to recover for 48hrs post transfection. Cells were then subjected to LY30 (25-200µM) 




antibodies (Fig 28A) and DR4 knock down (Fig 29A) in protecting HeLa cells against 
LY30+TRAIL.  
In summary, we‘ve shown that LY30 is able to sensitize HeLa, a moderately TRAIL-
sensitive cervival cancer cell line, to TRAIL-induced apoptosis through enhancing the 
apical apoptotic signaling events at the death receptor levels. However, we would also 
like to further establish such a sensitizing ability of LY30 on TRAIL mediated cell death 
in a variety of other TRAIL-sensitive or TRAIL-resistant tumor cell lines. 
 
 
6. LY30 SENSITIZES SHEP-1 NEUROBLASTOMA, HT29 COLON 
CARCINOMA AND JURKAT T-CELLS TO TRAIL-INDUCED APOPTOSIS.  
6.1 LY30 is able to sensitive SHEP-1 neuroblastoma to TRAIL-induced 
apoptosis, as well as causing DR5 aggregation in these cells.  
We carried out a series of experiments in SHEP-1 neuroblastoma cells that verified that 
25µM of LY30 can similarly sensitize this tumor cell line to TRAIL-induced apoptosis 
(Fig 34). There was a 20% increase in cell death compared to that induced by 20ng/ml of 
TRAIL alone after an hr of pre-incubation with LY30 followed by 4hrs exposure to 
TRAIL. Along the same line, we studied the surface death receptor staining distribution 
using confocal microscopy for SHEP-1 cells after treatment with LY30 for an hr. Just as 
we had observed for HeLa cells, both DR4 and DR5 had a diffused staining pattern in 
cells cultured in normal media, and also that DR5 colocalized with caveolin-1 rich rafts 
to a much greater extent than DR4 with caveolin-1 as indicated by the even yellow 
fluorescence along the perimeter of the cells stained for DR5 and caveolin-1. However, 
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the diffused yellow fluorescence for DR5 and caveolin-1 congregated into a punctuate 
yellow staining distribution after an hr of treatment with LY30 in Fig 35. DR4 and 
caveolin, on the other hand, were stained distinctly, red or green respectively, without 
overlapping on the surface of the cell in untreated cells and there was no change in this 
staining distribution even after 1 hr incubation with LY30.  
Subsequently, whole cell lysates of untreated and LY30-treated cells were collected in 
Triton-X containing buffer at low temperature and subjected to ultracentrifugation for 
21hrs on a sucrose-density gradient to gain a better insight into the localization of death 
receptors in raft regions. As Fig 36 shows, indeed DR4 was absent in raft fractions (2-5) 
in both treated and LY30-treated cells, concluding that LY30 does not affect the 
localization or spatial distribution of DR4 in this cell line. Furthermore, the western blot 
analysis of DR5 in rafts fractions reveal that they are originally localized in these areas 
(distinct bands of DR5 observed in control cells) and that LY30 treatment only induce a 
change in their distribution pattern, from diffused to congregated DR5, and not an exact 
translocation into these rafts regions.  
 
6.2 LY30 enhances cytotoxicity of TRAIL in Jurkat cells and HT29. 
To demonstrate the sensitizing effect in a non-solid tumor model, we performed similar 
experiments in the TRAIL-sensitive leukemia cell line, Jurkat. They were pretreated with 
25µM LY30 followed by 20ng/ml TRAIL for 18hrs before determining cell viability 
using MTT assay. There was an approximate 25% increase in non-viable cells with 





Figure 33: Antioxidant, Tiron scavenges ROS production induced by LY30 and 
confers protection against LY30+TRAIL induced death via inhibiting the 
increase in protein expression of death receptors at early time point. (A) HeLa 
cells (0.3x10
6
) were treated with the indicated drugs for 1h before they were harvested 
for Flow cytometric analysis for ROS production using oxidant sensitive probe 
DCFDA. (B) HeLa cells (0.1x10
6
) were pretreated with indicated doses of Tiron 
before undergoing TRAIL±LY30 treatment and viability observed using Crystal violet 
Assay. (C) Whole cell lysates of HeLa (0.5x10
6
) were collected to analyse for total 






fold increase, of caspase-2, -3, -8 and -9 activity in LY30+TRAIL treated cells compared 
to cells treated with TRAIL alone as observed in Fig 37A and 37B.  
TRAIL-resistant colon carcinoma cell line HT29 was also tested in preliminary studies. 
Cells were pre-treated with an hr of LY30 (25-100µM) followed by an 18hr exposure to 
increasing doses of TRAIL (50-100ng/ml) before cell viability was quantified using 
Crystal violet assay. TRAIL alone did not induce reduction in cell viability in these 
resistant cells while LY30 alone caused around 20% reduction in viability. However, 
there was a marked synergistic reduction in cell viability for HT29 cells treated with both 
100µM LY30 and 100ng/ml TRAIL where viability fell a further 30%, compared to 




Figure 34: LY30 enhances TRAIL-induced cell death in SHEP-1 neuroblastoma. 
SHEP-1 cells (0.1x10
6
) were plated and exposed to 25µM LY30 for an hr followed by 
4hrs of incubation with 20ng/ml TRAIL. Cells were harvested and viability quantified 
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Figure 35: LY30 induces clustering of DR5 but not of DR4 on SHEP-1 cell surface 
membrane. SHEP-1 cells (0.3x10
5
) were plated on glass-bottom chambers and exposed 
to 25µM LY30 for an hr. Confocal analysis for (A) DR4 and caveolin, and (B) DR5 and 
caveolin were carried out as described in Materials and Methods. Data shown are 









Figure 36: LY30 enhances TRAIL-induced apoptosis in SHEP-1 neuroblastoma 
without inducing DR4/5 relocalization to rafts domains. SHEP-1 cells (20x10
6
) were 
either treated with 25µM LY30 for an hr or left untreated, then harvested for sucrose-
gradient ultracentrifugation. Lipid raft-enriched fractions (2-5) were subjected to SDS-















                          



















Figure 37: LY30 can also sensitize leukemic Jurkat cells and HT29 colon 
carcinoma to TRAIL-induced apoptosis. (A) Jurkat cells (1x10
6
) were exposed to 
20ng/ml TRAIL for 18hrs with or without an hr pre-incubation with 25µM LY30. Cell 
viability was measured by the MTT assay (upper panel) and (B) Caspase activity was 
determined using the respective fluorescent-conjugated substrates. (C) HT29 cells 
(1x10
5
) were exposed to TRAIL (50 or 100ng/ml) for 18hr, with or without prior 
incubation with an hr of LY30 (25-100µM) and cell viability was determined by 






1. THE “INACTIVE” ANALOGUE OF THE PI3K INHIBITOR LY294002, 
LY303511, IS AN ACTIVE COMPOUND. 
The bulk of this thesis centers on the anti-tumor effect of LY30, a supposed inactive 
analogue used as a negative control for the commonly used PI3K inhibitor, LY29. The 
first reports demonstrating the anti-tumor activity of LY30 were described in two 
separate studies in 2005 [369, 370]. The ability to generate H2O2 in tumor cells was 
observed initially with the active analogue, LY29, independent of its ability to inhibit 
PI3K Interestingly, in a subsequent study, a similar effect was observed with LY30 in its 
its ability to sensitize LNCaP prostate cancer cells to the commonly used microtubule-
targeting chemptherapeutic agent, vincristine [369]. At the same time, Kristof et al, 2005, 
reported that LY30 was able to inhibit p70 S6 kinase (S6K), a downstream effector of 
mammalian target of rapamycin (mTOR), a serine/threonine kinase involved in the 
regulation of cell growth and proliferation, without affecting the PI3K/AKT axis [370]. In 
that study, LY30 blocked proliferation in human lung epithelial adenocarcinoma A549 as 
well as in primary pulmonary artery smooth muscles by inducing G2/M arrest through 
reduction in G2/M-specific cyclins, but without triggering apoptosis. Furthermore, it was 
confirmed to have an inhibitory effect on the activity of casein kinase 2, CK2, a known 
regulator of G1 and G2/M progression. They further demonstrated the antiproliferative 
effect of LY30 in vivo, whereby LY30 inhibited the growth of human prostate 
adenocarcinoma tumor implants in athymic mice without overt toxicity (e.g. weight loss 
and decreased activity) related to the daily administration of LY30 for up to 20 days. 
Since then, various other studies have shown that the LY compounds, LY29 and LY30, 
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possess PI3K-independent activities in a variety of biological systems [216, 244, 369-
373]. Due to the diverse role of PI3K in cellular responses, the LY compounds have been 
used in studies on neuronal, cardiovascular, immune and metabolic systems, in addition 
to transformed/cancer cells. It is this wide spread usage that has uncovered the 
remarkably diverse biological effects, such as the unexpected ability to block potassium 
channels in rat pancreatic β cells [372] and voltage-dependent calcium channels in portal 
vein myoctes . Several groups also identified the NF-κB inhibitory activity of LY30, 
whereby this analogue inhibited LPS-induced NO production in macrophages via 
blocking iNOS expression through inhibition of NF-κB [373].  LY29 and LY30 were also 
reported in another study to exhibit inhibitory effect on NF-κB in human umbilical vein 
endothelial cells, which was further corroborated by Choi et al in 2004 by demonstrating 
the ability of these compounds to inhibit monocyte chemoattractant protein-1 expression 
in endothelial cells, partly through inhibition of NF-κB [371].   
 
Keeping these in mind, although LY29 has been widely used as a pharmacological 
inhibitor of PI3K, additional approaches such as dominant-negative inhibition or use of 
several  pharmacological inhibitors with different structures or mechanisms of action are 
required to confirm the involvement of PI3K in a particular biological process. Besides, 
potassium and calcium channels play an important role in contraction–relaxation cycle 
and cellular signaling for various biochemical reactions in the case of cardiomyocytes 
and other excitory cells. The fact that LY29 can block potassium and calcium channels in 
a PI3K-independent manner warrants the caution of using this inhibitor among these 
excitatory cells.  
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2. PRE-TREATMENT WITH LY30 SYNERGISTICALLY AMPLIFIED TRAIL 
SIGNALING AND VIRTUALLY COMPLETELY INHIBITED 
CLONOGENIC ABILITY IN HUMAN CANCER CELLS.  
In order to determine the possibility of LY30 acting as a sensitizer in TRAIL-induced 
apoptosis, the TRAIL responsive cervical carcinoma HeLa cell line was selected as the 
model cell line for this study. Here, LY30 demonstrated a TRAIL apoptotic enhancing 
ability as seen by the reduction in cell viability in Fig 3B , accompanied by a synergistic 
increase in DNA fragmentation (Fig 4) as well as significant increases in caspase 
activation and activities (Fig 6 and 7).  It is interesting to note that activity of caspase-2 
was amplified to almost 9 folds in LYL30+TRAIL treated cells as compared to the 
untreated cells and this brings to mind a study reporting the ability of LY30 to inhibit 
CK2 which phosphorylates procaspase-2, thus keeping it in an inactive state [374]. 
Hence, LY30 could possibly be relieving the inhibitory signal on caspase-2 in this 
system, partly accounting for the robust increase in its enzymatic activity. The caspase 
dependency of these processes was highlighted when the loss in cell viability, caspases 
activation as well as DNA fragmentation was abolished with the use of the pan-caspase 
inhibitor ZVAD-fmk in Fig 8.  The processing of caspase-8 after DISC formation is the 
main initiating event that stimulates downstream death execution; however, the tetra-
peptide caspase-8 inhibitor, IETD-fmk, did not completely salvage cells from the 
synergistic effect of LY30+TRAIL (Fig 31A). Knockdown of caspase-8 was carried out 
subsequently to verify this experiment (Fig 31B) since these tetrapeptides might not be 
effective in their inhibition of the caspases. Loss of caspase-8 reduced the extent of cell 
death induced by LY30+TRAIL significantly (Fig 31B), alluding to the importance of 
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caspase-8 activation, downstream of death receptor engagement, in triggering cell death 
induced upon combined drug treatments. However, we have not studied the activation 
and activity profile of caspase-10, another known initiator caspase that can be recruited 
and activated at the DISC, apart from caspase-8, hence it is unknown as yet, the 
contribution, if any, of caspase-10 in this model. Additionally, the long term proliferative 
capacity of these treated cells were also compromised, as observed in their inability to 
form colonies compared to untreated cells (Fig 5).  
 
3. AMPLIFICATION OF MITOCHONDRIA-DEPENDENT DEATH 
SIGNALING IS REQUIRED IN LY30+TRAIL INDUCED DEATH  
Data here also suggest the involvement of the mitochondrial apoptotic pathway in LY30-
induced TRAIL sensitization as seen by the increase in cytosolic cytochrome c and 
Smac/DIABLO in cells co-treated with LY30 and TRAIL versus cells treated with the 
single agent (Fig 9). The release of these death-promoting proteins preceeds the maximal 
activity of caspase-9 observed at 12hrs (Fig 10B), a mitochondria-activated initiator 
caspase, whose activation is contingent upon the presence of cytosolic cytochrome c. 
Furthermore, there have been reports implicating the role of mitochondria in TRAIL 
sensitization via the downregulation or inactivation of members of the IAP family such as 
XIAP and c-IAP.  In line with that, an increase in the cleaved fragment of XIAP and a 
concomitant reduction in the full-length XIAP was observed in cells exposed to 
LY30+TRAIL for 6hrs (Fig 10A), a time point that corresponded with the cytoslic 
translocation of Smac/Diablo. The cleavage of XIAP produces 2 subunits: one that 
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comprises of BIR1 and BIR2, and the second, BIR3-RING, represented by the 30kDa 
fragment and similar to the fragment detected by Western blotting upon exposure to 
LY30 and TRAIL. The N-terminal BIR1-2 fragment has a reduced propensity to inhibit 
caspase-3 and 7 and is not detectable via western blotting since the residues that anti-
XIAP recognizes lies within the C-terminal region of XIAP, which is more susceptible to 
further caspase-mediated degradation. On the other hand, the inhibitory activity of 
caspase-9 is localized to the BIR3-RING domain of full length XIAP, and cleavage into 
its 30kDa fragment may represent a dominant negative form of XIAP. Interestingly, an 
earlier report showed similar cleavage of XIAP to a 30kDa fragment upon treatment with 
TNFα induced similar cleavage of XIAP to a 30kDa fragment enhanced by LY29, again 
alluding perhaps to the non-specificity of the LY compounds [375].  
 
Collectively, these data indicate that the involvement of mitochondria amplification of 
death signal following the initial trigger is vital and this is subsequently demonstrated in 
HeLa cells that overexpress Bcl-2 protein. It is known that members from the Bcl-2 
protein family serve as regulators of mitochondria-mediated apoptosis, with Bcl-2 
holding a prominent role in preventing mitochondrial outer membrane permeabilization 
and downstream execution. Therefore, to decipher the involvement of the mitochondrial 
pathway in LY30 induced sensitization to TRAIL, the effect of the combined treatment 
was assessed in Hela cells stably overexpressing Bcl-2.  Overexpression of Bcl-2 
significantly blocked apoptosis induced by LY30+TRAIL (Fig 11), thus providing 
evidence for a critical involvement of the mitochondrial amplification pathway in the 
TRAIL-sensitizing activity of LY30.  
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As caspase activation, mitochondrial amplification and DNA fragmentation are 
downstream events during death receptor-mediated apoptotic execution, it was imperative 
to unravel the upstream signal triggered upon exposure of cells to LY30 prior to ligation 
of the death receptors with TRAIL.  To that end, the ability of LY30 to amplify the effect 
of TRAIL via its effect on death receptor signaling was investigated.  TRAIL-mediated 
apoptosis follows a pathway similar to FasL and TNFα whereby binding of death ligands 
to respective death receptors induces receptor trimerization and serves to stimulate DISC 
assembly, leading to processing of procaspase-8 and initiating the caspase cascade with 
(Type II) or without (Type II) the need for amplification from the mitochondria [51, 52].  
 
4. LY30 INDUCES DEATH RECEPTOR CLUSTERING ON CERAMIDE-
ENRICHED PLATFORMS THAT FACILITATE TRAIL-APOPTOTIC 
SIGNALING  
4.1 LY30 induces death receptor clustering  
To begin with, we analyzed the basal levels of TRAIL death receptors on HeLa cells and 
observed that these cells expressed both the receptors on their cell surface; however the 
expression of surface DR5 was significantly higher than DR4.  Hence, we proceeded to 
do DR5-affinity immunoprecipitation in cells treated with LY30 for an hr followed by 
5mins of TRAIL treatment to study its effects on DISC formation. Interestingly, we 
observed an enhancement in the assembly and processing of the DISC components, 
namely, FADD and caspase-8, efficient processing of caspase 8 and its substrate Bid to 
tBid, which facilitates mitochondrial membrane permeabilization. These data were 
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further corroborated by confocal microscopy.  Indeed, LY30 induced distinct 
oligomerization of both death receptors on the cell surface (Fig 17) and induce formation 
of high molecular weights DR5 aggregates as observed by limiting DR5-affinity 
immunoprecipitation and gel filtration (Fig 16).  
Historically, members of the TNF receptor family (TNFRs) were thought to exist as 
monomeric receptor chains prior to stimulation and death receptor homotrimerization has 
been classically attributed as a downstream effect of ligand binding [376]. Hitherto, 
evidence has indicated that many TNFRs, including TRAIL receptors, actually exist as 
pre-assembled oligomers on the cell surface prior to ligand stimulation [377], which is 
regulated by the the pre-ligand assembly domain (PLAD) residing within the membrane 
distal cysteine-rich domains of the receptors [378-382]. There is growing evidence 
suggesting that there is a greater extent in regulation of cellular response at the receptor 
level apart from the classical view that ligand stimulation causes di/trimerization of 
receptors leading to activation of downstream signals. The PLAD has been identified to 
be involved in modulation of cellular response to TRAIL stimulation via PLAD-mediated 
receptor association, whereby it allows for the extracellular domains of death/decoy 
receptors to interact in a ligand independent manner [383]. In this scenario, the balance 
between the homotypic death receptors versus heterotypic mixed TRAIL receptor 
complexes may determine cellular response to TRAIL. Along this line, Giuliana Papoff et 
al, 1999 identified and characterized a novel CD95 ligand- and death domain-
independent oligomerization domain mapping to the NH(2)-terminal extracellular region 
of the CD95 receptor. In vitro and in vivo studies indicated that this domain, conserved 
among all soluble CD95 variants, mediates homo-oligomerization of the CD95 receptor 
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and of the soluble CD95 proteins, as well as hetero-oligomerization of the receptor with 
the soluble variants [378]. One possible biological advantage pre-assembled receptors 
offer over ligand-induced trimerization is that they may bind ligands with higher affinity 
than monomeric receptors. Indeed, it was reported that deletion of PLAD in TNFR1/2 
and DR5 severely compromised their ligand binding capacity, and since TNF-like 
cytokines are present at low concentrations physiologically, these pre-assembled 
receptors may facilitate rapid cellular responses to cytokine stimulation [380, 383]. As 
such, it is plausible that the TRAIL-sensitizing ability of LY30 could be due to its ability 
to induce multimerization of DR4 and DR5 (Fig 17), thus creating a favorable 
environment that augments the binding of TRAIL to its receptors, increasing its apoptotic 
index. For example, in the case of the CD95 (Apo1/Fas) death receptor, formation of 
macro-molecular aggregates, whereby multiple copies of pre-assembled homo-dimer 
clusters, is an essential intermediate step during receptor activation [384, 385]. Moreover, 
it has also been observed in many other studies that compounds such as cisplatin, 
resveratrol and doxorubicin accelerate TRAIL-mediated death via inducing aggregation 
of death receptors, stimulating a more robust DISC assembly [247, 275, 386].  
 Furthermore, LY30 reduced levels of the downstream inhibitor of DISC mediated 
caspase-8 activation, c-FLIPs, allowing for a more efficient transduction of the upstream 
apoptotic signal (Fig 14). The two- pronged effect of LY30 in enhancing upstream 
activating signal, as well as annulling inhibitory signal, at the death receptors level serves 
to increase the efficacy of TRAIL in inducing apoptosis in tumor cells. Such a clustering 
effect was also observed in the SHEP-1 neuroblastoma cells that were similarly sensitized 
to TRAIL-induced apoptosis by LY30 (Fig 35).   
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4.2 LY30 triggers formation of ceramide-enriched raft platforms on cell surface 
membrane leading to death receptor clustering  
The plasma membrane consists primarily of sphingolipids, cholesterol and other 
(glycerol) phospholipids. The lateral assemblies of sphingolipids (sphingomyelin being 
the most prevalent) and cholesterol that forms from the tight hydrophobic interactions 
between these molecules result in their segregation from other phospholipids into distinct 
microdomains, termed rafts [387-389]. These microdomains could be isolated by virtue 
of their detergent insolubility and further characterized by identifying their high content 
of cholesterol and the presence of bona fide raft-associated proteins, such as caveolin and 
flotillin in early fractions (2-5) after ultracentrifugation in a sucrose gradient density (Fig 
18) [390]. We show here that LY30 is able to trigger the distribution of both death 
receptors into membrane rafts of HeLa cells as seen by the presence of these proteins in 
the raft fractions by western blotting (Fig 19).  Further analysis by confocal microscopy 
confirmed that the death receptors formed patches of aggregates that colocalized with 
caveolin-1, the raft marker (Fig 17).  
The involvement of ceramide in rafts has been described previously.  For example, 
treatment of tumor cells with a variety of compounds, or the natural death receptor 
ligands, induces translocation of acid sphingomyelinase (ASM) to the extracellular leaflet 
of the cell membrane from intracellular stores within seconds to minutes [245, 386, 391-
393]. This brings ASM into close proximity of sphingomyelin that is contained 
predominantly in rafts on the outer leaflet of the plasma membrane, where it hydrolyzes 
sphingomyelin to release ceramide [394, 395]. The generation of ceramide within rafts 
dramatically alters the biophysical properties of these membrane domains, since ceramide 
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molecules have the tendency to spontaneously self-associate, to form ceramide-enriched 
microdomains that fuse and form large ceramide-enriched membrane platforms [396]. 
These platforms serve to reorganize the receptor molecules through two mechanisms; 
whereby they can directly cluster receptor molecules that are constitutively present in the 
rafts, or receptor molecules that are outside these rafts can be recruited into these 
platforms upon activation. Resveratrol had been shown to induce redistribution of three 
different death receptors, CD95, DR4 and DR5, into rafts indiscriminately accounting for 
its synergistic toxicity towards these death receptor ligands [247].  Similarly, Cahuzac, N 
et al, 2006 also observed a heightened cell death inducing effect of Fas ligand after their 
localization to the membrane rafts [397]. Interestingly, Psahoulia, FH et al, 2007 reported 
that quercetin, the parent compound of LY30, amplified TRAIL-induced apoptosis by 
affecting the redistribution of DR4 and DR5 into lipid rafts in colon adenocarcinoma 
cells [243].  
The data presented here shows that one hour of treatment with LY30 reduced the total 
levels of sphingomyelin, while increasing the amount of ceramide in the whole cell 
lysates measured using HPLC (Fig 20A). However, to further validate that the increase in 
ceramide occurs specifically in the raft domains, LY30-treated cells were first subjected 
to sucrose density ultracentrifugation before HPLC analysis on the pooled raft-containing 
fractions (fractions 2-5) (Fig 20B). We observed a similar increase in ceramide together 
with a reduction in sphingomyelin levels in LY30-treated cells, compared to the untreated 
cells. These data provide evidence that pretreatment of HeLa cells with LY30 induces the 
generation of ceramide in lipid rafts, which leads to the formation of larger ceramide-
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enriched platforms that serve to cluster the death receptors in rafts (Fig 17), similar to the 
effects of its parent compound, quercetin.   
It is noteworthy that DR5 in both HeLa cells and SHEP-1 neuroblastoma cells seems to 
be constitutively present in the rafts under unstimulated conditions (Fig 17 and Fig 35).  
It is however, only after LY30 treatment, that these homogenously distributed raft-related 
death receptors reorganize to form larger aggregates, as seen by the brighter and patchy 
staining pattern observed for DR5 and caveolin-1, in both HeLa and SHEP-1 cells. This 
was corroborated by the immunoblots (Fig 17) showing the presence of DR5 in the raft 
fractions of both the control cells and more of this protein after exposure to LY30. Hence, 
in this case, the production of ceramide triggered by LY30 resulted in the formation of 
larger ceramide-enriched raft platforms that served to cluster raft-associated DR5 in these 
tumor cells. On the other hand, DR4 was mainly distributed outside of the raft 
microdomains as seen by both immunoblotting of raft fractions and confocal analyses 
(Fig 17 and Fig 35) for both HeLa and SHEP-1 cells. There was no overlapping between 
the distribution of DR4 (red) and caveolin-1 (green) for these cells and there was a 
marked absence of DR4 in the raft fractions of SHEP-1 cells. Nonetheless, LY30 had a 
similar effect on DR4 in HeLa cells as it had on DR5. There was a redistribution of DR4 
into raft platforms after 1hr of exposure to LY30. Intriguingly, DR4 in SHEP-1 remains 
unaffected by LY30, though it is known that LY30 is able to upregulate the protein levels 
of both DR4 and DR5 in SHEP-1 cells within an hr, leading to sensitization towards 
TRAIL-induced apoptosis [216].  
The mechanisms regarding receptor clustering, and preferential trapping of any receptor, 
into these ceramide enriched domains are still not well characterized. Employing 
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chimeric proteins that consisted of the extra- and intracellular domain of CD40 and the 
transmembraneous domain of CD45 [398], it was shown that while wildtype CD40 
translocated into ceramide enriched domains upon stimulation the chimeric protein failed 
to cluster. A novel role for the death domain was suggested by Cottin, Doan et al 2002 by 
providing evidence that amino acid sequences located within the death domain of TNF-α 
receptor CD120a were both necessary and sufficient to promote the appropriate 
localization of the receptor to lipid rafts [399]. Deletion of the amino acid sequence 
resulted in uniform plasma membrane localization and was paralleled by a failure of the 
receptor to initiate apoptosis. A recent publication concluded that localization of Fas 
ligand to lipid raft appeared to be predominantly mediated by the characteristic 
cytoplasmic proline-rich domain of this ligand, as mutations of this domain resulted in 
reduced recruitment to lipid rafts and attenuated the death inducing activity of Fas ligand 
[400]. The discovery of such domains  lends credence to the possibility that LY30 might 
be able to stimulate clustering of receptors through regions, independent of ligand 
binding domain. 
However, there are still several aspects that we have to address before concluding that 
LY30-induced death receptor clustering is solely responsible for its ability to sensitize 
tumor cells to TRAIL in view of the plethora of biological effects it possess. The 
importance of ceramide formation and promotion of ceramide-enriched membrane 
domains in sensitizing tumor cells to death ligands was demonstrated in other studies 
when inhibition of ceramide enriched domain formation using cholesterol extracting 
drugs, such as nystatin or methyl-β-cyclodextrin (MBC) [247, 393, 401], or inhibitiors of 
ASM [245] abolished the ability of the compounds to sensitize tumor cells. Furthermore, 
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genetic deficiency of ASM in splenocytes abrogated apoptosis induced by doxorubicin 
with TRAIL, and in another study Fas-induced apoptosis in ASM-defective T cell 
lymphoma was ineffective [386, 402]; both systems required membrane ceramide 
platforms to induce effective apoptosis.  On the other hand, addition of natural ceramide 
also forms ceramide enriched platforms that are sufficient to cluster CD95 receptor 
molecules, and reinstate its apoptotic ability in ASM-deficient cells [394, 403]. In this 
regard, translocation of ASM to the outer leaflet of the plasma membrane has been 
demonstrated, where the surface ASM triggers the conversion of sphingomyelin in the 
membrane rafts to ceramide. Results reported here argue in favor of LY30-induced 
generation of ceramide from pre-existing sphingomyelin (Fig 20) rather than de novo 
synthesis. To further delineate the relevance of these ceramide-platforms in LY30‘s 
sensitizing effect on TRAIL, we employed cholesterol extracting drug MBC that 
successfully disrupted rafts (Fig 20) and hence clustering of death receptors (Fig 22 and 
Fig 23). Intriguingly, we realized that inhibition of receptor clustering failed to protect 
these cells against LY30+TRAIL treatment (Fig 24). Since it was well established that 
clustering of death receptors serves to enhance signaling by apoptotic ligands, it seems 
improbable that the clustering phenomenon we observe here has no biological 
significance. Therefore, we undertook a further experiment to investigate the effect of 
LY30-induced clustering on upstream signaling induced by TRAIL. Indeed, cells that 
underwent raft disruption, and consequently death receptor clustering (Fig 22 and Fig 
23), displayed lesser upstream caspase-8 activation (Fig 25A) at 2hrs and 4hrs, as well as 
a reduction in the cleavage of its downstream target, Bid (Fig 25B) as shown by the 
absence of tBid in cells treated with MBC prior to LY30+TRAIL. This suggests that 
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TRAIL-sensitizing ability of LY30 involves, but  is not solely dependent on the 
formation of preclustered death receptors and this would hardly be unexpected given the 
plethora of biological effects it has been reported to mediate. 
 
5. DEATH RECEPTORS PLAY AN IMPORTANT ROLE IN THE ABILITY OF 
LY30 IN ENHANCING TRAIL-MEDIATED CELL DEATH.  
5.1 LY30 upregulates the surface expression of death receptors via increasing 
total death receptor protein levels 
An extended study in the effects of LY30 on death receptors revealed that treatment of 
HeLa cells with LY30 resulted in an increase in total death receptor levels in whole cell 
lysates analyzed by western blotting by 3hrs and this was corroborated by a flow 
cytometric analysis of expression of surface death receptors, also displaying higher 
surface fluorescence for both death receptors. Death receptor upregulation is a classical 
mechanism employed by various compounds to sensitize tumor cells to TRAIL-induced 
apoptosis and this has been widely studied by several groups. Upregulation has been 
attributed to increased transcriptional and translational efficiency as well as reduced 
proteasomal degradation [234, 240, 248, 274]. LY30 has been reported recently to induce 
upregulation of death receptors via a ROS regulated, MAPK dependent pathway where 
activation of ERK and JNK, played crucial roles in inducing upregulation of death 
receptors resulting in greater sensitivity of SHEP-1 neuroblastoma cells to TRAIL-
induced apoptosis. As such, it is not inconceivable that LY30 could be propagating the 
same signals through MAPK to bring about the increase in total receptor levels since it is 
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also able to generate ROS in this system. Additionally, as summarized in Table 2, there 
are still a myriad of transcription factors that could account for the upregulation of death 
receptors, including NF-κB, C/EBP Homologous Protein (CHOP) and Activating 
Protein-1 (AP-1) [204, 239-242].  
 
5.2 Crucial role of death receptors in sensitization of HeLa cells to TRAIL and 
cytotoxicity of LY30 
Our result indicates that the combined effect of LY30 and TRAIL is caused by specific 
interaction between TRAIL and its receptors as observed by the improved efficiency of 
downstream DISC assembly and subsequent activation of caspase-8, leading to the 
amplification of mitochondria death signal through increased cleavage of Bid. 
Furthermore, knock down of both death receptors were sufficient to abrogate cell death 
induced by LY30+TRAIL (Fig 30). It is also interesting to note that, unlike the protective 
effect displayed upon knocking down of death receptors; pre-incubation with receptor 
blocking antibodies did not shield HeLa cells against LY30 cytotoxicity at 25µM. 
Though cytotoxicity of 20ng/ml TRAIL and 25µM LY30 was not significant, addition of 
receptor blocking antibodies salvaged the 15-20% of killing induced by TRAIL alone, 
but not so for LY30. In contrast, knock down of death receptor protein inhibited LY30-
induced cell death. Hence we can infer from these data that LY30 does not require the 
ligand binding site to induce death, either via mimicking the apoptotic effect of TRAIL 
through the ligand binding site or improving the cells‘ response to TRAIL via inducing 
any changes in the ligand binding site. Instead, it seems to function by inducing lateral 
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rearrangements and upregulation of death receptors on the cell surface to bring about 
more efficient DISC activation as discussed earlier whereby inhibition of death receptor 
clustering by MBC inhibited activation of caspase-8, as well as the abrogation of cell 
death when death receptors are knocked down.  
Hence, to pursue the significance of death receptors in LY30-induced cell death, we 
incubated HeLa cells with increasing doses with LY30 after knocking down both death 
receptors. Our data implicated an important role of death receptors in, not only the ability 
of LY30 in enhancing TRAIL-induced apoptosis (Fig 30), but also in the cytotoxicity of 
LY30 alone at higher concentrations, at least up till 100µM (Fig 32) whereby knocking 
down of both death receptors confer significant protection against LY30-induced 
cytotoxicity at higher doses of 50 and 100µM, from a viability of 60% to 90% compared 
to untreated cells. However, such protective effect was not observed when cell were 
treated with 200µM of LY30, indicative of either the ability of LY30 to trigger other 
death promoting pathways, independent of the death receptors, or that the extent of knock 
down of death receptors was not sufficient to counter-act the cytotoxic effect of LY30. 
The former situation would not be entirely surprising given the multiple effects that 
LY30 has on other important cellular signaling components. It should be kept in mind 
that introduction of antioxidant into HeLa cells could protect them against LY30-induced 
death, albeit minimal extent at 25µM of LY30, but it does provide some inkling of the 
role of ROS in LY-30 induced death and a possible relationship between increased 
intracellular ROS and clustering or upregulation of death receptors. This will be 
discussed in further detail in the following section. 
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6. POSSIBLE PHYSIOLOGICAL EFFECTS FROM GENERATION OF 
INTRACELLULAR ROS BY LY30. 
6.1 Intracellular H2O2 production: a permissive environment for sensitizing of 
tumor cells to drug-induced apoptosis. 
H2O2 has been shown to play vastly different roles in the cell, where slight perturbations 
in the delicate intracellular redox status can greatly affect cell physiology. Depending on 
its concentration, it was understood that large amounts of H2O2 induces necrotic cell 
death but it was later discovered that lower levels of H2O2 play significant roles in cell 
signaling where low exogenous amounts of H2O2, similar to the effect of O
2-
, can 
stimulate the proliferation of cells in culture [404, 405], through the tyrosine 
phosphorylation of growth factor receptors even in the absence of growth factor 
stimulation. Furthermore, it was implicated in mediating drug-induced apoptosis by 
creating an intracellular mileu permissive for caspase activation and death execution in 
different models [406].  It was shown that intracellular production of H2O2 upon 
cytotoxic insults can lead to a more reducing intracellular environment that would favor 
apoptotic signals via intracellular acidification and translocation of Bax to the 
mitochondria [364]. As such, H2O2 plays a decisive role in maintaining the 
survival/apoptotic homeostatic balance along with O2
.-
 and manipulations of this delicate 
balance can bring about an augmentation of the apoptotic capability of 
chemotherapeutics. They demonstrated that addition of sub-apoptotic concentrations of 
H2O2 significantly enhanced the sensitivity of tumor cells to drug-induced apoptosis, such 
as TNFα and TRAIL; while alternatively, scavenging of intracellular H2O2 by antioxidant 
measures hampered death execution [407]. Thus it is logical to utilize compounds that 
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can produce sufficient amounts of H2O2, to create a favourable environment, in 
conjecture with existing chemotherapeutic drugs to improve their efficacy. 
 
6.2 Role of ROS in sensitization of tumor cells to TRAIL-induced apoptosis. 
The effects ROS on TRAIL-induced apoptosis in solid cancers was studied by Izeredjene, 
K. et al, 2005 and they found that the classic uncoupler of oxidative phosphorylation, 
carbonyl cyanide m-chlorophenylhydrazone (CCCP), induced a generation of ROS that 
enhanced TRAIL-induced apoptosis in TRAIL-resistant human colon carcinoma cell 
lines (RKO, HT29, and HCT8) with increased Bax translocation and caspase activation. 
The importance of ROS was demonstrated when scavenging ROS completely abrogated 
apical caspase-8 activation and further downstream events leading to cell death [408]. 
Additionally, Meurette, O et al, 2005 explored the role of intracellular reduced 
glutathione (GSH), an important protein involved in intracellular antioxidant defense, 
level in cell sensitivity with regards cell death induced by TRAIL in combination with 
anti-cancer drugs like cisplatin or 5-florouracil and reported that GSH depletion was 
useful in increasing the therapeutic efficacy of cancer treatment by TRAIL/anticancer 
drug combinations [409] .   
Interestingly, many drugs that modulate sensitivity to TRAIL are also efficient producers 
of ROS, mainly hydrogen peroxide (H2O2).  In support of the hypothesis that ROS 
produced by these drugs is a critical upstream signaling molecule that plays an important 
role in sensitization to TRAIL, Shenoy et al, 2009 showed that pre-incubation of SHEP-1 
neuroblastoma cells with the H2O2 scavenger, catalase, completely prevented death 
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receptor upregulation and enhanced sensitivity to TRAIL [216]. Furthermore, drugs such 
as sulphoraphane and curcumin have been reported to sensitize hepatoma and renal 
cancer cells, respectively, to TRAIL-induced apoptosis via a ROS-mediated upregulation 
in protein levels of DR5. Additionally, pretreatment with antioxidants such as N-Acetyl 
Cysteine (NAC) and peroxiredoxin II abolished the increase in DR levels induced by 
these compounds [239, 297]. The role of ROS in sulforaphane-mediated TRAIL receptor 
upregulation was further corroborated in another study whereby over-expression of 
catalase completely blocks the increase in DR5 [297]. The proteasome inhibitor, MG132, 
has been shown to prevent NF-ĸB activation induced by TRAIL by inhibiting 
degradation of IĸB as well reducing protein levels of c-FLIP. However, a mechanism by 
which MG132 sensitizes tumor cells to TRAIL through production of ROS has also been 
described whereby ROS leads to an increase in p53-mediated DR5 upregulation. The 
binding of p53 to an intronic site on DR5, increase in DR5 levels and enhanced apoptosis 
are abrogated in the presence of NAC and GSH [204].  
ROS has also been identified to be involved in the down-regulation of c-FLIP by TRAIL 
sensitizing drugs, in addition to modulation by other mechanisms. For example, 
compounds like withaferin A trancriptionally regulate both c-FLIPs and c-FLIPL in a 
ROS-mediated, NF-κB dependent manner [248], whereby pre-incubation of human renal 
cancer cells with NAC abrogated the decrease in c-FLIPS and c-FLIPL obtained with 




6.3 Relevance of LY30-induced ROS in its death-sensitizing/inducing ability in 
HeLa cells.  
A dual role of LY30 in this system has been observed, whereby it is able to induce 
clustering of pre-exisitng death receptors into ceramide-enriched platforms, as well as 
causing an increase in protein levels of death receptors from 3hrs. We had mentioned in 
the previous section regarding the role of ROS in the upregulation of death receptors in 
various tumor cells treated by compounds such as curcumin [292] and sulphoraphane. 
We observed similar occurrence in the HeLa model where LY30 was able to elicit ROS 
production (Fig 32A) as early as 30 minutes after incubation with the compound that 
lasted for at least 6hs and this correlates with the upregulation of death receptors (Fig 26). 
Preincubation of the cells with antioxidant tiron blocked ROS production effectively (Fig 
33A), and also conferred significant protection of HeLa cells against LY30+TRAIL 
treatment, comparable to that afforded by knocking down of death receptors (Fig 33B). In 
fact, we observed that inhibition of ROS was associated with an inhibition of 
upregulation of death receptors (Fig 33C). This observation was more pronounced for 
DR4, and this reflects the greater ability of DR4 blocking antibodies (Fig 28A) and DR4 
knock down (Fig 29A) in protecting HeLa cells against LY30+TRAIL.  
Additionally, the role of ROS in inducing dearth receptor clustering has been widely 
reported as well. Huang HL et al, 2003 demonstrated that DNA damaging reagents such 
as cisplatin and gamma-irradiation promotes ROS production, which in turn contributes 
to Fas receptor aggregation and cell death. The absence of Fas greatly reduced the 
sensitivity to apoptosis mediated by these agents, indicating the dependence on death 
receptors for induction of apoptosis. ROS scavengers, such as NAC, MnTBAP and C60, 
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effectively prevented the clustering of Fas receptor induced by both agents. Furthermore, 
they showed that addition of FasL significantly improved the apoptotic efficacy of these 
agents, when used in combination. Moreover, ligand independent-induced cell death has 
been observed in several studies including the one by Huang HL et al, 2005 mentioned 
before. Likewise, Sheihk MS et al, 1998 showed that ultraviolet-irradiation-induced 
apoptosis is mediated via ligand independent activation of TNFR1 wherein the UV-
irradiation appeared to engage the apoptotic axis of TNFR1, independent of its ligand, to 
transducer its apoptotic signals. Glutamine deprivation was shown to mediate cell 
shrinkage, leading to apoptosis through a ligand-independent CD95 receptor signaling 
pathway as well. Cell transfection with plasmids expressing dominant negative FADD 
pointed to a functional clustering of CD95 receptors at the cell surface with activation of 
the extrinsic pathway caspase cascade. As such, it is reasonable to suggest that LY30 can 
induce a functional clustering, as well as upregulation, of surface death receptors, leading 
to enhanced ―activation‖ of the extrinsic apoptotic pathway upon TRAIL ligation, 
whereupon a knock down of death receptors was sufficient to abolish its cytotoxic 
effects.  
Likewise, there have been publications on the positive influence of ROS in the formation 
of ceramide-enriched platforms via the activation of ASM, leading to the conversion of 
ceramide from sphingomyelin and formation of ceramide-enriched raft platforms. 
Komatsu M et al, 2001 provided evidence for the pivotal role of ASM in apoptosis 
induction by H2O2 using Epstein-Barr virus (EBV)-transformed lymphoblast cells from 
type A NPD patient containing defined splicing site mutation in the ASM gene. They 
showed that these ASM-deficient cells were defective in H2O2-induced apoptosis. 
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Furthermore, Qiu et al. 2003 who demonstrated that oxidation at its cysteine residue 629 
activates ASM. Their results indicated that purified rhASM can be activated in vitro by 
loss of the free thiol on the C-terminal cysteine via chemical modification, dimerization, 
or deletion of this amino acid residue and they proposed that this represent a mean of 
post-translational regulation of ASM in vivo. Dumitru C A et al, 2006 reported that 
TRAIL and CD95 activate the ASM via a redox mechanism resulting in release of 
ceramide and formation of ceramide-enriched membrane platforms. Ceramide-enriched 
membrane platforms clustered DR5 upon stimulation and the use of antioxidants, tiron 
and NAC, prevented TRAIL-mediated stimulation of ASM, the release of ceramide, 
formation of ceramide-enriched membrane platforms and the induction of apoptosis by 
TRAIL.  
 
7. LY30 AND RELATED COMPOUNDS AS NOVEL SENSITIZERS OR 
AMPLIFIERS OF TRAIL SIGNALING 
7.1 LY30 sensitizes TRAIL-responsive (Jurkat and SHEP-1) and TRAIL-
resistant (HT29) to TRAIL-induced apoptosis. 
The bulk of the pilot study on the TRAIL-sensitizing ability of LY30 was done on the 
TRAIL-responsive cervivcal carcinoma cell line. However, we also recognized that there 
are other tumor cells that have either intrinsic or acquired resistance to TRAIL. 
Therefore, this system was also applied on several other tumor models, namely Jurkat T- 
cells and SHEP-1 neuroblastoma that are TRAIL-responsive, as well as in HT29 
adenocarcinoma, which is refractory to TRAIL-treatment. Indeed, preliminary work in 
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this thesis shows that the sensitizing ability of LY30 is not restricted to HeLa cells and 
that it is able to achieve an enhancement of TRAIL-induced cell death in Jurkat cells, a 
non-solid tumor model (Fig 34 and Fig 37). This was accompanied by the synergistic 
activation of caspases-2/3/8/9 (Fig 37B). We also provide evidence here that LY30 is 
able to revert sensitivity to TRAIL-resistant HT29 adenocarcinoma cell line and this has 
also been observed in other reports that showed that transfection with a dominant 
negative form of TRAIL receptor inhibited cell induced by isoquiritigenin in combination 
with TRAIL. 
 In addition, we were interested to investigate whether the ability of LY30 to induce 
surface death receptor applies across different tumor model; we studied its effects on 
death receptor redistribution in SHEP-1 neuroblastoma cell since others have already 
published the sensitizing effect of LY30 on TRAIL in this system. Similar to the results 
in HeLa cells, we observed that the initial smooth distribution of DR5 around the cell 
surface in SHEP-1 cells congregated to form caveolin-receptor patches after one hour 
exposure to LY30 (Fig 35). Pre-incubating these cells with receptor blocking antibodies 
also protected them against LY30+TRAIL treatment, further emphasizing the importance 
of death receptor signaling in the ability of LY30 to sensitize tumor cells to TRAIL.  
 
7.2 Potential of LY30 in chemotherapy. 
We have shown here, along with other numerous independent reports, the myriad ways 
by which TRAIL-mediated tumor cell death could be enhanced. This implies that there 
are multiple factors mediating the effector mechanisms underlying TRAIL-mediated 
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apoptosis. Our findings here suggest a viable strategy in chemotherapeutics aimed at 
enhancing susceptible tumor cells, or eliciting a response from tumor cells with intrinsic 
or acquired resistance, to TRAIL via combinatorial therapy with an adjuvant. The work 
in this thesis highlights the potential of LY30 as an adjuvant in tumor cells for TRAIL-
induced cell death, along with implications for the design of novel chemotherapeutic 
strategies to overcome the issue of TRAIL resistance in tumor cells. More interestingly, 
pre-treatment with LY303511 also enhanced sensitivity of tumor cells derived from 
clinical biopsies of lymphoma patients. 
 
However, the actual use of LY29 or LY30 as a sensitizing compound in chemotherapy 
may be limited by its insolubility in aqueous solutions. This could be circumvented by 
designing novel soluble variants of LY30 that retains the activity of LY30, without 
affecting PI3K. At the same time, the potency of LY30 as demonstrated in this thesis, and 
elsewhere, serves to highlight the potential PI3K-independent affects of its widely used 
sister compound, LY29, given their structural similarity. Work described here, and 
elsewhere, serves also as a reminder to those using the LY29 compound to study the 
PI3K-AKT pathway to the possible non PI3K related affects of the LY compounds and 





The innumerable ways by which TRAIL-mediated death could be enhanced points to a 
plethora of factors mediating the effector mechanisms underlying death receptor-
dependent apoptotic signaling. Similar to findings by other researchers, it has been shown 
that a TRAIL-sensitizing compound can elicit several responses from a tumor model 
simultaneously, such as the proteasome inhibitor bortezomib, whereby upregulation of 
death receptors, accompanied with a downregulation of c-FLIP as well as inhibition of 
NF-ĸB have been ascribed as the mechanisms utilized by bortezomib.  This study 
provides evidence for the first time, the ability of LY30, an inactive analogue of the PI3K 
inhibitor LY29, in enhancing TRAIL-induced apoptosis, contingent upon the expression 
of death receptors. Additionally, LY30 exhibited other physiological response such as a 
reduction in protein levels of c-FLIP and triggering the mitochondrial death amplification 
pathway through recruitment of Bid. The data offers an explanation for the sensitizing 
ability of LY30 by demonstrating that it could enhance TRAIL induced apoptosis via 
amplification of death receptor signaling, a function of priming the cells for TRAIL 
through a spatial rearrangement and clustering of death receptors on cell surface, 
lowering the threshold for efficient TRAIL-induced apoptosis in tumor cells. This is in 
line with recent study demonstrating the significance of ligand-independent death 
receptor clustering in the sensitization to Fas-mediated apoptosis. In this regard, this 
current study of LY30 would appear to be more than just simply a word of caution in 
wrongly attributing the sensitizing ability of the LY compounds (LY29 in particular) to 
chemotherapeutic agents (Shingu et al., 2003), or simply as a proof of the ability of LY30 
to provide a conducive intracellular milieu for the induction of apoptosis. In fact, the 
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ability of LY30 to singularly induce cell death through death receptor signaling, 
independent of its ligand could also provide a novel tool with which to study the 
relatively unknown mechanistic aspects of death receptor surface signaling events in a 
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